Final Programme - The British Society for Rheumatology

Final Programme 

www.rheumatology.org.uk 

Programme production kindly supported by: Chugai/Roche

Acknowledgements 

The British Society for Rheumatology (BSR) and 

British Health Professionals in Rheumatology 

(BHPR) would like to thank the Heberden 

Committee for their hard work in coordinating the 

programme for Rheumatology 2010: 

Dr Richard Watts 

Dr Gavin Clunie 

Prof Chris Denton 

Prof Michael Ehrenstein 

Ms Keri Hutchinson 

Dr Andrew Keat 

Dr Hoda Mirjafari 

Prof Robert Moots 

Prof Costantino Pitzalis 

Dr Elizabeth Price 

Dr Clive Ryder 

Dr David Sansom 

Chair 

Council Member 

Vice Chair 


BHPR Representative 


RATS Representative 

Rheumatology 

Representative 

Member (co-opted) 

Member 

BSPAR Representative 

Non Clinical Scientist 

Representative 

Dr Claire Wenham RATS Representative - 

academic 

We are also extremely grateful for the assistance of 

everyone who gave up their time to review abstracts. 

A full list of abstract reviewers can be found at the 

back of this programme. 

BSR and BHPR would also like to thank the 

following companies for their generous support 

of Rheumatology 2010: 

Abbott Immunology for their support of the BSR 

Innovation in Rheumatology Awards 

MSD for their support of the 

BSR Young Investigator Awards 

Shire for their support of the Osteoporosis Award 

2010 ‘Pioneering best practice in osteoporosis: 

prevention of falls and fractures’ 

Arthritis Research UK (formerly arc) for supporting 

the BHPR Silver Medal Prizes 

Chugai Roche for supporting the production of the 

event announcements and the final programme 

Arthritis Research UK for providing a Cyber Café at 

Rheumatology 2010 

MSD, Wyeth, Abbott Immunology and UCB 

for supporting the educational element of the 

BHPR’s 25th Anniversary Dinner 

Abbot Immunology, Actelion, Amgen, GSK, Roche 

(RoACTEMRA), Roche (Mabthera) and UCB for the 

provision of industry supported educational symposia 

for delegates 

We would also like to thank our exhibitors for their attendance at Rheumatology 2010. Delegates really value the 

exhibition and so we would like to thank all our exhibitors for their ongoing support. 

Printed 

with 

natural 

soy ink 

Rheumatology 2010 Final Programme has been 

printed on recycled material using natural soy ink

Contents 

Presidents’ welcome 2 

General information 3 

Plan of The ICC 5 

BSR Prizes and awards 6 

BHPR Prizes and awards 8 

Keynote speakers 9 

Highlights of Rheumatology 2010 12 

Guided poster tours 13 

Rheumatology 2011 14 

Rheumatology 2010 | 21-23 April 

Meeting at a glance 17 

BSR and BHPR membership 

Programme: Tuesday 20 April 2010 21 

Programme: Wednesday 21 April 2010 23 

Social events 

Programme: Thursday 22 April 2010 33 

Programme: Friday 23 April 2010 45 

Oral presentation of abstracts 57 

Poster viewing: Wednesday 21 April 2010 71 

Poster viewing: Thursday 22 April 2010 87 

Poster viewing: Friday 23 April 2010 105 

Exhibition Floorplan 121 

BSR, Bride House, 18-20 Bride Lane, London EC4Y 8EE 

Telephone: +44 (0) 20 7842 0900 Fax: +44 (0) 20 7842 0901 

Email: conferences@rheumatology.org.uk 

Website: www.rheumatology.org.uk/conference 

A Company limited by guarantee with charitable status VAT No. 404 5637 66 

Company Reg. No. 3470316 Charity Reg. No. 1067124 

1

Presidents’ welcome 

Dear Friends and Colleagues, 

We are delighted to welcome you to Rheumatology 2010. 

Rheumatology 2010 is the UK’s foremost conference in rheumatology, offering you the opportunity to 

network with colleagues and keep up to date with advances in the field. This year, in response to 

delegate feedback, we are pleased to launch the conference in its new succinct three day format to 

meet the needs of busy practising clinicians and researchers alike. 

The major themes of Rheumatology 2010 fall under the following categories: Clinical (pain/injury, 

immunology/infection, spondyloarthropathies and rheumatoid arthritis), Political, Training and Allied 

Health Professionals. Turn to page 18 for our Meeting at a glance grids where you can browse the 

programme by stream. 

An eminent faculty of both national and international speakers have been secured including the 

prestigious line-up of keynote lecturers for this year. We thank Prof Nigel Arden, Droitwich Lecturer, 

Prof Sir John Savill, Heberden Orator, Prof John Isaacs, Heberden Roundsman and Prof Ken Smith, 

State of the Art Lecturer for their invaluable contributions to the exciting and inspiring programme that 

our delegates have come to expect. 

Other sessions will address complementary medicine, the immune system, research, service delivery 

and footwear aiding mobility to name but a few. Two highly topical sessions will also feature: one from 

the BSR Biologics Register, bringing you up to date with plans for its development and an ARMA run 

session on the positioning of musculoskeletal services in the face of the challenge posed by NHS 

spending restraints following the general election. Also not to be missed are the sessions run by BSR 

and BHPR Special interest groups. 

We also encourage you to visit the exhibition in Hall 3 where our industry partners are waiting to 

meet you. 

Finally, the BHPR is 25 this year. This important milestone is a testament to the amount of work put 

in from its inception to create an organisation to specifically support Allied Health Professionals in 

rheumatology. Come and celebrate with us on Thursday 22 April at our Anniversary dinner held at 

The ICC. 

We hope that you find Rheumatology 2010 to be of educational value and welcome feedback to 

ensure that your annual meeting meets your needs. Don’t forget to turn to page 14 for information on 

Rheumatology 2011 and how you can get involved. 

We look forward to meeting you at Rheumatology 2010. 

With best wishes 

Deborah Bax 

President, BSR 

Diana Finney 

President, BHPR 

2

General information 

Registration opening hours 

Tuesday 20 April 08.00-19.30 

Wednesday 21 April 07.30-17.00 

Thursday 22 April 07.30-17.00 

Friday 23 April 08.00-15.30 

Conference opening hours 

Tuesday 20 April 19.30-20.45 



Friday 23 April 07.00-18.00 

Exhibition opening hours 



Friday 23 April 08.30-14.00 

Badges 

Your name badge gives you access to all scientific 

sessions on the days for which you have registered. 

You are also permitted access to the exhibition hall 

during open hours. It is essential that you visibly 

display your badge at all times as event/venue staff 

will not allow people without badges to access 

sessions or exhibition areas. 

CPD 

We have been informed by the CPD office of the 

Royal College of Physicians that we are limited to 

6 credits per day. Therefore, the annual meeting 

will accrue you the following: 

Abstract supplement 

As usual, all accepted abstracts have been 

published as a supplement in the journal 

Rheumatology. This year, the abstract book has 

been supplied on a complimentary USB 

stick which will be presented to all delegates at the 

registration desk. Subscribers to the journal will also 

be able to access abstracts online at: 

http://rheumatology.oxfordjournals.org 

Catering 

Your registration fee for the conference includes 

lunch and tea and coffee for each day that you are 

registered. All catering will be served within the 

main exhibition in Hall 3 (see Exhibition floorplan on 

page 121 for location). Please refer to the 

“Meeting at a Glance” section for timings. 

Accommodation 

If you have booked through our appointed 

accommodation agents, Fresh Reservations 

(formerly Virtuoso), you can contact them directly 

with queries on: 

Telephone: 0845 310 3333 

email: hotels@freshres.co.uk 

Onsite contacts 

If you have a query onsite regarding Rheumatology 

2010, please contact a member of the events 

team via the registration desk: 


Wednesday 21 April 6 

Thursday 22 April 6 

Friday 23 April 6 

A certificate of attendance is included in your 

delegate bag. 

Accreditation from the Royal College of Nursing 

has been applied for. For further information, 

please enquire at the registration desk. 

Louis Bellintani 

Stephanie Tame 

Briony Wilson 

James Glavin 

BSR Events Officer 

BSR Senior Events Officer 

BSR Senior Events Officer 

BSR Head of Education, 

Events and Journal 

Speaker preview 

Check-in is required of all speakers. 

The speaker preview room is located in the Media 

Suite of The ICC (see the venue map on page 5 for 

location). Please check-in to the speaker preview 

room to upload and check your presentation on 

arrival at The ICC, no later than two hours prior to 

your session start time. 

3

Cyber café 

The cyber café, kindly sponsored by Arthritis 

Research UK, will be situated in the registration 

area (see Exhibition floorplan on page 121 for 

location). It is free for all delegates to use. 

Delegate code of conduct 

We hope that the conference is a positive 

experience for all attendees and ask that delegates 

abide by the following code of conduct: 

• BSR cannot guarantee capacity in any 

particular session. Although we will do our best 

to avoid disappointment, there may be 

occasions when a room is full. We ask that you 

arrive as early as possible to ensure access. 

Legally we are not allowed to let you into a 

room if it is full. 

• Delegates are responsible for all their property. 

Neither BSR nor the venue accepts liability for 

loss of or damage to personal items. 

• Bags and packages must be in your possession 

at all times. The safety and security of 

delegates is paramount and unattended 

items may cause security alerts. 

• If any delegate is deemed to be acting 

inappropriately BSR will require them to 

leave the venue. No refund will be due in 

this instance. 

Presentation relay room 

Occasionally session rooms do become very busy, 

but delegates can assist in the smooth running of 

all sessions by sitting as far forward in the auditoria 

as possible and filling rows from the centre 

outwards, so that spare seats are easily accessible. 

In instances where rooms go over capacity we have 

set up a presentation relay area in the foyer of Hall 

1. Should you be prevented from entering a 

session room please check with The ICC or event 

staff if the session is being simultaneously 

streamed in this area. See the venue map on 

page 5 for its location. 

Business centre 

The ICC business centre is open for use from 

08.45 to 16.45 Wednesday to Friday. Fax, 

photocopying, internet access and other business 

services are available here. See the venue map on 

page 5 for its location. 

4 

The ICC wi-fi service 

A wi-fi network is available in the venue foyers and 

Hall 3, accessed via a username and password. 

Please contact event staff for the password. 

Local information 

If your query relates to The ICC or the local area, 

please visit The ICC Information Desk, located at 

the Business Centre. See the venue map on page 5 

for its location. 

Cloakroom 

The main cloakroom will be open and available for 

all conference delegates. The cost of this service 

is £1 per item. 

Prayer space 

A prayer room is located off the main mall, directly 

behind Café Vite. This is for use by all religious 

groups and is accessed via the security keypad by 

the entrance door. A sign is situated in the room to 

indicate which direction is east. 

Under 16s 

Unfortunately it is not permissible for children under 

the age of 16 to have access to the meeting 

because we do not have sufficient liability insurance 

to cover a minor should it be required. 

First aid 

Trained first-aiders will be on duty throughout the 

event; please contact one of the event/venue staff 

in the event of an incident. 

Smoking policy 

Smoking is not permitted anywhere within The ICC. 

Car parking 

Parking for the venue is located within The NIA, 

which is just a short walk away from The ICC. 

There are four car parks located at The NIA 

North – King Edward’s Road (open 24 hours) 

South Upper – Sheepcote Street 

(open 06.45 – 19.00, Monday – Friday) 

South Lower – St Vincent Street 

Community Hall – Junction of King Edward’s Road 

and Sheepcote Street (07.00-midnight) 

Disclaimer 

Please note that BSR and BHPR accept no 

responsibility for views expressed by speakers 

at the event.

5 

Rheumatology 2010 | 21-23 April

BSR Prizes and awards 

The prize giving ceremony will be held on Thursday 22 April 16.00 – 16.30 in Hall 1 

Michael Mason Prize 

Awarded for excellence in clinical or scientific 

research in the field of rheumatology, the winner 

receives: £1,000, the Michael Mason medal, 

complimentary conference registration and the 

opportunity to present their work during the 

plenary session of that year. 

Dr Chris Murphy 

Hypoxia, a force for good in cartilage: 

implications for joint repair 

Garrod Prize 

Awarded to scientists for excellence in a 

non-clinical background currently working in 

rheumatology or a related discipline, the winner 

receives: £1,000, complimentary conference 

registration and the opportunity to present their 

work during the plenary session of that year. 

Dr Andrew Judge 

Monitoring fairness in access to hip and knee 

replacement surgery in England 

The winners of the Michael Mason and 

Garrod prizes 2009 will be presenting their 

work on Friday 23 April 10.00-12.00 as 

part of the Rheumatoid arthritis: 

aetiopathogenesis concurrent oral session 

Innovation in Rheumatology Awards 

supported by Abbott Laboratories 

Awarded to entrants that have demonstrated how 

their innovative work has benefited the treatment 

and care of rheumatology patients. The winners 

receive: £500 plus a £500 donation to research 

within a charity/organisation of their choice, 

complimentary registration to Rheumatology 

2010 and an opportunity to present their work at 

the conference, plus complimentary registration 

to either EULAR or ACR. 

The winning entrants will present their work as 

part of the Innovations and service delivery 

concurrent oral session on 

Thursday 22 April at 14.00. 

Innovation in practice (category 1) 

Dr Athimalaipet V Ramanan 

Regional uveitis clinic for children with juvenile 

idiopathic arthritis (JIA) associated uveitis: 

addressing an unmet need 

Innovation in development (category 2) 

Dr Philip Riches 

Osteoporosis associated with neutralising 

osteoprotegerin antibodies 

Medical Student Bursaries 

Awarded to UK medical students whose abstract 

submission was judged by the Heberden 

Committee to be of particularly good quality. 

Winners receive: complimentary conference 

registration, travel expenses, two nights’ 

accommodation and the opportunity to 

present their work at Rheumatology 2010. 

Dr Carsten Ezard 

What is meant by ‘active’ disease in the NICE 

recommendation on use of combination therapy 

in early RA? 

Dr Michael Cocker 

Sarcopenia is highly prevalent in the very elderly 

and predicts mortality in males 

Dr Carolyn Lavelle 

Effect of B cell depletion therapy (Rituximab) 

in 46 caucasian patients with connective 

tissue disease 

Dr Laura R Spiers 

Hypovitaminosis D in patients with connective 

tissue disease 

6

Dr Laura Clarke 

Basdai changes in ankylosing spondylitis patients 

treated with anti-tumour necrosis factor therapy 

Dr Susanna White 

Bone mineral density and fracture risk among a 

UK cohort of HIV-positive men 

Osteoporosis Award 2010 ‘Pioneering best 

practice in osteoporosis: prevention of falls 

and fractures’ 

supported by Shire 

Awarded to projects or initiatives which 

demonstrate best practice and improved patient 

care within the field of osteoporosis. The winner 

receives £500 plus a £500 donation to research 

and development within a charity/organisation of 

their choice and complimentary registration to 

Rheumatology 2010. 

Dr Nicola Peel 

Fracture risk assessment service 

Young Investigator Award 

supported by MSD 

Awarded to young investigative rheumatologists 

who have included an imaginative hypothesis 

with results that could advance knowledge within 

the field. Winners receive: complimentary 

registration to Rheumatology 2010, £500, 

plus the opportunity to present the research at 

Rheumatology 2010. 

Dr James Galloway 

Risk of septic arthritis in patients with 

rheumatoid arthritis treated with anti-TNF 

therapy: results from the BSR Biologics 

Register (BSRBR) 

Dr Sarah Wythe 

Targeting the inflamed microvasculature in 

rheumatoid arthritis 

Dr Laura Coates 

Achieving minimal disease activity (MDA) criteria 

with anti-TNF therapy in psoriatic arthritis can 

prevent progressive joint damage 

Dr Luke Gompels 

Quantifying in vivo fluorescence imaging in 

murine arthritis by targeting e-selectin 

Dr Michele Bombardieri 

Rheumatoid synovial fibroblasts support aid 

expression and IG class-switching in B cells via 

a baff-dependent TLR3-stimulated pathway 

Dr Louise Mercer 

The risk of non-melanoma skin cancer in 

patients receiving anti-TNF therapies for 

rheumatoid arthritis: results from the British 

Society for Rheumatology Biologics Register 

Droitwich Medical Trust Prize 

The Droitwich Prize, funded by the Droitwich 

Medical Trust and worth £250 will be awarded 

to the best clinical case report. The award 

winner will be announced during the oral 

presentation session devoted to case reports 

on Wednesday 21 April at 11:00. 

BSR is proud to recognise and celebrate 

achievements and innovations that change 

the face of rheumatology. Every year the 

BSR runs a programme of prizes and 

awards to raise the profile of achievements 

within rheumatology and to encourage 

those working to improve patient care. 

To find out more about our popular range 

of bursaries, prizes and awards please visit 

www.rheumatology.org.uk/prizes 


7

BHPR Prizes and awards 

The prize giving ceremony will take place on Friday 23 April 13.45 – 15.15 in Hall 1 

BHPR Clinical Prize 

Awarded to a BHPR member for a piece of 

clinical work carried out that is relevant to 

clinical practice. The winner receives £200 

and be required to submit an article for the 

BHPR newsletter. 

Prize not awarded in 2010 

Arthritis Research UK BHPR Silver Medal 

Research Prize 

Awarded to the applicant deemed to have 

submitted a piece of research which is of the 

highest quality and overall contribution to 

rheumatology. The winner receives £500, a 

medal and the opportunity to present their 

work at Rheumatology 2010. 

Dr Tessa Sanderson 

Developing of rheumatoid arthritis patients’ 

priorities 

BHPR Student/Recently Qualified Health 

Professional Prize 

Awarded to any student in the UK undergoing 

health professional training at the 

undergraduate/diploma level, or within two years 

of qualifying who has submitted a piece of work 

that enhances patient care/contributes to the 

body of knowledge of rheumatology practice. 

The winners receive £150, complimentary 

registration for Rheumatology 2010, travel costs 

up to £100 and two nights’ accommodation. 

Dr Matthew Everson 

The multidisciplinary team on the diagnosis and 

management of patients with rheumatoid 

arthritis 

Chris Moran Poster Prize 

The winner receives £50. This prize is awarded at 

the conference. 

Arthritis Research UK Physiotherapy Silver 

Medal Prize 

Awarded to applicants deemed to have submitted 

a piece of research or clinical work that is of the 

highest quality and overall contribution to 

rheumatology physiotherapy. The winner receives 

£500, a medal and the opportunity to present 

their work at Rheumatology 2010. 

Dr Lisa Roberts 

Improving patients’ experience in MSK 

physiotherapy 

8

Keynote speakers 


11.00 – 12.00 

Droitwich Lecture Hall 1 

Osteoarthritis: a journey from orthopaedics to a multidisciplinary 

disease 

Prof Nigel Arden trained at St Thomas’s Hospital, London, where he also 

completed four years of research into the genetics of osteoporosis. During 

this time, he gained an MSc in Epidemiology and an MD. 


Prof Nigel Arden, Professor of 

Rheumatic Diseases and 

Consultant in Rheumatology, 

University of Southampton 

He moved to the South Coast in 1996 and in 1998 spent six months as 

Visiting Assistant Professor in Epidemiology at the University of San 

Francisco. 

In 2000 he commenced his post as Senior Lecturer in Rheumatology and 

Honorary Consultant Rheumatologist at Southampton University NHS 

Trust. In 2008, he commenced an appointment with the University of 

Oxford to develop a joint research department between the two 

universities of Oxford and Southampton. He is based jointly at the 

Medical Research Council Epidemiology Resource Centre, Southampton 

and the Botnar Research Centre, Oxford, where he continues his research 

into osteoarthritis and osteoporosis. 

He has published 107 research papers and written five books in the field 

of rheumatology. Currently Prof Arden is a member of the National 

Osteoporosis Society Scientific Advisory Board and sits on the EULAR 

(European League Against Rheumatism) Osteoarthritis guideline 

committee and OARSI (Osteoarthritis Research Society International) 

committees for the treatment of osteoarthritis and the use of MRI in 

the diagnosis of osteoarthritis. 

16.30 – 17.30 

Heberden Round Hall 1 

Prof John Isaacs, Professor of 

Clinical Rheumatology, University 

of Newcastle upon Tyne 

Moab is my medicine: lessons and messages from 20 years 

of therapeutic immunology 

Prof John Isaacs is Professor of Clinical Rheumatology at Newcastle 

University and consultant rheumatologist at the Freeman Hospital. He 

graduated from London University with a first class degree in Physiology 

and Medicine, followed by junior posts in London (Hammersmith Hospital) 

and Harvard (Beth Israel Hospital). He was subsequently registrar on the 

Hammersmith Renal Unit before moving to Cambridge with MRC funding, 

to read for his PhD in Immunology. Over the past 20 years his work has 

focussed on the potential of novel immunotherapies to treat rheumatoid 

arthritis, ranging from target identification to early and late stage clinical 

9

trials. He has performed several pioneering translational studies in patients 

with inflammatory disease, challenging existing dogma and informing the 

design of subsequent generations of therapeutic agents. Currently his team 

is preparing for a first-into-man study, in RA patients, of a tolerogenic 

dendritic cell vaccine that has been developed in Newcastle. In 1999 he 

received the BSR Michael Mason Medal. 

Prof Isaacs moved to Newcastle University in 2002, where he developed 

the translational and innovative Wilson Horne Immunotherapy Centre for 

early phase studies of novel immunotherapeutics. Nationally he chairs the 

Arthritis Research UK’s Clinical Study Group for Inflammatory Arthritis, 

developing an internationally competitive research strategy for the UK. 

He is a member of the Committee for the Safety of Medicine’s Expert 

Advisory Group on Clinical Trials and is secretary to the Royal College of 

Physician’s Joint Specialty Committee for Rheumatology. He sits on several 

scientific and clinical advisory boards and is a member of the European 

League Against Rheumatism’s scientific committee. In 2008 he was 

awarded a National Rheumatoid Arthritis Society’s Healthcare 

Champions award. 


16.30 – 17.30 

Heberden Oration Hall 1 

Prof Sir John Savill, Vice Principal 

and Head of the College of 

Medicine and Veterinary Medicine, 

Chair of Experimental Medicine, 

University of Edinburgh 

Clearance of cells dying by apoptosis and regulation of inflammation 

Prof Sir John Savill graduated in Physiological Sciences from Oxford in 

1978 and in Medicine from Sheffield in 1981 and received a PhD 

(London) in 1989. After junior hospital appointments in Sheffield, 

Nottingham and London, he spent seven years in the Department of 

Medicine at the 

Royal Postgraduate Medical School, Hammersmith Hospital, with spells 

as an MRC Clinical Training Fellow and Wellcome Trust Senior Clinical 

Research Fellow. 

In 1993, he moved to the Chair of Medicine at Nottingham, then to 

Edinburgh as Professor of Medicine in 1998 where he set up and became 

the first Director of the University of Edinburgh/MRC Centre for 

Inflammation Research. 

In 2002, he became the first Vice-Principal and Head of the College of 

Medicine and Veterinary Medicine; he moved to the Chair of Experimental 

Medicine in 2006. 

10

On 1 June 2008, he was appointed Chief Scientist for the Scottish 

Government Health Directorates (part-time). 

His work has been recognised by fellowships of the Royal Colleges of 

Physicians of London and Edinburgh, the Academy of Medical Sciences, 

the American Society of Nephrology and the Royal Society of Edinburgh. 

He was a member of the Medical Research Council from 2002 to 2008 

and chaired two Research Boards during this period. He was knighted in 

the 2008 New Year’s Honours List for services to clinical science. 



15.30 – 16.30 

State of the Art Hall 4 

Prof Ken Smith, Genzyme 

Professor of Experimental 

Medicine, University of Cambridge 

Evolution and augury in autoimmune disease: FcRs, malaria and 

CD8 T cells 

Prof Ken Smith is Professor of Medicine and Head of the Department of 

Medicine at the University of Cambridge. He is a Fellow and Director of 

Studies in Clinical Medicine at Pembroke College, Cambridge and is the 

Khoo Oon Teik Professor of Nephrology, National University of Singapore. 

Prof Smith studied medicine at the University of Melbourne, and 

completed a BMedSc in the Nuffield Department of Surgery in Oxford. 

He trained in nephrology with an interest in autoimmune disease at the 

Royal Melbourne Hospital, and then completed pathology training 

specialising in clinical immunology. His PhD (with David Tarlinton and 

Gus Nossal: Walter and Eliza Hall Institute) examined aspects of B cell 

immunology, work subsequently built upon in two years working with 

Douglas Fearon in Cambridge. 

He now runs a laboratory in the Cambridge Institute for Medical Research 

which has two main components. The first studies basic immunological 

mechanisms, and how defects in regulatory control of the immune system 

can lead to autoimmunity and alter defence against infection, with one 

focus on the inhibitory receptor FcγRIIb. The second component is a 

translational programme in autoimmune disease (particularly SLE and 

vasculitis) and has led to the discovery of novel prognosis-predicting 

biomarkers, and the identification of important genes involved in disease 

pathogenesis. In 2006 he was elected a Fellow of the Academy of 

Medical Sciences, and in 2007 was awarded the Lister Institute 

Research Prize. 

11

Highlights of Rheumatology 2010 


09.00 – 10.30 

Opening Plenary: jewels in the crown Hall 1 

Including the 2010 Michael Mason and Garrod 

prize winner presentations, this session will also 

showcase the very best of this year’s abstracts 

11.00 – 12.00 


Osteoarthritis: a journey from orthopaedics 

to a multi-disciplinary disease 

Prof Nigel Arden, Professor of Rheumatic 

Diseases and Consultant in Rheumatology, 

University of Southampton 

16.30 – 17.30 


Moab is my medicine: lessons and messages 

from 20 years of therapeutic immunology 

Prof John Isaacs, Professor of Clinical 

Rheumatology, University of Newcastle upon 

Tyne 


14.00 – 15.30 

RATs Workshop Hall 11 

Will I have a job and what will it be? The future 

for rheumatologists: clinical and academic 

Prof Chris Buckley and 

Dr Gabrielle Kingsley, London 

16.00 – 16.30 

BSR Prize giving Hall 1 

16.30 – 17.30 


Clearance of cells dying by apoptosis and 

regulation of inflammation 

Prof Sir John Savill, Vice Principal and Head 

of the College of Medicine and Veterinary 

Medicine, Chair of Experimental Medicine, 

University of Edinburgh 


13.45 – 15.15 

ARMA late breaking session: putting 

musculoskeletal services centre stage Hall 5 

Following the general election the NHS faces an 

unprecedented and sustained period of spending 

restraint and the challenge of delivering 

£15-20bn savings within the next four years. The 

desired outcome would be transformational with 

quality and efficiency gains as buzz words. So 

how are musculoskeletal services positioning 

themselves in the face of this challenge? ARMA 

has assembled some key commentators to 

discuss the issues and to showcase initiatives 

that aim to reposition their work 

13.45 – 15.15 

BHPR Prize giving Hall 1 

15.30 – 16.30 

State of the Art Hall 4 

Evolution and augury in autoimmune disease: 

FcRs, malaria and CD8 T cells 

Prof Ken Smith, Genzyme Professor of 

Experimental Medicine, University of 

Cambridge 

12

Guided Poster Tours at Rheumatology 2010 

New to Rheumatology 2010! Poster Tours guided by leaders in the field will be conducted on each day 

of the conference highlighting a selection of BSR and BHPR posters. See below for details of the Poster 

Tour topics and timings. Numbers are limited so remember to sign up at the registration desk in advance 

of the tour. Tours will leave from the registration area. 



12.45 – 13.30 

Case reports 

Spondyloarthropathies (including psoriatic arthritis) 


09.00 – 09.45 

Osteoporosis and metabolic bone disease 

Rheumatoid arthritis: treatment 


09.00 – 09.45 

BHPR: audit/service delivery and BHPR: research 

Epidemiology 

Rheumatoid arthritis: clinical aspects 

13


2011 

12-14 April | Brighton 

Rheumatology by the sea… 

We are pleased to be taking Rheumatology 2011 to Brighton, a unique setting boasting both a seaside 

location and a dynamic city atmosphere. Getting to Brighton is easy – it’s less than an hour from London 

and a mere 30 minutes from Gatwick airport. This creative and cultural city is also easy to get around 

(earning it the nickname of the ‘10 minute city’) with all major venues, sights and hotels within a short 

walk of each other. As well as a huge range of accommodation options for all budgets (from the 

traditional to the cool and contemporary) you’ll also find a wealth of shops and restaurants amongst 

Brighton’s cosmopolitan and quirky streets. 

Rheum with a view… 

The conference will be hosted by two of Brighton’s premier hotels – The Hilton Metropole (the recent 

recipient of an £8m facelift) and The Grand – Grand by name, and grand in style and scale. These two 

seafront hotels are the perfect setting for a first rate conference. 

An evolving event… 

In keeping with a vibrant and changing city, the conference is developing and evolving too. Rheumatology 

2011 will take on a slightly different format, building on changes implemented in 2010. The three day 

event will still include the usual high quality combination of sessions and keynote lectures, but in a more 

streamlined format. The first day of the conference (12 April) will feature stand alone 

focused symposia on a range of topics, with the main conference launching in 

the late afternoon with a thought-provoking plenary session featuring the 

prestigious State of the Art Lecture. 

Join us in Brighton to be rejuvenated by the 

fresh sea air and inspired by an exciting and 

innovative conference 

Mark 

your 

calendar

Call for proposals 

What happens at Rheumatology 2011 is in part 

up to you. The BSR and BHPR are proud to 

announce a call for proposals for sessions at 

Rheumatology 2011. Proposals should address 

cutting edge aspects of rheumatology. 

Please send your proposal to: 

Briony Wilson, BSR Senior Event Officer at: 

bwilson@rheumatology.org.uk indicating 

• Type of session 

• Suggested length of session 

(90 minutes or 120 minutes) 

• Session title and brief synopsis 

(include one aim and three 

outcomes of the session) 

• Lecture titles and suggested speakers 

Deadline: 7 May 2010 

All topics suggested will be considered by the 

Heberden Committee at their May meeting. 

Unfortunately as we anticipate demand for 

sessions will be particularly great in 2011, any 

topics submitted after the deadline will not be 

considered. You may also contact 

bwilson@rheumatology.org.uk if you wish to 

discuss a full pre-conference day proposal. 

Call for papers 

The BSR and BHPR invite you to submit an 

abstract to Rheumatology 2011 via our online 

submission website, which will be launched at the 

end of summer 2010. Accepted abstracts will be 

presented at Rheumatology 2011 and will be 

printed in the peer-reviewed journal Rheumatology. 

Full details can be found on the conference 

website at www.rheumatology.org.uk/abstracts 

Deadline: 22 November 2010 

Call for prize submissions 

Turn to pages 6-8 for information on the vast array 

of prestigious prizes that will be awarded at 

Rheumatology 2011. Don’t miss the chance to 

share and celebrate your work with the wider 

rheumatology community. 

Deadline: To appear shortly at 

www.rheumatology.org.uk/conference 

15

Meeting at a glance 

20-23 April 2010 

Meeting at a glance 

20-23 April 2010

Become a BSR or BHPR member 

You can find BSR and BHPR at Stand 33 

Sign up today to get free 

membership for 2010 * 

Visit the BSR/BHPR stand at lunchtime on Wednesday or Friday 

to meet members who can tell you more about membership 

and help you with your application 

Join BSR to enjoy: 

Membership of one of the largest rheumatology 

communities, with excellent networking opportunities 

Subscription to Rheumatology, an international peer 

review journal publishing the highest quality papers 

Access to a wide range of Special interest groups on 

everything from clinical trials to vasculitis 

Opportunities to work with colleagues to influence 

health policy and drive clinical practice 

Support for members’ Clinical Excellence Awards 

applications 

BSR publications, guidelines and monthly 

e-newsletter 

Eligibility to apply for BSR prizes such as the 

prestigious Michael Mason Prize and Garrod Prize 

Significant discounts for BSR education courses 

and conference 

Join BHPR to enjoy: 

Members’ Directory 

Monthly e-newsletter 

Bi-annual hard copy newsletter 

Eligibility for BHPR Bursaries and Awards 

Significant discounts for attending BHPR annual conference 

A forum via our conference for research activity to be widely disseminated and debated 

Education opportunities and information 

BHPR works closely with BSR to produce guidelines, and to evaluate NICE appraisals 

Two-year subscription to Musculoskeletal Care (in association with Wiley Publishers) 

*This offer is only available to delegates attending Rheumatology 2010 who registered at the non-member rate. Completed membership applications must be received 

by 7 June 2010. To be eligible for the offer, you must set up a Direct Debit for your subscriptions (does not apply to overseas members).

Additional meetings 


Open meetings 

07.30 – 09.00 

CMF breakfast 

Executive Room 2 

12.30 – 13.30 

Rheumatologists at Training – lunch provided 

Hall 11 

NASS best practice in AS document launch – 

lunch provided 

Hall 9 

BSR Standards Guidelines and Audit Working 

Group – lunch provided 

Hall 8 

Closed meetings (invitees only) 

10.30 – 12.00 

CAC regional chairs 


12.00 – 15.00 

TACIT 


12.30 – 13.30 

Rheumatology editorial board meeting 


15.30 – 16.00 

MRC Registry 


16.00 – 17.00 

TRACTISS 


17.00 – 18.00 

TRACTISS Management Committee 




11.00 – 13.00 

METEOR 


12.00 – 14.00 

ERAN AGM 

Artists’ Lounge 

12.30-14.30 

PsA Guidelines meeting 




12.00 – 13.45 

Arthritis Research UK Education Strategy 

Committee 

Artists’ Lounge 

Meeting at a glance | 20-23 April 2010 

17

19.30 

09.00 

10.30 

11.00 

12.00 

12.30 

14.00 

16.00 

16.30 

17.30 

18.00 


Tuesday 20 April 

Industry supported symposium GlaxoSmithKline Hall 9 

Wednesday 21 April 

Clinical 1: pain/injury Clinical 2: spondyloarthropathies Allied health professionals Concurrent oral 

Opening plenary: jewels in the crown Hall 1 

including Michael Mason and Garrod Prize winners 2010 

Exhibition: Tea/Coffee Hall 3 

Fibromyalgia 

Hall 5 

Ankylosing spondylitis 

Hall 4 


BHPR AGM Hall 1 

RA: treatment 

Hall 6 

Exhibition: Lunch and Poster Viewing Hall 3 

Complementary medicine 

Hall 11 

Dermatology: a joint session with BAD 

Hall 4 

Diagnosing and 

treating complex 

regional pain 

syndrome Hall 5 

What is important 

to people with 

musculoskeletal 

problems? Hall 8 

Genetics and 

epidemiology 

Hall 6 

Exhibition: Tea and Coffee Hall 3 


Industry Supported Symposia catering 

Industry Supported Symposia 

Abbott Hall 11 

Roche (RoACTEMRA) Hall 8 

Case reports 

Hall 7 

Basic science 

Hall 7

08.30 

10.00 

12.00 

14.00 

15.30 

16.00 

17.30 

18.00 

Rheumatology 2010 - Thursday 22 April 

Clinical 1: Clinical 4: 

pain/injury immunology/ 

infection 

Training Allied health professionals Concurrent oral Special interest groups 

Performing 

arts and 

sports 

Hall 9 

Immune 

system 

Hall 4 

Exhibition: Lunch Hall 3 

BSR AGM Hall 7 

Infection and 

rheumatic 

disease Hall 1 

Exhibition: Tea/Coffee and Poster Viewing Hall 3 

So you want to do research? 

An Arthritis Research UK 

and BSR workshop Hall 5 

RATS workshop 

Hall 11 

BHPR Plenary oral 

presentation of abstracts 

Hall 8a 

12.30 - 14.00 

BHPR Prevention of work 

disability in patients with 

rheumatoid arthritis Hall 6 

You want 

to know 

what? 

Hall 9 

Exhibition: Tea and Coffee Hall 3 

A national 

network for AHP 

rheumatology 

students Hall 5 

Spondyloarthropathies 

Hall 8b 

RA: clinical 

aspects 

Hall 8a 

Innovations and 

service delivery 

Hall 8b 

07.30 - 09.00 

BSR: 

Arthritis Research UK /BSR education Hall 7a 

Musculoskeletal ultrasound Hall 11b 

Myositis Executive Room 2 

Osteoarthritis Hall 8a 

Scleroderma Hall 11a 

Sjörgen's syndrome Hall 6b 

Soft tissue rheumatism and sports medicine 

Hall 9 

08.30 - 09.30 

BHPR: 

Rheumatoid arthritis Hall 8b 

Connective tissue disease Hall 7b 

Osteoporosis Executive Room 1 

Medicine management Hall 6a 

BSR Prize Giving and Heberden Oration Hall 1 



UCB Pharmaceuticals Hall 8 

Roche (Mabthera) Hall 11

07.00 

07.30 

08.30 

10.00 

12.00 

13.30 

13.45 

15.15 

15.30 

Rheumatology 2010 - Friday 23 April 

Clinical 3: RA Training Allied health professionals Political Concurrent oral Special interest groups 

NOAR at 20 

Hall 5 

Service provision 

in rheumatology 

Hall 1 


07.30 - 09.00 Industry Supported Symposia 

Actelion Hall 9 | Amgen Hall 8 

Exhibition: Tea/Coffee and Poster Viewing Hall 3 

Footwear aiding 

mobility but 

restricting 

activity Hall 9 

Commissioning 

for 

rheumatology 

Hall 11a 

RA: 

aetiopathogenesis 

with Michael 

Mason and Garrod 

Prize winners 

2009 Hall 7 

Connective 

tissue 

disease 

Hall 6 

12.00 - 13.30 

BSR: 

Cardiovascular co-morbidity in RA 

and SLE Hall 11a 

Genetics of rheumatic disease 



Paediatric rheumatology Hall 11b 

Polymyalgia rheumatica and giant cell 

arteritis Hall 8a 

Systemic lupus erythematosus Hall 8b 

Vasculitis Hall 6 

BSR Biologics 

Register 

Hall 9 

Lunch Hall 3 

Make your way to afternoon sessions 

BHPR Prizes and awards 

Hall 1 

ARMA Late breaking 

session: putting 

MSK services 

centre stage Hall 5 

Osteoarthritis 

Hall 7 

16.30 - 18.00 

BSR: 

MS health of the ethnic minority 


Heritable disorders of connective 

tissue Hall 8a 

Musculoskeletal pain Executive Room 1 

Make your way to Hall 4 for State of the Art Lecture 

State of the Art Lecture Hall 4

Programme: 

Tue 20 April 2010 


Tuesday 20 April 2010

Tuesday 20 April 2010 

19.30 – 20.45 

Industry supported symposium 

GlaxoSmithKline Hall 9 

Programme: Tuesday 20 April 2010 

GlaxoSmithKline looks forward to welcoming you to their symposium 

“ Targeting BLyS Inhibition for Systemic Lupus Erythematosus“ 

Tuesday 20 th April 

ICC Hall 9 

19.00-19.30 Buffet & refreshments 

19.30-20.45 Symposium 

Chairman’s Introduction – Prof. Graham Hughes 

A brief overview of the history of Lupus – Prof. Graham Hughes 

Unmet Needs in Lupus: A Patient and Physician Perspective – Prof. Caroline Gordon 

Rationale for BLyS Inhibitors in Lupus – Dr Munther Khamashta 

Clinical Effect of BLyS Inhibition: Evidence from clinical trials – Prof. David D’Cruz 

MUS/PRJ/10/45619/1 March 2010 

GSKEDC-UK-2010-1778-D1.indd 1 

3/15/2010 8:45:14 PM 

21




Wed 21 April 2010

Welcome reception 

Wednesday 21 April 2010 19.45 – 21.30 

Birmingham Museum and Art Gallery 

Join us on Wednesday evening for drinks and canapés to network with 

your colleagues and our industry supporters. We are delighted to 

welcome you to the Birmingham Museum and Art Gallery for an 

informal gathering where you can catch up with friends and 

discuss the hot topics for 2010. 

This event is free for all delegates who are registered for the 

Wednesday of the conference. 

Please note that the event is ticketed. If you did not receive 

your ticket in the post or at registration, please check 

with events staff. 

25th Anniversary dinner 


Hall 4, The ICC 

The BHPR is 25! To mark this occasion please 

join us on Thursday evening at The ICC for our 

birthday celebrations. With a four course dinner 

and dancing to the excellent eighties tribute 

band ‘A kick up the 80s’ it will be a great 

chance to have fun with your colleagues and 

help us to celebrate our silver jubilee. 

Drinks reception: 19.30 

Dinner: 20.00 

Followed by dancing, with carriages at midnight 

The evening will feature an after dinner talk 

from Dr Jackie Hill, Leeds on 25 years of the 

BHPR: the allied health professional’s journey. 

Tickets are £25 and can be purchased at 

the registration desk, subject to availability. 

Kindly supported by MSD, 

Wyeth, Abbott and UCB


C1: Clinical stream one – Pain/injury 

C2: Clinical stream two – Spondyloarthropathies 

A1: AHP stream 

09.00-10.30 


Chair: Prof Deborah Bax, President BSR and Ms Diana Finney, President BHPR 

Programme: Wednesday 21 April 2010 

Michael Mason Prize winner 

Hypoxia, a force for good in cartilage: implications for joint repair 

Dr Chris Murphy, London 

Garrod Prize winner 

Monitoring fairness in access to hip and knee replacement surgery in England 

Dr Andrew Judge, Oxford 

OP1 Use of conservative and surgical foot care in rheumatoid arthritis: the ERAS cohort 

OP2 Methotrexate is not disease modifying in psoriatic arthritis, a new treatment paradigm 

is required 

OP3 Belimumab, a BLyS-specific inhibitor, reduced disease activity, flares and prednisone use in 

patients with active seropositive SLE: phase 3 BLISS-52 study 

Italics indicate oral abstracts. Please see pages 57-70 for full details 

10.30-11.00 

Tea/Coffee Hall 3 

11.00-12.00 


Chair: Ms Diana Finney, President BHPR and Mrs Lindsay Hawley, Bournemouth 

Osteoarthritis: a journey from orthopaedics to a multidisciplinary disease 

Prof Nigel Arden, Professor in Rheumatic Diseases and Consultant 

Rheumatologist, MRC Epidemiology Resource Centre, University of Southampton 

23

11.00-12.30 

C1 BSR Fibromyalgia Hall 5 

Chair: Dr Jeremy Jones, Bangor 

Aim: To explore the issue that while fibromyalgia is one of the most frequent diagnoses in the 

rheumatology clinic, many rheumatologists are uncomfortable when confronted by these patients. This is 

because in addition to the many physical symptoms, psychosocial issues are at play. These nullify the 

medical model, the modus operandi of so many rheumatologists. This session will look at fibromyalgia 

from the point of view of both a bio-psychosocially based rheumatologist and a psychiatrist 

Outcomes: To emphasise the non-medical aspects of fibromyalgia and consider exciting new biomedical 

findings shown on functional MR imaging. To see how this knowledge can help rheumatologists better 

understand patients with fibromyalgia and so deal with them more adequately 

What is fibromyalgia? A rheumatologist’s point of view 

Dr Geoffrey Littlejohn, Melbourne, Australia 

What is fibromyalgia? A psychiatrist’s point of view 

Prof Boudewijn Van Houdenhove, Leuven, Belgium 

What is fibromyalgia? A neuroimager’s point of view 

Dr Stuart WG Derbyshire, Birmingham 

How does all this help a rheumatologist deal with fibromyalgia more adequately? 

Prof Geoffrey Littlejohn, Melbourne, Australia 

C2 BSR Ankylosing spondylitis Hall 4 

Chair: Dr Karl Gaffney, Norwich 

Aim: To discuss the impact ankylosing spondylitis has on patients’ lives, clinical predictors and the role of 

MRIs in diagnosis management and prognosis of the disease 

Outcomes: Delegates will gain an understanding of the impact of ankylosing spondylitis and the role of 

MRI within ankylosing spondylitis 

Early ankylosing spondylitis: moving along 

Dr Helena Marzo-Ortega, Leeds 

The impact of ankylosing spondylitis on the patient and society 

Dr Annalies Boonen, Maastricht, The Netherlands 

Imaging the Spine in SpA: role in diagnosis, treatment and prognosis 

Dr Alex Bennett, Epsom 

BSR Concurrent oral presentations of abstracts 

Rheumatoid arthritis: treatment Hall 6 

Chair: Dr Karim Raza, Birmingham 

OP4 

OP5 

Inhibition of radiographic progression and improvements in physical function at two years, with 

increasing clinical efficacy over time, in rheumatoid arthritis (RA) patients treated with 

Tocilizumab (TCZ): the LITHE study 

Benefit of concomitant DMARD use on the persistence with anti-TNF therapies in rheumatoid 

arthritis: results from the British Society for Rheumatology Biologics Register (BSRBR) 

24

OP6 

OP7 

OP8 

OP9 

Rituximab plus Methotrexate (MTX) inhibits joint damage and improves clinical outcomes in 

patients with early, active rheumatoid arthritis (RA) who are naive to MTX 

An assessment of the serious infection rate in Rituximab-treated rheumatoid arthritis (RA) 

patients who subsequently received other biologic therapies: a follow-up from Rituximab 

clinical trials 

Genetic polymorphisms in key Methotrexate (MTX) pathway genes associated with response 

to MTX treatment in rheumatoid arthritis 

A comparison of Tocilizumab (TCZ) and Methotrexate (MTX) monotherapies in MTX- or 

DMARD-naive patients with rheumatoid arthritis (RA) 



BSR Concurrent oral presentations of abstracts 

Case reports Hall 7 

Chair: Dr Richard Watts, Ipswich and Dr Elizabeth Price, Bath 

OP10 

OP11 

OP12 

OP13 

OP14 

OP15 

Percutaneous endoscopic gastrostomy (PEG) feeding: a life saving intervention in systemic 

sclerosis-myositis overlap with pharyngeal dysfunction 

Rapid response to anakinra in the treatment of traps 

Idiopathic recurrent pericarditis: the role of anakinra and immunosuppressive treatments 

Thoracic spine osteitis: a distinct clinical entity or a variant on SAPHO? A series of four cases 

A fatal combination: rhabdomyolysis after macrolide therapy and a long term statin 

Infliximab for sarcoidosis: angel or devil? 


12.00-12.30 

BHPR AGM Hall 1 

12.30-14.00 

Lunch and Poster Viewing Hall 3 

Poster Tours Hall 3 

See page 13 (Please note these must be booked in advance) 

12.30-13.30 

Open meetings (see page 17) 

14.00-16.00 

C1 BSR Complementary medicine Hall 11 

Chair: Dr Gareth Jones, Aberdeen 

Aim: To firstly review the evidence on the use of complementary and alternative medicines in the 

management of rheumatic diseases. Secondly, to review the evidence from management studies of 

pain that the non-specific effects of many managements are just as important as specific effects 

25

Outcomes: An understanding of the evidence from a recent Arthritis Research UK report which examined 

the evidence in relation to oral and topical CAMs in the management of RA, OA and fibromyalgia, the 

controversial inclusion of acupuncture as a recommended treatment in the NICE guidelines for the 

management of back pain presenting to primary care and the placebo response in the management of 

pain and how it is relevant for managing patients with osteoarthritis 

Complementary and alternative medicines in management of RA, OA and fibromyalgia: 

evaluating the evidence 

Prof Gary McFarlane, Aberdeen 

Acupuncture in the management of back pain 

Dr Adrian White, Plymouth 

The placebo response and its relevance to managing patients with osteoarthritis 

Prof Paul Dieppe, Plymouth 

C2 BSR Dermatology: a joint session with BAD Hall 4 

Chair: Dr Mark Goodfield, Leeds 

Aim: To highlight topics of interest to dermatologists and rheumatologists on psoriatic disease. Patients 

are often treated separately for their skin and joint disease yet there are benefits to the patient in having 

combined consultations 

Outcomes: An understanding of the impact of joint working in screening for arthritis in people with 

psoriasis, on co-morbidities such as cardiovascular risk and clinical phenotypes of this dermatologically 

heterogeneous disease. Rheumatologists will also recognise the skin component, and the impact of 

biologic treatment on both skin and joints 

Collaborative working between dermatology and rheumatology improves disease management 

and may reduce cardiovascular risk in psoriatic disease 

Dr David Burden, Glasgow 

Screening for psoriatic arthritis in people with psoriasis: is it worth it, how may it be done 

and who should do it? 

Dr Philip Helliwell, Leeds 

Clinical phenotypes of psoriasis and classification 

Prof Christopher Griffiths, Manchester 

Treatment of psoriatic disease with biologic drugs 

Prof Neil McHugh, Bath 

BSR Concurrent oral presentation of abstracts 

Genetics and epidemiology Hall 6 

Chair: Dr Alex McGregor, Norwich 

OP16 

OP17 

OP18 

OP19 

Genetic variation in the dream pain modulation pathway is associated with the extent 

of musculoskeletal pain 

Cardiovascular risk factors are increased In people reporting chronic pain symptoms 

Baseline but not change in body mass index is a risk factor for bilateral knee pain at 15 years 

Meta-analysis of six genome-wide association studies in >25,000 case-control samples 

identifies seven new rheumatoid arthritis risk loci 

26

OP20 

OP21 

OP22 

OP23 

A specific MMP1-MMP3 haplotype is associated with high levels of MMP-1 and shows 

interaction with smoking in relation to erosive disease in rheumatoid arthritis 

The impact of post-onset pregnancy on disease outcome in women with recent onset 

inflammatory polyarthritis 

The influence of lifestyle factors on disease severity and atheromatous plaque presence in 

an early inflammatory polyarthritis cohort-results from the Norfolk Arthritis Register (NOAR) 

Genetic polymorphisms in key Methotrexate (MTX) pathway genes associated with response 

to MTX treatment in juvenile idiopathic arthritis 



Basic science Hall 7 

Chair: Prof Robert Moots, Liverpool 


OP24 HDAC activity: a therapeutic target in rheumatoid arthritis? 

OP25 Essential role for the ER stress induced transcription factor, CHOP10, in the regulation 

of IL-23 gene expression 

OP26 KIR3DL2 interaction with HLA-B27 promotes the survival of Th17 cells in ankylosing 

spondylitis 

OP27 Association of circulating matrix Metalloproteinase-8 levels with mortality in rheumatoid 

arthritis 

OP28 Novel autoantigen for anti-endothelial cell antibody (AECA) identified by proteomics in 

vasculitis 

Young Investigator Award prize winner 

OP29 Targeting the inflamed microvasculature in rheumatoid arthritis 

OP30 Lipid antigen presentation by B cells is important to trigger iNKT cell expansion for mediation 

of an anti-inflammatory response 

OP31 CXCR1/2 signalling is required for the phenotypic stability of human articular chondrocytes 


A1 BHPR Diagnosing and treating Complex Regional Pain Syndrome Hall 5 

Chair: Mr Robert Field, Bournemouth and Ms Sue Gurden, Torfaen 

Aim: To enable members of the multi-disciplinary team to identify the symptoms of Complex 

Regional Pain Syndrome (CRPS) and have an awareness of therapeutic approaches 

Outcome: An understanding of the common presenting symptoms of CRPS, including recognition 

of early disease and the potential pathological mechanisms, current therapeutic approaches, the 

therapist’s role in the care of those with CRPS and the importance of psychological support 

Diagnosing CRPS 

Dr Richard Haigh, Exeter 

Current therapeutic approaches for CRPS 

Prof Candy McCabe, Bath 

The role of the therapist in the care of CRPS 

Mr Darren Peters, Devon and Dr Jane Hall, Bath 

Psychological approaches for those with CRPS 

Dr Karen Rodham, Bath 

27

A1 BHPR What is important to people with musculoskeletal problems? Looking beyond 

the symptoms Hall 8 

Chair: Ms Vicki Cameron, London and Dr Lynne Goodacre, Preston 

Aim: To encourage health professionals to look beyond health conditions and impairments and towards 

functioning and participation in life when assessing and managing individuals with musculoskeletal 

conditions. In addition the multi-national approaches to the assessment and rehabilitation of 

participation restriction will be compared and contrasted 

Outcomes: Health professionals will learn how to apply a biopsychosocial approach to the assessment 

and management of participation in adults with musculoskeletal conditions. Delegates will also be able 

to describe individual and general factors which are important when determining restricted social 

participation in older adults with joint pain 

Understanding the impact of arthritis on role participation: measuring what matters in life 

Dr Monique Gignac, Toronto, Canada 

Improving mobility but restricting activity: the success and failures of foot health interventions 

Dr Anita Williams, Salford 

Climbing over the wall: fighting against fibromyalgia to what is important to me 

Ms Carol Rhodes and Dr Clare Jinks, Keele 

Communicating joint pain: what drives help-seeking and what’s said once you’re there? 

Ms Rachael Gooberman-Hill, Bristol 

Participating as and when you want despite the symptoms of joint disease 

Dr Ross Wilkie, Keele 

16.00-16.30 


16.30-17.30 


Chair: Prof Deborah Bax, BSR President 

Moab is my medicine: lessons and messages from 20 years of therapeutic immunology 

Prof John Isaacs, Professor of Clinical Rheumatology, University of Newcastle upon Tyne 

28

18.00-19.30 

Industry Supported Symposium 

Abbott Hall 11 

What a difference a change can make: practical solutions for the clinic 

How we need to evolve our service to meet future needs: a clinical director’s perspective 

Prof Paul Emery, Arthritis Care UK Professor of Rheumatology 

How we improved patient care without a change in resources: a clinician’s perspective 

Dr Andrew Östör, Cambridge 

The impact of practical changes on patients’ lives: patients’ perspectives 

Mrs Tricia Cornell, Poole 

TICORA in clinical practice: the inside story 

Dr Duncan Porter, Glasgow 


Industry Supported Symposium 

Roche (RoACTEMRA) Hall 8 

Your chance to participate in a satellite symposium with a difference. Join an expert faculty to 

debate current ‘inflammatory issues’ in RA. 

Introduction 

Prof David GI Scott, Norwich 

New biological treatments for RA 

Prof Peter Taylor, Imperial College, London 

Peer-to-Peer group debates 

Audience debates issues in small groups 

Feedback, discussion and closing remarks 

Prof David GI Scott, Norwich 

The debates. 

New biological drugs - optimising uptake at the front end of the treatment algorithm 

• Prof Peter Taylor, London 

• Dr Maya Buch, Leeds 

Early RA intervention to prevent radiographic progression 

• Prof Philip Conaghan, Leeds 

• Dr Allister Taggart, Belfast 

The impact of new biologicals - how should new MOA be utilised? 

• Dr Ernest Choy, London 

• Prof John Isaacs, Newcastle upon Tyne 

CV risk and RA 

• Prof George Kitas, Dudley 

The perceived risks of biological treatments in RA 

• Dr Lesley Kay, Freeman Hospital, Newcastle upon Tyne 

• Prof David GI Scott, Norwich 

How to expand access to biologics and move RA up the political agenda 

• Dr Andrew Bamji, Sidcup 

All aspects of this promotional symposium are sponsored by Roche Products Ltd and 

Chugai Pharma UK Ltd 

29

19.45-21.30 

Rheumatology 2010 Welcome Reception 

Birmingham Museum and Art Gallery 

To welcome delegates on the opening day of the annual meeting, the BSR invites you to join 

your colleagues for welcome drinks and canapés 

30

Inflammatory Issues. 

Convene. Converse. Collaborate. 

Participate in the RA Peer-to-Peer Debate. 

Wednesday 21 April 2010. 

Indian buffet 5:30pm. Symposium 6:00 - 7:30pm. 

ICC Hall 8, Level 5. 

The Chair. 

Prof David Scott, Norfolk and Norwich University Hospitals. 

Facilitating the Debates. 

Prof Peter Taylor, Imperial College, London. 

Dr Maya Buch, University of Leeds. 

Prof Philip Conaghan, University of Leeds. 

Dr Allister Taggart, City Hospital, Belfast. 

Dr Ernest Choy, King’s College Hospital, London. 

Prof John Isaacs, University of Newcastle upon Tyne. 

Prof George Kitas, Russell’s Hall Hospital, Dudley. 

Dr Lesley Kay, Freeman Hospital, Newcastle upon Tyne. 

Dr Andrew Bamji, Queen Mary's Hospital, Sidcup. 

All aspects of this symposium are sponsored by 

Chugai Pharma UK Ltd and Roche Products Ltd 

ACTE00400 February 2010 

IT DOESN’T 

TAKE A LOT 

TO MAKE A 

DIFFERENCE 

Find out how at stand 

number 73 and come 

to our symposium: 

What a difference 

a change can make: 

practical solutions 

for the clinic 

Wednesday 21st April 

18.00 – 19.30 

Hall 11 (level 3) 

Hot buffet and drinks will 

be served at the symposium 

from 17.30 

Date of preparation: February 2010 AXHUR100552




Thu 22 April 2010

BSR 

The British Society for Rheumatology 

Education 

Courses 2010 

82% 

of delegates would 

recommend the course 

to a colleague 

“Excellent - the most 

informative and 

well organised 

course I have 

ever been to!” 

Delegate, Core Course 

September 2009 

“The ‘hands on’ 

nature of the training 

was fantastic” 

Delegate, Foot and Ankle course 

September 2009 

“Very well organised, 

excellent course, 

definitely 

recommended” 

Delegate, Basic Ultrasound course 

November 2009 

“Thoroughly enjoyable” 

Delegate, Advanced Course 

December 2009 

88% 

of delegates scored our 

courses 10 out of 10 

www.rheumatology.org.uk/education


C1: Clinical stream one – Pain/injury 

C4: Clinical stream four – immunology/infection 

T1: Trainee stream 

A1: AHP stream 

Programme: Thursday 22 April 2010 

07.30-09.00 

BSR Special interest group 

Arthritis Research UK/BSR education Hall 7a 

Chair: Dr Andy Hassell, Stoke on Trent 

Aim: Themed around developments in education and education research planned by Arthritis Research 

UK and the BSR, the aim of the session is to foster projects and collaborations around education 

research and delivery within the area of musculoskeletal disorders 

Arthritis Research UK educational strategy 

Dr Andrew Hassell, Stoke on Trent 

E-rheumatology TRIP adviser: development of a project to promote evaluation of available 

electronic learning resources 

Dr David Walker, Newcastle upon Tyne 

Can educational research learn from the clinical research group model? 

Prof Helen Foster, Newcastle upon Tyne 

Collaborations on the development of e-learning opportunities 

Prof John Axford, London 


Musculoskeletal ultrasound Hall 11b 

Chair: Dr Cristina Estrach, Liverpool 

Aim: To update on the development of a UK training pathway following the success of 2009. 

In addition, in view of the raising interest and uptake of this new skill, clinical governance issues 

and regulation will be discussed, as well as the issue of allowing subgroups, such as paediatric 

rheumatology, to integrate their training under the SIG and BSR umbrella. 

Training group update on the training plans for rheumatology ultrasound in the UK 

Dr Cristina Estrach, Liverpool 

Paediatric rheumatology 

Dr Madeleine Rooney, Belfast 

The comparison of magnetic resonance imaging and ultrasonography for knee enthesitis in early 

spondyloarthritis 

Dr Sibel Aydin, Istanbul, Turkey 

Confounding factors in the acquisition of ultrasound images in patients with inflammatory arthritis 

Dr Ahmed Zayat 

33


Myositis Executive Room 2 

Chair: Dr Hector Chinoy, Manchester 

Aim: To promote collaborations within the UK myositis community, encourage a wider interest into 

myositis clinical practice and research, disseminate findings of studies and discuss future potential 

approaches 

Update on MYOGEN genetic collaboration 

Prof Michael Hanna, London 

JDM muscle pathology and mechanisms 

Dr Robert Cooper, Salford and Prof Bill Ollier, Manchester 

Assessing muscle function with isotonic tests 

Dr Lucy Wedderburn, London 

IIM fatigue and muscle fatiguability study 

Dr Patrick Kiely, London 

Novel myositis autoantibody update 

Richard Campbell 

IBM update 

Dr Harsha Gunawardena, Bath 


Osteoarthritis Hall 8a 

Chair: Dr Fraser Birrell, Newcastle upon Tyne 

Aim: To disseminate knowledge of Arthritis Research UK osteoarthritis Clinical Studies Group and provide 

networking opportunities. Delegates will know the strategy, submission and review processes of the 

Arthritis Research UK osteoarthritis Clinical Studies Group. Delegates will also learn how to become 

involved in ongoing studies. Finally delegates will have had the opportunity to network with other 

researchers and discuss research ideas 

Introduction and welcome 

Dr Fraser Birrell, Newcastle upon Tyne 

Clinical studies group for OA and related disorders strategy 

Prof Philip Conaghan, Leeds 

A series of workshops: translating ideas into action and results: 

Hand osteoarthritis 

Dr Krysia Dziedzic, Arthritis Research UK (facilitator) 

Knee osteoarthritis 

Dr George Peat, Keele (facilitator) 

Hip osteoarthritis 

Prof Nigel Arden, Southampton (facilitator) 

Plenary feedback/question and answer session 

34


Scleroderma Hall 11a 

Chair: Prof Chris Denton, London 

Aim: Assessment and treatment of scleroderma remains challenging. Exciting and novel approaches to 

assessment are the development of new biomarkers. This can be unbiased using proteomic methods 

or focused on potential pathogenic mediators. Use of KL-6 levels in scleroderma lung disease has 

been recently explored. Simple clinical tools can be invaluable and a new hand ischemia tool will be 

discussed. Finally the EULAR supported observational study of therapy in diffuse scleroderma will 

be presented, reflecting the value of rigorous analysis of best practice strategies in the context of 

investigator choice (or bias) 

Overview and introduction 

Prof Chris Denton, London 

Biomarkers in systemic sclerosis: unbiased screening strategies 

Dr Franceso del Gardo, Leeds 

Longitudinal assessment of epithelial damage in systemic sclerosis associated lung fibrosis: 

is KL-6 a biomarker? 

Dr Rachel Hoyles, Oxford 

Development and validation of a hand ischemia assessment tool in secondary Raynaud’s 

Dr Frances Hall, Cambridge 

Examining ‘biased approaches’ to treating diffuse scleroderma: the new SSc observational study 

Dr Ariane Herrick, Manchester 



Sjögren’s syndrome Hall 6b 

Chair: Dr Simon Bowman, Birmingham 

Aim: To update on clinical aspects of oral and ocular disease in Sjögren’s syndrome for general 

rheumatologists, nurse specialists and other professionals involved in the care of patients. There 

will also be an update on the MRC Registry and planned Rituximab study 

Update on management of ocular features of Sjögren’s syndrome 

Dr Saaeha Rauz, Birmingham 

Update on management of oral features of Sjögren’s syndrome 

Mr John Hamburger, Birmingham 

Update on MRC registry 

Dr Fai Ng, Newcastle Upon Tyne 

Update on Rituximab study 

Dr Simon Bowman, Birmingham 


Soft tissue rheumatism and sports medicine Hall 9 

Chair: Dr Jonathan Rees, Oxford 

Exercise prescription in inflammatory arthritis 

Aim: To explore exercise prescription in inflammatory arthritis. It will cover principles of exercise 

prescription and the new exercise prescription programme in ankylosing spondylitis 

35

Principles of exercise prescription in inflammatory arthritis 

Dr Jonathan Rees, Oxford 

Exercise prescription in anklyosing spondylitis: the new NASS (National Ankylosing Spondylitis 

Society) exercise programme 

Dr Tim Jones, Leicester 

Open sports and exercise medicine forum 

08.30-09.30 

BHPR Special interest group 

Connective tissue disease Hall 7b 

Chair: Sister Sue Brown, Bath 

Sjögren’s syndrome: an update on diagnosis and treatments 

Aim: This multi-disciplinary SIG will update you on recent developments in the diagnosis and treatment 

of Sjögren’s syndrome. The session will also include a presentation on nursing support and interventions 

for those with Sjögren’s 

Diagnosing and treating Sjögren’s syndrome 

Dr Elizabeth Price, Bath 

Supporting patients with Sjögren’s: the role of the CNS 

Sister Sue Brown, Bath 


Medicines management Hall 6a 

Chair: Dr Stewart E Glaspole 

Developing the specialist curriculum for Pharmacists 

Research agenda: adding value to the MDT 

Sharing good professional practice 

New medicines update 



Aim: The special interest group will discuss fracture liaison services within/combined with rheumatology 

services, the role of specialist nurses, AHPs, education sessions offered and how to set them up, 

pitfalls and meeting NICE standards 

Programme not available at time of going to print 

36


Rheumatoid arthritis Hall 8B 

Chair: Janet Cushnaghan, Southampton 

Sleep in rheumatoid arthritis 

Ways in which physical activity and sleep can be improved: a project 

Dr Claire Goodchild, London 

Assessing and managing sleep disturbance 

Mrs Penny Storrs, Manchester 

08.30-10.00 

Poster Viewing with Tea/Coffee Hall 3 




10.00-12.00 

C1 BSR Performing arts and sports Hall 9 

Chair: Dr Elizabeth Price, London 

Aim: To explore the injuries that affect professional dancers and athletes. Treatments and rehabilitation 

including hyper mobility, physiology of foot injuries and bone stress injuries will also be discussed 

Outcome: Delegates will gain an understanding of the injuries sustained by professional sports 

people and performers and how to treat them 

Performing arts medicine: the state of the art 

Mr Nick Allen, Birmingham Royal Ballet 

Is hypermobility the key to performing arts medicine? 

Prof Rodney Grahame, London 

Foot injures: the physiology of foot injuries in dancers, performers and athletes 

Dr Matthew Wyon, Walsall 

Bone stress injuries in dancers and athletes 

Dr Roger Wolman, London 

C4 BSR Immune system Hall 4 

Chair: Prof Michael Ehrenstein, London and Prof John Issacs, Newcastle upon Tyne 

Aim: To explore how biologic therapy is being used in autoimmune/inflammatory diseases outside the 

field of rheumatology 

Outcome: Delegates will discover whether there are any lessons that we can apply to patients from 

these other disease areas. We will also cover the mechanism of action of biologic therapy in 

autoimmunity 

37

The ups and downs of using Campath-1H (alemtuzumab) to treat multiple sclerosis 

Dr Alasdair Coles, Cambridge 

Inducing adaptive regulatory T cells in vivo to restore self-tolerance in autoimmunity: 

from autoimmune diabetes to rheumatoid arthritis 

Dr Lucienne Chatenoud, Paris, France 

Anti-TNF as a tool to unravel human immunity in patients with rheumatoid arthritis 

Prof Michael Ehrenstein, London 

Lessons learned from Rituxan Phase III trials: post hoc analyses of EXPLORER 

and LUNAR 

Prof John Monroe, San Francisco, USA 

T1 & A1 BSR So you want to do research? An Arthritis Research UK and BSR workshop Hall 5 

Co Chair: Mr Michael Patnick, Arthritis Research UK and Prof David GI Scott, Norwich 

Aim: To provide guidance to clinicians (both in training and substantive post and including AHPs) on 

the opportunities for undertaking formal research as well as combining research with clinical activities. 

Outcomes: Delegates will learn the benefits of research activity and how to combine research with full time 

clinical training. Delegates will have explored some of the research opportunities for full time clinicians 

Introduction: benefits of research activity 

Dr Tonia Vincent, London 

How to do worthwhile research whilst working full time clinically during training 

Dr Maya Buch, Leeds 

Clinical Research Fellowships: why and how 

Dr Ian Giles, London 

Research opportunities for full time clinicians: what research is feasible? 

Dr Nick Shenker, Cambridge 

Role of National Institute for Health Research 

Dr Tony Redmond, Leeds 

Role of Arthritis Research UK 

Dr Elizabeth Waterman, Arthritis Research UK 

Barriers to clinicians participating in research 

Prof Deborah Symmons, Manchester 

BHPR Plenary oral presentation of abstracts Hall 8a 

Chair: Ms Keri Hutchinson, Cardiff and Mr Laurence Wood, Keele 

OP32 

OP33 

OP34 

OP35 

OP36 

OP37 

OP38 

Is nurse-led care effective in rheumatology? A systematic review 

A missed opportunity to improve inflammatory arthritis? Access to dental hygiene: 

we could do better 

A patient perspective core set: rheumatoid arthritis patient priorities for pharmacological 

interventions (RAPP-PI) 

Patients’ opinions matter: using a patient focus group to develop therapy services 

A model osteoarthritis consultation for general practice: development by consensus 

Reducing the impact of rheumatoid arthritis fatigue: a randomized controlled trial 

of cognitive behavioural therapy 

Improvements in physical function were sustained for 2½ years following ESCAPE-knee 

pain: an integrated rehabilitation programme for chronic knee pain 

38

OP39 

The consequence of using different methods of joint assessment on the eligibility for 

access to anti-TNF in psoriatic arthritis 

Italics indicate concurrent oral presentations. Please see pages 57-70 to view all details of the session 

BSR Concurrent oral presentation of abstracts Hall 8b 

Spondyloarthropathies 

Chair: Dr Neil McHugh, Bath 

OP40 Association of IL23r and IL12b polymorphisms with psoriatic arthritis 

Young investigator award prize winner: 

OP41 Achieving minimal disease activity criteria with anti-TNF therapy in psoriatic arthritis can 

prevent progressive joint damage 

OP42 Relationship between bone formation in patients with ankylosing spondylitis and clinical signs 

and symptoms 

OP43 Ankylosing spondylitis: time from onset to effective treatment 

OP44 Golimumab, a new, human, TNF alpha antibody, administered subcutaneously every four 

weeks in psoriatic arthritis patients: 104-week efficacy and safety results of the randomized, 

placebo-controlled GO-reveal study 

OP45 Influence of baseline inflammation and oligoarthritis vs polyarthritis on psoriasis response to 

etanercept therapy in subjects with both psoriasis and psoriatic arthritis 

OP46 A 12-week randomized, double-blind, multicenter study to evaluate the early effect of 

etanercept (ETN) 100 mg Vs 50 mg weekly in subjects with ankylosing spondylitis (AS) 

OP47 Patients with well established ankylosing spondylitis show limited deterioration in a ten-year 

prospective cohort study 



12.00-14.00 

Lunch Hall 3 

BSR AGM Hall 7 

Lunch will be available at the meeting 

12.30-14.00 

A1 BHPR Prevention of work disability in patients with rheumatoid arthritis Hall 6 

Chair: Dr Lynne Goodacre, Preston and Dr Suzanne Verstappen, Manchester 

Aim: To illustrate the possibilities of managing work while having rheumatoid arthritis and to give an 

overview of possible interventions to prevent work disability in daily practice 

Outcomes: Delegates will gain an understanding of the prevention of work disability and possible 

preventative interventions 

The effect of anti-tumour necrosis factor agent use on rheumatoid arthritis work disability 

Dr Suzan Verstappen, Manchester 

Capturing work disability and barriers 

Dr Julie Keysor, Boston, USA and Dr Saralynn Allaire, Boston, USA 

39

Working with arthritis in practice 

Mr John McGregor, Arthritis Care 

Reducing work disability for people with musculoskeletal conditions: future research 

Dr Ross Wilkie, Keele 

14.00-15.30 

T1 RATs workshop Hall 11 

Chair: Dr Luke Gompels, London and Dr Claire Wenham, Oxford 

Aim: This interactive session which will provide an overview for trainees of the issues affecting the 

future of both academic rheumatology and clinical (NHS) rheumatology 

Outcomes: To identify key issues which concern trainees, for example service provision, junior 

consultant posts, funding for research and discuss these in an open, interactive session. At the end 

of the session, trainees will have had an opportunity to discuss identified issues with an experienced 

rheumatologist and be aware of how this may affect them in the future. They will have a better 

understanding of future career pathways and potential challenges 

Will I have a job and what will it be? The future for rheumatologists: clinical and academic 

Prof Chris Buckley, Arthritis Research UK and Dr Gabrielle Kingsley, London 

C4 BSR Infection and rheumatic disease Hall 1 

Chair: Dr Lesley Kay, Newcastle Upon Tyne 

Aim: This session will explore infections of bone, vaccination in immunocompromised patients and 

tropical infections and arthritis 

Outcome: Delegates will gain greater understanding of possible bone infections, vaccinations in 

patients with immune systems that have been impaired by disease or treatment and tropical infections 

and arthritis 

Infections of bone 

Speaker to be confirmed 

Vaccination in immunocompromised patients 

Dr Richard Watts, Ipswich 

Tropical infections and arthritis 

Prof Mike McKendrick, Sheffield 


Rheumatoid arthritis: clinical aspects Hall 8a 

Chair: Prof David L Scott, London 

Young Investigator Award prize winner: 

OP48 The risk of non-melanoma skin cancer in patients receiving anti-TNF therapies for rheumatoid 

arthritis: results from the British Society for Rheumatology Biologics Register 


OP49 Risk of septic arthritis in patients with rheumatoid arthritis treated with anti-TNF therapy: 

results from the BSR Biologics Register 

40

OP50 

OP51 

OP52 

OP53 

Apolipoprotein B:A1 is superior to conventional atherogenic indices for the prediction of 

atheromatous plaque in patients with early inflammatory polyarthritis: results from the 

Norfolk Arthritis Register (NOAR) 

Cardiovascular disease detected at autopsy in rheumatoid arthritis patients: results from an 

inception cohort from the 1980s-90s 

Goal directed therapy for rheumatoid arthritis in routine practice achieves increased rates of 

remission and improves function compared to usual care 

Treatment decisions in rheumatoid arthritis: do we under treat the elderly population? 



Innovations and service delivery Hall 8b 

Chair: Prof Elaine Hay, Keele 


Innovations in Rheumatology Award winner: 

Osteoporosis associated with neutralising osteoprotegerin antibodies 

Dr Philip Riches, Edinburgh 

Innovations in Rheumatology Award winner: 

Regional uveitis clinic for children with juvenile idiopathic arthritis (JIA) associated uveitis: 

addressing an unmet need 

Dr Athimalaipet V Ramanan, Bristol 

OP54 Non-persistence to anti-osteoporosis medications in the UK using the general practice 

research database (GPRD) 

OP55 West and East Midlands region-wide rheumatology case mix survey 

OP56 Who is referred to musculoskeletal clinical assessment and treatment services (CATS) at the 

primary-secondary care interface? The SAMBA study 

OP57 Clinic based MSK ultrasound in the diagnosis and treatment of shoulder pain, a randomized 

prospective study 

0P58 ‘My feet, my world’: a descriptive phenomenological study of living with feet affected by 

rheumatoid arthritis 


A1 BHPR You want to know what?! Hall 9 

Chair: Dr Sophie Taylor, Liverpool and Ms Victoria Chamberlain, Manchester 

Aim: To provide an understanding of a range of approaches for improving delivery of patient 

education/self-management group programmes. The session will also help to identify the effectiveness 

of rheumatology AHP education and the needs of carers 

Outcome: Delegates will have a wider comprehension of approaches for improving delivery of 

education programmes and how effective AHP education can be 

Setting up a patient education group: what works and what doesn’t 

Dr Alison Hammond, Salford 

What do patients really want to know? Results from the Educational Needs 

Assessment Tool (ENAT) 

Dr Jackie Hill, Leeds 

41

Education for rheumatology health professionals: is it ticking the right boxes? 

Dr Sarah Ryan, Stoke on Trent 

What do carers want to know? 

Mr Richard Bevis-Lacey, Winchester 

A1 BHPR Creating a national, supportive network for AHP rheumatology PhD 

and MSc students Hall 5 

Chair: Dr Stewart Glaspole, Brighton and Ms Dorothy Pattison, Manchester 

Aim: The BHPR clinical academic career symposium last year highlighted that many PhD and MSc 

students feel isolated as AHP musculoskeletal students. Many supervisors realised that their students 

would benefit from networking within the specialty at BHPR meetings. The AHP postgraduate student 

community in rheumatology need to develop a supportive network that is also supported by senior 

academics. This will give students both formal and informal support within the rheumatology community 

Outcome: It is hoped that this session will generate enthusiasm and help the community decide on the 

format for such a scheme 

What is a PhD or MSc and why would I want one? 

Prof Candy McCabe, Bath 

Maximising the potential from your PhD 

Dr Tessa Sanderson, Bristol 

Being an effective PhD student: the supervisor’s perspective 

Prof Jim Woodburn, Glasgow 

Where now? What features would you like for a BHPR network and for future meetings? 

Prof Sarah Hewlett, Bristol 

15.30-16.00 


16.00-16.30 

BSR Prize Giving Hall 1 

16.30-17.30 


Chair: Prof Deborah Bax, President BSR 

Clearance of cells dying by apoptosis and regulation of inflammation 

Prof Sir John Savill, Vice Principal and Head of the College of Medicine and Veterinary Medicine, 

Professor of Experimental Medicine, University of Edinburgh 

42

18.00-19.30 

Industry Supported Symposium Hall 8 

UCB Pharmaceuticals 

A patient-focused approach to the management of rheumatoid arthritis 

Welcome 

Prof Peter C Taylor, London 

A patient-led model of care: what is the RA patient really looking for? 

Mrs Ailsa Bosworth, National Rheumatoid Arthritis Society 

Meeting the needs of RA patients in the ‘real-world’ 

Dr Tony Hammond, Maidstone and Tunbridge Wells 

Spotlight on RA management: the commissioning perspective 

Mr Craig Black, Cambridge 

Treating RA: the benefits and challenges of new and emerging treatments 


Case study and discussion 


Summary and close 



Industry Supported Symposium Hall 11 

Roche (Mabthera) 

To B or not to B: what is YOUR question? 

Join a panel of experts from the field of rheumatology including Prof John Isaacs, Prof Andrea Rubbert, 

Dr Tom Sheeran and Patricia Cornell, along with GP and media medic Dr Dawn Harper who will be 

facilitating the session, at To B or not to B: what is YOUR question? A symposium session with a 

difference. With no presentations and no set agenda, To B or not to B: what is YOUR question? 

offers you the chance to choose the topics and ask the questions 

Roche financially supports every aspect of the To B or not to B: what is YOUR question? symposium 

and has chosen and reimbursed the faculty for their participation and all associated expenses. 

This is a promotional meeting 

19.30 

BHPR 25th Anniversary Dinner, Hall 4, The ICC 

43

Welcome 

A patient-led model of care: 

What is the RA patient really looking for? 

Meeting the needs of RA patients 

in the ‘real-world’ 

Spotlight on RA management: 

The commissioning perspective 

Treating RA: The benefits and challenges 

of new and emerging treatments 

Case study and discussion 


Professor Peter C Taylor 

Imperial College, London 

Mrs Ailsa Bosworth 

National Rheumatoid Arthritis Society 

Dr Tony Hammond 

Maidstone and Tunbridge Wells NHS Trust 

Mr Craig Black 

Cambridge University Hospitals NHS Foundation Trust 


Led by Professor Peter C Taylor 


BSR 

The British Society for Rheumatology




Fri 23 April 2010


Actelion Satellite Symposium 

Question Time: Rapid referral vs effective local care in PAH 

What is best for the patient? 

Friday, April 23rd 2010, 07:30 – 09:00, breakfast provided 

 

 

 

 

 

45


C3: Clinical stream three – Rheumatoid arthritis P1: Political stream 

T1: Trainee stream A1: AHP stream 

07.30-09.00 


Actelion Hall 9 

Chair: Mr Jon Snow, Journalist, TV and Radio presenter 

Co-Chair: Dr David Kiely, Sheffield 

Question Time: Rapid referral vs effective local care in PAH 


Welcome breakfast 

Welcome and introduction of the panel 

Mr Jon Snow, Journalist, TV and Radio presenter 

Managing an aggressive disease 

Dr David Kiely, Sheffield 

Question time: Panel to discuss and debate the optimal management for PAH associated 

with systemic sclerosis 

• Identification of patients: what is the value of identifying asymptomatic patients? 

• What do specialist PAH centres offer vs local care? 

Panel members: 

Prof Neil McHugh, Bath, Dr Frances Hall, Cambridge and Dr Gerry Coghlan, London 

Audience Q & A 




Amgen/GlaxoSmithKline Hall 8 

Full details are available at the Amgen/GlaxoSmithKline Stand (no 39) in Hall 3 

46

Programme: Friday 23 April 2010 

08.30-10.00 

Poster Viewing with Tea/Coffee Hall 3 



10.00-12.00 

C3, T1 BSR NOAR at 20 Hall 5 

Chair: Prof David GI Scott, Norwich 

Aim: The session will synthesise the results of 20 years of study into early arthritis in The Norfolk 

Arthritis Register. NOAR celebrates its 20th anniversary in 2010. It is one of the longest running cohort 

studies of early arthritis in the world and its findings have had a major impact on shaping our current 

understanding of the risk factors determining the development and outcome of early RA 

Outcome: Delegates will understand the results in a global context and will gain an understanding of 

the relevance of the findings to the treating of patients with early RA and managing disease outcomes 

Rewriting the chapter on RA epidemiology 

Prof Alex MacGregor, Norwich 

Susceptibility: why me? 

Dr Anne Barton, Manchester 

Therapy: what is the best treatment for me? 

Prof Deborah Symmons, Manchester 

Outcomes: what will happen to me in the long term? 

Dr Ian Bruce, Manchester 

P1, T1 Service provision in rheumatology Hall 1 

Chair: Dr Andrew Bamji, Sidcup 

Aim: To explore issues of political importance, managing biologics including ordering, exceptional 

treatment applications, audit, NICE and the Biologics Register and looking at college guidelines for 

clinics. We will also cover the ACCEA process. 

47

Outcome: Delegates will have an understanding of the above and will learn how to make the ACCEA 

process work for them 

Introduction: the politics of service provision 

Dr Andrew Bamji, Sidcup 

Providing a high quality service 

Dr Ian Rowe, Worcester 

Keeping tabs on what you do: a database solution 

Dr David Collins, Swindon 

Implementing NICE RA guidelines: a Scottish perspective 

Dr Duncan Porter, Glasgow 

Implementing NICE biologics guidelines 

Dr Raashid Luqmani, Oxford 

How to win friends and influence people: the ACCEA process - making it work for you 

Dr Colin Pease, Leeds 


Rheumatoid arthritis: aetiopathogenesis Hall 7 

(including the 2009 Michael Mason and Garrod prize winner presentations) 

Chair: Prof Andy Cope, London 

Michael Mason 2009 prize winner: 

Early rheumatoid arthritis: the window narrows 

Dr Karim Raza, Birmingham 

Garrod 2009 prize winner: 

The role of lipid rafts in lupus T cell pathology 

Dr Elizabeth Jury, London 

OP59 The value of Interleukin-17 serum level in rheumatoid arthritis immunopathogenesis 

OP60 Defective CD3+CD8+CD28- suppressor function in RA patients is partially restored after 

anti-TNFα inhibitor therapy and may be associated with reduced ICOS and PD-1 expression 


OP61 Rheumatoid synovial fibroblasts support aid expression and IG class-switching in B cells via a 

baff-dependent TLR3-stimulated pathway 


OP62 Quantifying in vivo fluorescence imaging in murine arthritis by targeting e-selectin 

OP63 TSG-6: an autocrine regulator of inflammatory joint disease? 

OP64 Osteoclast-mediated bone resorption: regulation by hypoxia-inducible factor (HIF) and 

angiopoietin-like 4 (ANGPTLl4) 



Connective tissue disease Hall 6 

Chair: Dr Arianne Herrick, Manchester 

OP65 

OP66 

Molecular and cellular evolution of functional tertiary lymphoid structures in salivary glands 

of NOD mice 

Indirect costs estimation in primary Sjögren’s syndrome 

48

OP67 Thrombocytosis and high skin score associate with elevated serum IL-6 level in systemic 

sclerosis 

OP68 A potential role for Interleukin-6 in the pathogenesis of systemic sclerosis 

OP69 Superior mesenteric artery vasculopathy in systemic sclerosis patients 

OP70 Body mass index is assiciated with malabsorption but no other clinical manifestations in 

patients with systemic sclerosis 

OP71 Naturally occurring free thiols within β 2-GLYCOPROEIN I in vivo: functional implications in 

the regulation of oxidative stress induced endothelial cell injury 

Medical Student Bursary Award winner: 

OP72 Hypovitaminosis D in patients with connective tissue disease 



A1 BHPR Footwear aiding mobility but restricting activity: the solutions? Hall 9 

Chair: Ms Andrea Graham, Salford and Ms Helene Mitchell, Leicester 

Aim: To provide a clear understanding of all factors of therapeutic footwear including the impact of foot 

problems and footwear on activity and mobility, insight into the patient’s perspective of foot problems 

and wearing footwear and to consider the importance of foot health to general wellbeing and the role 

of podiatry in achieving this 

Outcome: Delegates will have gained an understanding in all factors of therapeutic footwear 

Footwear: still a Cinderella service? 

Dr Anita Williams, Salford 

The sole of the matter: foot health and podiatry 

Dr Simon Otter, Eastbourne 

My feet versus your footwear: that is the problem 

Ms Ailsa Bosworth, NRAS 

Cosmetic surgery for feet? Function versus appearance 

Mr Frank Webb, Salford 

A1 BHPR commissioning for rheumatology Hall 11a 

Chair: Mrs Trish Cornell, Poole and Dr Kanta Kumar, Birmingham 

Aim: To provide an understanding of the process of commissioning for rheumatology. World class 

commissioning processes and issues for primary care trusts will be outlined, and the results of a pilot 

practice based commissioned community rheumatology service will be presented and the challenges of 

pathway redesign will be explored 

Outcome: Delegates will gain an understanding of the implications commissioning will have for both 

clinical practice and service delivery 

Commissioning a world class rheumatology service 

Ms Sheena Hennell, Wirrel 

A pilot practice based commissioned community rheumatology service 

Ms Dawn Homer, Birmingham and Dr Ben Empson, Birmingham 

Opportunities and threats: changing pathways of care 

Ms Susan Oliver, Oldham 

49

12.00-13.30 

Lunch Hall 3 


Cardiovascular co-morbidity in RA and SLE - RA outcomes joint session Hall 11a 

Chair: Dr George Kitas, Dudley and Dr Adam Young, St Albans 

Aim: To update on the new NIHR structure for research and development in the UK, including the 

recently developed CSG in inflammatory arthritis, and how research and development in RA is influenced 

by NICE, and a review of the new RA collaborative networks in genetics and randomised studies for 

cardiovascular disease in RA 

Introduction: CLRN and research in RA in the UK 

Dr Adam Young, St Albans 

Clinical study groups for inflammatory arthritis 

Prof John Isaacs, Norwich 

NICE and RA research 

Prof Chris Deighton, London 

Collaborative genetic and RA networks in the UK 

Dr Ann Morgan, Leeds 

Update on the TRACE study 

Dr George Kitas, Dudley 


Genetics of rheumatic disease Executive Room 2 

Chair: Dr Anne Barton, Manchester 

Aim: This special interest group will update members on progress in the fields of rheumatoid arthritis, 

juvenile idiopathic arthritis, psoriatic arthritis and ankylosing spondylitis. Enormous progress has been 

made in identifying susceptibility genes underlying many forms of inflammatory arthritis. Particular 

emphasis will be placed on how these findings may be translated in the future into clinical utility to help 

physicians. 

Rheumatoid arthritis genetics update: how do findings from susceptibility studies inform 

prognosis? 

Dr Jane Worthington, Manchester 

Gene environment interactions 

Dr Ann Morgan, Leeds 

Juvenile idiopathic arthritis: genetic similarities and differences with RA 

Dr Wendy Thomson, Manchester 

Potential to translate genetic findings into clinical practice using psoriatic arthritis as an example 

disease 

Dr Anne Barton, Manchester 

Ankylosing spondylitis: what have genetic studies taught us about the disease? 

Prof Paul Wordsworth, Oxford 

50



Chair: Dr Emma Clark, Bristol 

Aim: A general session on osteoporosis covering new medical therapies for osteoporosis and 

hyperparathyroidism that will soon be licensed, and the potential association between 

bisphosphonates and atypical subtrochanteric fractures 

Atypical subtrochanteric fractures associated with bisphosphonates 

Prof Stuart Ralston, Edinburgh 

New options in the medical treatment of hyperparathyroidism 

Dr David Hosking, Nottingham 

An update on new pharmacotherapy for osteoporosis 

Prof Jon Tobias, Bristol 



Paediatric rheumatology Hall 11b 

Chair: Dr Liza McCann, Liverpool, Dr Alison Jordan, Birmingham and Dr Lindsay Robinson, London 

Aim: To explore how services for young people with rheumatic disease can be improved. This SIG will 

stimulate discussion via feedback of an audit of current provision as well as presentations on the 

development of paediatric rheumatology networks and training in adolescent care 

Improving the experience of young people moving from paediatric to adult care: presentation of 

audit findings and interactive discussion 

Dr Alison Jordan 

Development of paediatric rheumatology networks 

Dr Kathy Bailey, Nuneaton 

Training update: including discussion of the adolescent curriculum and e-learning package 

Dr Richard Hull, Portsmouth 


Polymyalgia rheumatica and giant cell arteritis Hall 8a 

Chair: Prof Bhaskar Dasgupta, Southend 

Aim: To educate delegates on proposed new trials in PMR and GCA. These include a comparison of the 

diagnostic accuracy of temporal artery ultrasound versus biopsy, RCT of Leflunomide in PMR and GCA 

and studies with more recent glucocorticoids in PMR. Attendees will be updated on the ACR EULAR 

PMR Classification study. The attendees will also learn about proposed patient focus group based 

research on patient experiences in PMR as well as updates on the continuing development of the 

national group PMR-GC UK and regional groups for PMR and GCA 

A prospective comparative study of accuracy of temporal artery ultrasound versus biopsy 

in suspected GCA 


Update from the PMR Classification criteria prospective study 

Prof Bhaskar Dasgupta, Southend 

A randomized controlled trial of leflunomide in PMR and GCA 

Dr Nada Hassan, Southend 

The educational needs of patients with PMR and GCA 

Dr Richard Watts, Ipswich 

51

An update on the national patient group: PMR-GC UK 

PMR-GC UK representative 

Clinical trials of novel glucocorticoid formulations and delivery systems in PMR 

Dr John R Kirwan, Bristol 


Systemic lupus erythematosus Hall 8b 

Chair: Prof Ian Bruce, Manchester 

Aim: To review several ongoing studies to encourage participation across the UK including the BSR SIG 

members and focus on NIHR portfolio studies 

NIHR networks and opportunities 

SLE Special interest group speaker 

The BILAG observational cohort 

Prof Ian Bruce, Manchester and Dr E Pattison 

Lupus nephritis susceptibility and outcome 

SLE Special interest group speaker 


Vasculitis Hall 6 

Chair: Dr Raashid Luqmani, Oxford 

Aim: We will review several ongoing studies to encourage participation across the UK including the 

BSR Special interest group and focus on NIHR portfolio studies 

Classification criteria and diagnostic test in vasculitis 

Dr Neil Basu Aberdeen and Dr Richard Watts, Ipswich 

ACR/EULAR prospective study of classification and diagnostic criteria in vasculitis 

Dr Ravi Suppiah 

Quality of life in vasculitis: progress report 

Dr Neil Basu, Aberdeen 

Use of the General Practice Research Database for long term outcomes in vasculitis 


Paediatric vasculitis assessment 

Dr Nick Wilkinson, Oxford 

Disease activity and damage assessment in vasculitis 


EUVAS studies update including PEXIVAS 


13.45-15.15 

C3 BSR Biologics Register Hall 9 

Chair: Prof David Isenberg, London 

Aim: To explain the work of the BSR Biologics Register (BSRBR), latest results and plans for the future 

52

Outcomes: To understand the past, present and future of the Register. To understand the current 

data on serious adverse events for biologic therapies. To find out practical information about being a 

contributor to the Register 

A welcome and introduction to this year’s Biologics Register session, with a summary of the 

events and achievements of the previous year 

Professor David Isenberg, London 

BSRBR results and aspirations: a view from the coalface 

Dr Kimme Hyrich, Manchester 

An update from the University of Manchester’s Arthritis Research UK epidemiology unit on the 

most recent data emerging from this large national cohort: 

An insight into working on the Biologics Register from a Nurse’s perspective 

Ms Samantha Moore, London 

An insight into the future of the register and current key developments 

BSRBR Steering Committee Chair Elect 

Questions and an opportunity to voice opinions on current Register activities 


P1 ARMA late breaking session: putting musculoskeletal services centre stage Hall 5 

Aim: Following the general election the NHS faces an unprecedented and sustained period of spending 

restraint and the challenge of delivering £15-20bn savings within the next 4 years. The desired 

outcome would be transformational: a redefined NHS providing new models of care and new delivery 

organizations, more competition and patient choice, integration and patient pathways, and shifting 

delivery out of hospitals and into the community and the home. Quality and efficiency gains will be the 

buzz words. So how are musculoskeletal services positioning themselves in the face of this challenge? 

ARMA has assembled some key commentators to discuss the issues and to showcase initiatives that 

aim to reposition our work. 

Panel: 

Dame Carol Black - National Director for Health and Work, 

Paul Carroll - Assistant Director of Commissioning (Acute Services) Ashton Leigh & Wigan PCT and 

Neil Betteridge, Department of Health Patient and Public Advisor on Elective Care and Chief 

Executive, Arthritis Care 

Dr Ian Bernstein FRCGP FLCOM, Musculoskeletal Physician, Ealing and Harrow Community 

Services GP Trainer, Ealing PCT Clinical Advisor to Ealing PCT 

BHPR Prizes and awards Hall 1 

Chair: Ms Diana Finney, President BHPR 

Introduction from the panel 

Ms Diana Finney, BHPR President, Prof Alan Silman, Manchester, Ms Keri Hutchinson, Cardiff 

and Mrs Ailsa Bosworth, NRAS 

NRAS presentation of awards 

BHPR presentation of awards 

Arthritis Research UK prize winner presentations: 

Podiatry: Mr Simon Otter 

Nurse: Dr Joanna Nicklin 

Occupational Therapy: Ms Sandi Derham 

Silver medal, physiotherapy: Dr Lisa Roberts 

Silver medal, research: Dr Tessa Sanderson 

53


Osteoarthritis Hall 7 

Chair: Prof Paul Dieppe, Oxford 

OP73 

OP74 

OP75 

OP76 

OP77 

OP78 

Mechanical load drives inflammatory gene expression and disease in murine OA 

Chondrocyte IL-1β EXPRESSION is a clinically significant marker of progression and 

radiographic severity in osteoarthritis of the hip 

Mild radiographic features predict structural progression of knee osteoarthritis 

Incidence and progression of radiographic knee osteoarthritis in a symptomatic population 

Inter-rater reliability and validity of ultrasound imaging for features of osteoarthritis in the knee 

in the community 

Short-term effects of transcutaneous electrical nerve stimulation (TENS) and exercise on knee 

osteoarthritis (OA) 


15.30-16.30 

State of the Art Lecture Hall 4 

Chair: Dr Deborah Bax, President BSR 

Evolution and augury in autoimmune disease: FcRs, malaria and CD8 T cells 

Prof Ken Smith, Genzyme Professor of Experimental Medicine, Department of Medicine, 

University of Cambridge 

16.30-18.00 


MS health of the ethnic minority Executive Room 2 

Chair: Prof Kuntal Chakravarty, Brentwood 

Aim: To address issues about the health of the ethnic minority generally and to explore where MSK in 

ethnic minority stand in the national agenda. The rest of the session will be on the incidence of vasculitis 

in ethnic minorities and association with genetics followed by a talk from the Birmingham group on 

access to MSK health by ethnic minorities. This is a new Special interest group and has quickly become 

popular amongst conference delegates and BSR members. 

The influence of ethnicity on the extent of and reasons underlying delay in GP consultation in 

patients with RA 

Mrs Kanta Kumar, Birmingam and Dr Karim Raza, Birmingham 

Multiethnic minority and issues in health care: a general view 

Prof Michael Kelly 

The proposal for a national audit (HQUIP) in accessibility of musculoskeletal health in multiethnic 

minority 

Dr Ash Samanta, Leicester 

54


Heritable disorders of connective tissue Hall 8a 

Chair: Prof Rodney Grahame, London and Dr Howard Bird, Leeds 

Aim: The establishment of the new NCG Ehlers-Danlos syndrome diagnostic service is a landmark 

development, providing diagnostic assistance (clinical, genetic and laboratory) for the benefit of patients 

across the country. This meeting will provide delegates with comprehensive information on how it will 

function 

The new national commissioning group (NCG) EHLERS-DANLOS syndrome diagnostic service 

Introduction to Ehlers-Danlos syndrome 

Prof Peter Beighton 

Clinical service in Sheffield 

Dr Glenda Sobey, Elland 

Laboratory service in Sheffield 

Dr Anne Dalton, Sheffield 

Clinical service in London 

Prof Mike Pope, Harrow 

Laboratory service in London 

Dr Phillip Sawle, London 

Genetic counselling 

Dr Marion Turnbull, London 

Speakers panel: summing up and conclusions 



Musculoskeletal pain Executive Room 1 

Chair: Prof Garry Macfarlane, Aberdeen 

Musculoskeletal pain therapy: putting patients at the centre 

Aim: To assist all HCPs wanting to improve the quality of life for patients with musculoskeletal pain. 

Lay and patient attendees also welcome 

BSR musculoskeletal pain guidelines in a nutshell 

Prof Anthony Jones, Manchester 

How to make quality improvement happen 

Dr Maxine Power, Manchester 

Compliance: what are the issues? 

Dr Lis Cordingley, Manchester 

55

Oral presentation 

of abstracts 

Oral presentation 

of abstracts

BSR and BHPR oral presentation 

of abstracts – author listing 


09.00 – 10.30 


OP1 

USE OF CONSERVATIVE AND SURGICAL FOOT CARE IN RHEUMATOID ARTHRITIS: 

THE ERAS COHORT 

Michael R. Backhouse 1 , Anne-Maree Keenan 2 , Adam Young 3 , David James 3 , Nigel Cox 3 , 

Peter Williams 3 , R. Musa 3 , Philip S. Helliwell 1 , Anthony C. Redmond 1 ; 

1 

Section of Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom. 2 NIHR 

Biomedical Research Unit, University of Leeds, Leeds, United Kingdom. 3 ERAS Department of 

Rheumatology, City Hospital, St Albans, United Kingdom. 

Oral presentation of abstracts | 21-23 April 2010 

OP2 

OP3 

METHOTREXATE IS NOT DISEASE MODIFYING IN PSORIATIC ARTHRITIS: 

A NEW TREATMENT PARADIGM IS REQUIRED 

Gabrielle H. Kingsley 1 , Jonathan C. Packham 2 , Neil J. McHugh 3 , Diarmuid M. Mulherin 4 , 

George D. Kitas 5 , Kuntal Chakravarty 6 , Fowzia Ibrahim 1 , Helen Taylor 1 , Anna Kowalczyk 1 , 

Peter J. Maddison 7 , David L. Scott 1 ; 

1 

Rheumatology, King’s College London, London, United Kingdom. 2 Rheumatology, Haywood 

Hospital, Stoke on Trent, United Kingdom. 3 Rheumatology, Royal National Hospital for Rheumatic 

Diseases, Bath, United Kingdom. 4 Rheumatology, Cannock Chase Hospital, Cannock, United 

Kingdom. 5 Rheumatology, Russells Hall Hospital, Dudley, United Kingdom. 6 Rheumatology, 

Queens Hospital, Romford, United Kingdom. 7 School of Medical Science, University of Bangor, 

Bangor, United Kingdom. 

BELIMUMAB, A BLYS-SPECIFIC INHIBITOR, REDUCED DISEASE ACTIVITY, FLARES, AND 

PREDNISONE USE IN PATIENTS WITH ACTIVE SEROPOSITIVE SLE: PHASE 3 BLISS-52 STUDY 

David D’Cruz 1 , Coman Tanasescu 2 , Sandra Navarra 3 , Renato Guzman 4 , Alberto Gallacher 5 , 

Roger A. Levy 6 , Edmund K. Li 7 , Mathew Thomas 8 , Renato E. Jimenez 9 , Manuel G. Leon 10 , 

Stephen Hall 11 , Joung-Liang Lan 12 , Ho-Youn Kim 13 , Lilia Pineda 14 , John Zhong 14 , 

William W. Freimuth 14 ; 

1 

St Thomas’ Hospital, London, United Kingdom. 2 Spitalul Clinic Colentina, Bucharest, Romania. 

3 

University of Santo Tomas Hospital, Manila, Philippines. 4 Saludcoop Clinic 104, Bogota, 

Colombia. 5 Hospital Británico, Buenos Aires, Argentina. 6 Universidade do Estado do Rio de 

Janeiro, Rio de Janeiro, Brazil. 7 Prince of Wales Hospital, Hong Kong, China. 8 Kerala Institute of 

Medical Sciences, Trivandrum, India. 9 Hospital Dr Gustavo Fricke, Viña del Mar, Chile. 10 Instituto 

de Ginecología y Reproducción, Lima, Peru. 11 Cabrini Hospital, Malvern, VIC, Australia. 12 Veterans 

General Hospital , Taichung, Taiwan. 13 Catholic University, Yoido St Mary’s Hospital, Seoul, Korea, 

Republic of. 14 Human Genome Sciences, Inc., Rockville, MD, United States. 

57

11.00 – 12.30 

Rheumatoid arthritis: treatment Hall 6 

OP4 

OP5 

OP6 

OP7 

INHIBITION OF RADIOGRAPHIC PROGRESSION AND IMPROVEMENTS IN PHYSICAL FUNCTION 

AT 2 YEARS, WITH INCREASING CLINICAL EFFICACY OVER TIME, IN RHEUMATOID ARTHRITIS 

(RA) PATIENTS TREATED WITH TOCILIZUMAB (TCZ): THE LITHE STUDY 

R. Fleischmann 1 , R. Burgos-Vargas 2 , P. Ambs 3 , E. Alecock 4 , J. Kremer 5 ; 

1 

Metroplex Clinical Research Center, Dallas, TX, United States. 2 Hospital General de México, 

Mexico City, Mexico. 3 F. Hoffmann-La Roche, Basel, Switzerland. 4 F. Hoffmann-La Roche, Welwyn, 

United Kingdom. 5 Alnbany Medical Centre, Albany, NY, United States. 

BENEFIT OF CONCOMITANT DMARD USE ON THE PERSISTENCE WITH ANTI-TNF THERAPIES 

IN RHEUMATOID ARTHRITIS: RESULTS FROM THE BRITISH SOCIETY OF RHEUMATOLOGY 

BIOLOGICS REGISTER (BSRBR) 

Moetaza M. Soliman 1 , Darren M. Ashcroft 1 , Kath D. Watson 2 , Mark Lunt 2 , Deborah P. Symmons 2 , 

Kimme L. Hyrich 2 , On behalf of the BSR Biologics Register 3 ; 

1 

School of Pharmacy and Pharmaceutical Sciences, The University of Manchester, Manchester, 

United Kingdom. 2 arc Epidemiology Unit, The University of Manchester, Manchester, United 

Kingdom. 3 British Society for Rheumatology, London, United Kingdom. 

RITUXIMAB PLUS METHOTREXATE (MTX) INHIBITS JOINT DAMAGE AND IMPROVES CLINICAL 

OUTCOMES IN PATIENTS WITH EARLY, ACTIVE RHEUMATOID ARTHRITIS (RA) WHO ARE NAÏVE 

TO MTX 

Paul P. Tak 1 , William Rigby 2 , Andrea Rubbert 3 , Charles Peterfy 4 , Ronald F. van Vollenhoven 5 , 

William Stohl 6 , Eva Hessey 7 , Annie Chen 8 , Helen Tyrrell 7 , Tim Shaw 7 ; 

1 

Academic Medical Centre/University of Amsterdam, Amsterdam, Netherlands. 2 Dartmouth 

Hitchcock Medical Center, Lebanon, OH, United States. 3 University of Cologne, Cologne, Germany. 

4 

Synarc Inc., San Francisco, CA, United States. 5 Karolinska University Hospital, Stockholm, 

Sweden. 6 USC, Los Angeles, CA, United States. 7 Roche Products Ltd, Welwyn Garden City, United 

Kingdom. 8 Genentech Inc, South San Francisco, CA, United States. 

AN ASSESSMENT OF THE SERIOUS INFECTION RATE IN RITUXIMAB-TREATED RHEUMATOID 

ARTHRITIS (RA) PATIENTS WHO SUBSEQUENTLY RECEIVED OTHER BIOLOGIC THERAPIES: A 

FOLLOW-UP FROM RITUXIMAB CLINICAL TRIALS 

Mark C. Genovese 1 , Ferdinand C. Breedveld 2 , Paul Emery 3 , Stanley B. Cohen 4 , 

Edward C. Keystone 5 , Eric L. Matteson 6 , Laura S. Burke 7 , Akiko Chai 8 , William G. Reiss 9 , 

Marianne T. Sweetser 10 , Tim M. Shaw 11 ; 

1 

Immunol-Rheumatol , Stanford University, Palo Alto, CA, United States. 2 Rheumatology, Leiden 

University, Leiden, Netherlands. 3 Musculoskel Dis, Chapel Allerton Hospital, Leeds, United 

Kingdom. 4 Rheumatology, Metroplex Clin. Res. Center, Dallas, TX, United States. 5 Rheumatology, 

Mount Sinai Hospital, Toronto, ON, Canada. 6 Rheumatology, Mayo Clinic, Rochester, MN, United 

States. 7 Medical Science, Roche Inc., Welwyn Garden City, United Kingdom. 8 Biostatistics, 

Genentech, South San Francisco, CA, United States. 9 Clinical Dev, Genentech, South San 

Francisco, CA, United States. 10 Drug Safety, Biogen Idec, Cambridge, MA, United States. 11 Clin. 

Sci. Inflamm, Roche Ltd., Welwyn Garden City, United Kingdom. 

58

OP8 

OP9 

GENETIC POLYMORPHISMS IN KEY METHOTREXATE PATHWAY GENES ASSOCIATED WITH 

RESPONSE TO MTX TREATMENT IN RHEUMATOID ARTHRITIS 

Sally A. Owen 1 , Stephen Eyre 1 , Paul Martin 1 , Samantha Hider 2 , Ian N. Bruce 1 , Anne Barton 1 , 

Wendy Thomson 1 ; 

1 

arc Epidemiology Unit, The University of Manchester, Manchester, United Kingdom. 2 arc 

National Primary Care Centre, Keele University, Staffordshire, United Kingdom. 

A COMPARISION OF TOCILIZUMAB (TCZ) AND METHOTREXATE (MTX) MONOTHERAPIES IN 

MTX- OR DMARD-NAÏVE PATIENTS WITH RHEUMATOID ARTHRITIS (RA) 

G. Jones 1 , J. J. Gomez-Reino 2 , M. B. Lowenstein 3 , J. Tornero 4 , A. Sebba 5 , E. Alecock 6 , 

E. Guarin 7 , M. Genovese 8 ; 

1 

Menzies Research Institute, University of Tasmania, Hobart, TAS, Australia. 2 Universidad de 

Santiago de Compostela, Santiago de Compostela, Spain. 3 Arthritis Center, Palm Harbour, FL, 

United States. 4 Hospital General Universitario de Guadelajara, Guadelajara, Spain. 5 University 

of South Florida, Palm Harbour, FL, United States. 6 F. Hoffmann-La Roche, Welwyn, United 

Kingdom. 7 F. Hoffmann-La Roche, Basel, Switzerland. 8 Stanford University Medical center, Palo 

Alto, CA, United States. 


Case reports Hall 7 

OP10 PERCUTANEOUS ENDOSCOPIC GASTROSTOMY (PEG) FEEDING: A LIFE SAVING 

INTERVENTION IN SYSTEMIC SCLEROSIS-MYOSITIS OVERLAP WITH PHARYNGEAL 

DYSFUNCTION 

Leena Das 1 , Andrew Bowden 2 , Robert G. Cooper 1 , William Mitchell 3 , Margaret O’Sullivan 4 , 

Ariane L. Herrick 1 ; 

1 

Rheumatology, Salford Royal NHS Foundation Trust, Salford, Lancashire, United Kingdom. 

2 

Rheumatology, Rochdale Royal Infirmary, Rochdale, United Kingdom. 3 Rheumatology, Furness 

General Hospital, Barrow-In-Furness, United Kingdom. 4 Rheumatology, North East Wales NHS 

Trust, Wrexham, United Kingdom. 

OP11 RAPID RESPONSE TO ANAKINRA IN THE TREATMENT OF TRAPS 

Sarah J. Evans 1 , Thomas M. Lawson 1 , Stefan Siebert 1 ; 

1 

Rheumatology, Princess of Wales Hospital, Bridgend, United Kingdom. 

OP12 IDIOPATHIC RECURRENT PERICARDITIS: THE ROLE OF ANAKINRA AND 

IMMUNOSUPPRESSIVE TREATMENTS 

Ian C. Scott 1 , Vijay Hajela 1 ; 

1 

Rheumatology Department, University Hospital of Lewisham, London, United Kingdom. 

OP13 THORACIC SPINE OSTEITIS: A DISTINCT CLINICAL ENTITY OR A VARIANT ON SAPHO? 

A SERIES OF FOUR CASES 

Gillian M. Peffers 1 , Steven James 2 , Alistair Stirling 2 , Paresh Jobanputra 1 ; 

1 

Rheumatology, Selly Oak Hospital, Birmingham, United Kingdom. 2 Radiology, Royal Orthopaedic 

Hospital, Birmingham, United Kingdom. 

OP14 A FATAL COMBINATION: RHABDOMYOLYSIS AFTER MACROLIDE THERAPY AND A 

LONG-TERM STATIN 

Sayam R. Dubash 1 , Shehnoor Tarique 1 , Leo Pinto 2 , Syed Ayas 1 ; 

1 

Rheumatology, Aneurin Bevan Health Board, Nevill Hall Hospital, Abergavenny, United Kingdom. 

2 

Endocrinology/ General Medicine, Aneurin Bevan Health Board, Nevill Hall Hospital, 

Abergavenny, United Kingdom. 

59

OP15 INFLIXIMAB FOR SARCOIDOSIS: ANGEL OR DEVIL? 

Brian Fang 1 , Shweta Bhagat 1 , Robert Busch 1 , Helen Parfrey 1, 2 , Nicola Simler 2 , Frances Hall 1 ; 

1 

Medicine, University of Cambridge, Cambridge, Cambridgeshire, United Kingdom. 2 Department of 

Chest Medicine, Papworth Hospital, Papworth, United Kingdom. 

14.00 – 16.00 

Genetics and epidemiology Hall 6 

OP16 GENETIC VARIATION IN THE DREAM PAIN MODULATION PATHWAY IS ASSOCIATED WITH THE 

EXTENT OF MUSCULOSKELETAL PAIN 

Kate L. Holliday 1 , John McBeth 1 , Wendy Thomson 1 ; 

1 

arc Epidemiology Unit, University of Manchester, Manchester, United Kingdom. 

OP17 CARDIOVASCULAR RISK FACTORS ARE INCREASED IN PEOPLE REPORTING CHRONIC PAIN 

SYMPTOMS 

Nicola J. Goodson 1, 3 , Blair H. Smith 4 , Andreas Goebel 2, 3 ; 

1 

Rheumatology, University Hospital Aintree, Liverpool, United Kingdom. 2 Pain Relief Institute, 

Walton centre for Neurology and Neurosurgery, Liverpool, United Kingdom. 3 University of Liverpool, 

Liverpool, United Kingdom. 4 Centre of Academic Primary Care, University of Aberdeen, Aberdeen, 

United Kingdom. 

OP18 BASELINE BUT NOT CHANGE IN BODY MASS INDEX IS A RISK FACTOR FOR BILATERAL KNEE 

PAIN AT 15 YEARS 

Lyndsey M. Goulston 1 , Anushka Soni 2 , Kirsten M. White 2 , Amit Kiran 2 , Mohammed K. Javaid 2 , 

Deborah J. Hart 3 , Timothy D. Spector 3 , Nigel K. Arden 1, 2 ; 

1 

MRC Epidemiology Resource Centre, University of Southampton, Southampton, Hampshire, United 

Kingdom. 2 Musculoskeletal Biomedical Research Unit, University of Oxford, Oxford, Oxfordshire, 

United Kingdom. 3 Twin Research & Genetic Epidemiology Unit, St Thomas’ Hospital, Kings College 

London, London, United Kingdom. 

OP19 META-ANALYSIS OF SIX GENOME-WIDE ASSOCIATION STUDIES IN >25,000 CASE-CONTROL 

SAMPLES IDENTIFIES SEVEN NEW RHEUMATOID ARTHRITIS RISK LOCI 

Eli Stahl 2 , Stephen Eyre 1 , Anne Hinks 1 , Anne Barton 1 , Edward Flynn 1 , Annette Lee 5 , Jonathan 

Coblyn 2 , Gang Xie 4 , Leonid Padyukov 4 , Robert Chen 2 , Lars Klareskog 4 , Katherine Siminovitch 3 , 

Soumya Raychaudhuri 2 , Peter Gregersen 5 , Robert Plenge 2 , Jane Worthington 1 ; 

1 

Arthritis Research Campaign (arc)–Epidemiology Unit, The University of Manchester, Manchester, 

United Kingdom. 2 Division of Rheumatology, Immunology, and Allergy, Brigham and Women’s 

Hospital, Boston, MA, United States. 3 Dept of Medicine, University of Toronto, Toronto, ON, 

Canada. 4 Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden. 5 The Feinstein Institute for 

Medical Research, North Shore-Long Island Jewish Health, Manhasset, NY, United States. 

OP20 A SPECIFIC MMP1-MMP3 HAPLOTYPE IS ASSOCIATED WITH HIGH LEVELS OF MMP-1 AND 

SHOWS INTERACTION WITH SMOKING IN RELATION TO EROSIVE DISEASE IN RHEUMATOID 

ARTHRITIS 

Ying Chen 1, 2 , Peter T. Dawes 2 , Derek L. Mattey 1, 2 ; 

1 

Institute of Science and Technology in Medicine, Keele University, Stoke-on-Trent, United 

Kingdom. 2 Rheumatology, Haywood Hospital, Stoke-on-Trent, United Kingdom. 

60

OP21 THE IMPACT OF POST-ONSET PREGNANCY ON DISEASE OUTCOME IN WOMEN WITH RECENT 

ONSET INFLAMMATORY POLYARTHRITIS 

Elizabeth Camacho 1 , Tracey Farragher 1 , Mark Lunt 1 , Suzanne Verstappen 1 , Diane Bunn 2 , 

Deborah Symmons 1 ; 

1 

arc Epidemiology Unit, The University of Manchester, Manchester, United Kingdom. 2 Norfolk 

Arthritis Register, University of East Anglia, Norwich, United Kingdom. 

OP22 THE INFLUENCE OF LIFESTYLE FACTORS ON DISEASE SEVERITY AND ATHEROMATOUS 

PLAQUE PRESENCE IN AN EARLY INFLAMMATORY POLYARTHRITIS COHORT- RESULTS FROM 

THE NORFOLK ARTHRITIS REGISTER (NOAR) 

Hoda Mirjafari 1 , Tracey Farragher 1, 5 , Suzanne M. Verstappen 1 , Valentine Charlton-Menys 2 , Diane 

Bunn 3 , Tarnya Marshall 3 , Helena Edlin 4 , Paddy Wilson 3 , Deborah P. Symmons 1 , Ian N. Bruce 1 ; 

1 

arc Epidemiology Unit, The University of Manchester, Manchester, United Kingdom. 

2 

Cardiovascular Research Group, The University of Manchester, Manchester, United Kingdom. 

3 

Norfolk and Norwich University Hospital, Norfolk, United Kingdom. 4 Department of Vascular 

Surgery, Manchester Royal Infirmary, Manchester, United Kingdom. 5 Centre for Medical Statistics 

and Health Evaluation, The University of Liverpool, Liverpool, United Kingdom. 


OP23 GENETIC POLYMORPHISMS IN KEY METHOTREXATE (MTX) PATHWAY GENES ASSOCIATED 

WITH RESPONSE TO MTX TREATMENT IN JUVENILE IDIOPATHIC ARTHRITIS 

Anne Hinks 1 , Halima Moncrieffe 2 , Paul Martin 1 , Sham D. Lal 1 , Simona Ursu 2 , Laura Kassoumeri 2 , 

Lucy R. Wedderburn 2 , Wendy Thomson 1 ; 

1 

arc epidemiology unit, University of Manchester, Manchester, United Kingdom. 2 Rheumatology 

Unit, UCL Institute of Child Health, London, United Kingdom. 

Basic science Hall 7 

OP24 HDAC ACTIVITY: A THERAPEUTIC TARGET IN RHEUMATOID ARTHRITIS? 

Justin Gillespie 1 , Sinisa Savic 1 , Chi Wong 1 , Paul Emery 1 , Ron Grigg 2 , Michael F. McDermott 1 ; 

1 

NIHR Leeds Musculoskeletal Biomedical Research Unit (LMBRU) , Leeds Institute of Molecular 

Medicine (LIMM) , Leeds, United Kingdom. 2 Molecular Innovation, Diversity and Automated 

Synthesis (MIDAS) Centre, School of Chemistry, Leeds, United Kingdom. 

OP25 ESSENTIAL ROLE FOR THE ER STRESS INDUCED TRANSCRIPTION FACTOR, CHOP10, 

IN THE REGULATION OF IL-23 GENE EXPRESSION 

Jane C. Goodall 1 , Changxin Wu 1 , Yongsheng Zhang 1 , Lou Ellis 1 , Louise O’Brien 1 , Hill Gaston 1 ; 

1 

Medicine, University of Cambridge, Cambridge, United Kingdom. 

OP26 KIR3DL2 INTERACTION WITH HLA-B27 PROMOTES THE SURVIVAL OF TH17 CELLS IN 

ANKYLOSING SPONDYLITIS 

Simon Kollnberger 1 , Anna Ridley 1 , Jacqueline Shaw 1 , Antoni T. Chan 1 , Fraser Cummings 1 , 

Miles Fleming 1 , Paul Bowness 1 ; 

1 

MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, Oxford, United 

Kingdom. 

OP27 ASSOCIATION OF CIRCULATING MATRIX METALLOPROTEINASE-8 LEVELS WITH MORTALITY IN 

RHEUMATOID ARTHRITIS 

Derek L. Mattey 1, 2 , Nicola B. Nixon 2 , Peter T. Dawes 2 ; 

1 

Institute of Science and Technology in Medicine, Keele University, Stoke-on-Trent, United 

Kingdom. 2 Rheumatology, Haywood Hospital, Stoke-on-Trent, United Kingdom. 

61

OP28 NOVEL AUTOANTIGEN FOR ANTI-ENDOTHELIAL CELL ANTIBODY (AECA) IDENTIFIED BY 

PROTEOMICS IN VASCULITIS 

Rie Karasawa 1 , Tomohiro Kato 2 , Shoichi Ozaki 3 , Kazuo Yudoh 1 ; 

1 

Institute of Medical Science, St. Marianna University School of Medicine, Kawasaki, Japan. 

2 

Department of Biochemistry, St. Marianna University School of Medicine, Kawasaki, Japan. 

3 

Department of Rheumatology and Allergy, St. Marianna University School of Medicine, Kawasaki, 

Japan. 

Young investigator award winner: 

OP29 TARGETING THE INFLAMED MICROVASCULATURE IN RHEUMATOID ARTHRITIS 

Sarah E. Wythe 1 , Dani DiCara 1 , Ciara Finucane 3 , Stella Man 2 , Rita Jones 1 , Ahuva Nissim 2 , 

Stephen J. Mather 3 , Yuti Chernajovsky 2 , Pitzalis Costantino 1 ; 

1 

Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts 

and The London School of Medicine and Dentistry, London, United Kingdom. 2 Bone and Joint 

Research Unit, William Harvey Research Institute, Barts and The London School of Medicine and 

Dentistry, London, United Kingdom. 3 Centre for Molecular Oncology & Imaging, Institute of Cancer, 

Barts and The London School of Medicine and Dentistry, London, United Kingdom. 

OP30 LIPID ANTIGEN PRESENTATION BY B CELLS IS IMPORTANT TO TRIGGER INKT CELL EXPANSION 

FOR MEDIATION OF AN ANTI-INFLAMMATORY RESPONSE 

Anneleen Bosma 1 , Rita Vasconcellos 1 , Natalie A. Carter 1 , David A. Isenberg 1 , Elizabeth C. Jury 1 , 

Claudia Mauri 1 ; 

1 

Centre for Rheumatology Research, University College London, London, United Kingdom. 

OP31 CXCR1/2 SIGNALLING IS REQUIRED FOR THE PHENOTYPIC STABILITY OF HUMAN ARTICULAR 

CHONDROCYTES 

Joanna C. Sherwood 1 , Pramod Achan 1 , Manoj Ramachandran 1 , Costantino Pitzalis 1 , 

Francesco Dell’Accio 1 ; 

1 

Centre for Experimental Medicine and Rheumatology, Barts and The London School of Medicine 

and Dentistry, London, United Kingdom. 


10.00 – 12.00 

BHPR plenary oral presentation of abstracts Hall 8a 

OP32 IS NURSE-LED CARE EFFECTIVE IN RHEUMATOLOGY? A SYSTEMATIC REVIEW 

Mwidimi Ndosi 1 , Karen Vinall 1 , Claire Hale 1, 3 , Howard Bird 2 , Jackie Hill 1 ; 

1 

Academic & Clinical Unit for Musculoskeletal Nursing, University of Leeds, Leeds, United 

Kingdom. 2 Academic Section of Musculoskeletal Disease, University of Leeds, Leeds, United 

Kingdom. 3 School of Healthcare, University of Leeds, Leeds, United Kingdom. 

OP33 A MISSED OPPORTUNITY TO IMPROVE INFLAMMATORY ARTHRITIS? ACCESS TO DENTAL 

HYGIENE WE COULD DO BETTER 

Patricia Cornell 1 , Sarah Westlake 1 , Selwyn Richards 1 ; 

1 

Rheumatology Department, Poole Hospital NHS Foundation Trust, Poole, United Kingdom. 

62

OP34 A PATIENT PERSPECTIVE CORE SET: RHEUMATOID ARTHRITIS PATIENT PRIORITIES FOR 

PHARMACOLOGICAL INTERVENTIONS (RAPP-PI) 

Tessa Sanderson 1 , Michael Calnan 2 , Marianne Morris 1 , Pam Richards 3 , Sarah Hewlett 1 ; 

1 

University West of England, Bristol, United Kingdom. 2 Kent University, Canterbury, United 

Kingdom. 3 Bristol University, Bristol, United Kingdom. 

OP35 PATIENTS’ OPINIONS MATTER: USING A PATIENT FOCUS GROUP TO DEVELOP THERAPY 

SERVICES 

Amanda Richards 1 , Sophie Taylor 1, 2 ; 

1 

Therapies Department, Royal Liverpool and Broadgreen University Hospitals NHS Trust, 

Liverpool, United Kingdom. 2 Faculty of Health, Psychology and Social Care, Manchester 

Metropolitan University, Manchester, United Kingdom. 

OP36 A MODEL OSTEOARTHRITIS CONSULTATION FOR GENERAL PRACTICE: DEVLOPMENT BY 

CONSENSUS 

Mark Porcheret 1 , Janet Grime 1 , Kelvin Jordan 1 , Krysia Dziedzic 1 ; 

1 

Arthritis Research Campaign National Primary Care Centre, Keele University, Keele, 

Staffordshire, United Kingdom. 


OP37 REDUCING THE IMPACT OF RHEUMATOID ARTHRITIS FATIGUE: A RANDOMIZED CONTROLLED 

TRIAL OF COGNITIVE BEHAVIOURAL THERAPY 

Sarah Hewlett 1 , Nick Ambler 2 , Bev Knops 2 , Alena Cliss 1 , Celia Almeida 1 , Denise Pope 3 , Alison 

Hammond 4 , Annette Swinkels 1 , Karen Kitchen 3 , Jon Pollock 1 ; 

1 

University of the West of England, Bristol, United Kingdom. 2 Frenchay Hospital, Bristol, United 

Kingdom. 3 University Hospitals, Bristol, United Kingdom. 4 University of Salford, Salford, United 

Kingdom. 

OP38 IMPROVEMENTS IN PHYSICAL FUNCTION WERE SUSTAINED FOR 2½ YEARS FOLLOWING 

ESCAPE-KNEE PAIN: AN INTEGRATED REHABILITATION PROGRAMME FOR CHRONIC KNEE 

PAIN 

Mike Hurley 1 , Nicola Walsh 2 , Helene Mitchell 3 , Jennifer Nicholas 4 ; 

1 

Academic Physiotherapy, King’s College London, London, United Kingdom. 2 Faculty of Health 

Life Sciences, University of the West of England, Bristol, United Kingdom. 3 Psychology 

Department, De Montfort University, Leicester, United Kingdom. 4 Health and Social Care 

Research Division, King’s College London, London, United Kingdom. 

OP39 THE CONSEQUENCE OF USING DIFFERENT METHODS OF JOINT ASSESSMENT ON THE 

ELIGIBILITY FOR ACCESS TO ANTI-TNF IN PSORIATIC ARTHRITIS. 

Stephen H. Day 1 , Sayqa Butt 1 , Chris Deighton 1 , Kate Gadsby 1 ; 

1 

Rheumatology, Derby Royal Hospital, Derby, Derbyshire, United Kingdom. 

Spondyloarthropathies Hall 8b 

OP40 ASSOCIATION OF IL23R & IL12B POLYMORPHISMS WITH PSORIATIC ARTHRITIS. 

Deepak R. Jadon 1 , Charlotte Cavill 2 , Nicola Waldron 1 , Ann Barton 3 , Eleanor Korendowych 1 , 

Neil J. McHugh 1, 2 ; 

1 

Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom. 

2 

Rheumatology, Bath Institute for Rheumatic Diseases, Bath, United Kingdom. 3 arc Epidemiology 

Unit, University of Manchester, Manchester, United Kingdom. 

63


OP41 ACHIEVING MINIMAL DISEASE ACTIVITY CRITERIA WITH ANTI-TNF THERAPY IN PSORIATIC 

ARTHRITIS CAN PREVENT PROGRESSIVE JOINT DAMAGE 

Laura C. Coates 1 , Philip S. Helliwell 1 ; 

1 

LIMM, Section of Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom. 

OP42 RELATIONSHIP BETWEEN BONE FORMATION IN PATIENTS WITH ANKYLOSING SPONDYLITIS 

AND CLINICAL SIGNS AND SYMPTOMS 

D. van der Heijde 1 , P. Emery 2 , K. Patra 3 , F. Lavie 4 ; 

1 

Leiden University Medical Center, Leiden, Netherlands. 2 Leeds Teaching Hospital, Leeds, United 

Kingdom. 3 Abbott Laboratories, Abbott Park, IL, United States. 4 Abbott Laboratories, Rungis, 

France. 

OP43 ANKYLOSING SPONDYLITIS: TIME FROM ONSET TO EFFECTIVE TREATMENT 

Jane Skerrett 1 , Ingrid van der Weide 1 , Julie Barlow 2 , Andrew Keat 3 ; 

1 

National Ankylosing Spondylitis Society, Richmond, United Kingdom. 2 Coventry University, 

Coventry, United Kingdom. 3 Rheumatology, Northwick Park Hospital, Harrow, United Kingdom. 

OP44 GOLIMUMAB, A NEW, HUMAN, TNFα ANTIBODY, ADMINISTERED SUBCUTANEOUSLY EVERY 4 

WEEKS IN PSORIATIC ARTHRITIS PATIENTS: 104-WEEK EFFICACY AND SAFETY RESULTS OF 

THE RANDOMIZED, PLACEBO-CONTROLLED GO-REVEAL STUDY 

Dafna Gladman 1 , Arthur Kavanaugh 2 , Chandrabhusan Chattopadhyay 3 , Philip Mease 4 , Gerald G. 

Krueger 5 , Julie Zrubek 6 , Anna Beutler 6 , Benjamin Hsu 6 , Surekha Mudivarthy 6 , Michael Mack 6 , 

Iain B. McInnes 7 , On behalf of the GO-REVEAL Investigators 6 ; 

1 

Toronto Western Hospital, Toronto, ON, Canada. 2 University of California San Diego, La Jolla, CA, 

United States. 3 Wrightington Hospital, Wigan, United Kingdom. 4 Swedish Hospital Clinical 

Research Center, Seattle, WA, United States. 5 University of Utah Health Sciences Center, Salt 

Lake City, UT, United States. 6 Centocor Research & Development, Inc., Malvern, PA, United 

States. 7 University of Glasgow, Glasgow, United Kingdom. 

OP45 INFLUENCE OF BASELINE INFLAMMATION AND OLIGOARTHRITIS VERSUS POLYARTHRITIS ON 

PSORIASIS RESPONSE TO ETANERCEPT THERAPY IN SUBJECTS WITH BOTH PSORIASIS AND 

PSORIATIC ARTHRITIS 

Bruce Kirkham 1 , Oliver FitzGerald 2 , Debbie Robertson 3 , Joanne Estojak 3 , Joanne Foehl 3 , 

Charles Molta 3 , Bruce Freundlich 3 ; 

1 

Guy’s and St. Thomas’s Hospital, London, United Kingdom. 2 University College Dublin School of 

Medicine and Medical Science, Dublin, Ireland. 3 Pfizer Inc, Collegeville, PA, United States. 

OP46 A 12-WEEK RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY TO EVALUATE THE EARLY 

EFFECT OF ETANERCEPT (ETN) 100 MG VS 50 MG WEEKLY IN SUBJECTS WITH ANKYLOSING 

SPONDYLITIS (AS) 

Federico Navarro 1 , Jose Luis Fernandez Sueiro 2 , Juan Carlos Torre Alonso 3 , Ruben Queiro 4 , 

Carlos Gonzalez 5 , Jordi Gratacos 6 , Eduardo Loza 7 , Luis Linares 8 , Pedro Zarco 9 , Xavier Juanola 10 , 

Jose Andrés Román Ivorra 11 , Emilio Martín Mola 12 , Raimon Sanmartí 13 , Juan Mulero 14 , 

Gema Díaz 15 , Ejessie Alfonso 16 , Eduardo Collantes 17 ; 

1 

H Virgen Macarena, Sevilla, Spain. 2 H Juan Canalejo, A Coruña, Spain. 3 H Monte Naranco, 

Oviedo, Spain. 4 H Central de Asturias, Oviedo, Spain. 5 H Gregorio Marañon, Madrid, Spain. 

6 

H Parc Taulí, Barcelona, Spain. 7 H Civil de Navarra, Pamplona, Spain. 8 H Virgen de la Arrixaca, 

Murcia, Spain. 9 H Fundación Alcorcón, Alcorcón, Spain. 10 H de Bellvitge, Barcelona, Spain. 

11 

H Dr Peset, Valencia, Spain. 12 H La Paz, Madrid, Spain. 13 H Clinic i Provincial, Barcelona, Spain. 

14 

H Puerta de Hierro, Madrid, Spain. 15 Fundacion Jiménez Díaz , Madrid, Spain. 16 Wyeth, Madrid, 

Spain. 17 H Reina Sofía, Cordoba, Spain. 

64

OP47 PATIENTS WITH WELL-ESTABLISHED ANKYLOSING SPONDYLITIS SHOW LIMITED 

DETERIORATION IN A 10 YEAR PROSPECTIVE COHORT STUDY 

Emma L. Healey 1, 3 , Kirstie L. Haywood 2, 1 , Kelvin P. Jordan 1 , Andrew M. Garratt 4 , 

Jonathan C. Packham 3, 1 ; 

1 

Arthritis Research Campaign National Primary Care Centre, Keele University, 

Newcastle-under-Lyme, Staffordshire, United Kingdom. 2 Royal College of Nursing Institute, 

School of Health & Social Studies, University of Warwick, Coventry, West Midlands, United 

Kingdom. 3 Staffordshire Rheumatology Centre, Haywood Hospital, Stoke-on-Trent, Staffordshire, 

United Kingdom. 4 National Resource Centre for Rehabilitation in Rheumatology, Diakonhjemmet 

Hospital, Oslo, Norway. 

14.00 – 15.30 

Rheumatoid arthritis: clinical aspects Hall 8a 


OP48 THE RISK OF NON-MELANOMA SKIN CANCER IN PATIENTS RECEIVING ANTI-TNF THERAPIES 

FOR RHEUMATOID ATHRITIS: RESULTS FROM THE BRITISH SOCIETY FOR RHEUMATOLOGY 

BIOLOGICS REGISTER 

Louise K. Mercer 1 , William G. Dixon 1 , Kath D. Watson 1 , James Galloway 1 , Mark Lunt 1 , . BSRBR 

Control Centre Consortium 1 , Deborah P. Symmons 1 , Kimme L. Hyrich 1 , . on behalf of the BSR 

Biologics Register 2 ; 

1 

arc Epidemiology Unit, The University of Manchester, Manchester, United Kingdom. 2 British 

Society for Rheumatology, London, United Kingdom. 



OP49 RISK OF SEPTIC ARTHRITIS IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH 

ANTI-TNF THERAPY: RESULTS FROM THE BSR BIOLOGICS REGISTER (BSRBR) 

James Galloway 1 , Kimme Hyrich 1 , Louise Mercer 1 , Will Dixon 1 , Andy Ustianowski 2 , Kath Watson 1 , 

Mark Lunt 1 , . BSRBR Control Centre Consortium 3 , Deborah Symmons 1 , . On behalf of the BSR 

Biologics Register 1 ; 

1 

arc Epidemiology Unit, University of Manchester, Manchester, United Kingdom. 2 Department of 

Infectious Diseases and Tropical Medicine, North Manchester General Hospital, Manchester, 

United Kingdom. 3 British Society of Rheumatology, London, United Kingdom. 

OP50 APOLIPOPROTEIN B:A1 IS SUPERIOR TO CONVENTIONAL ATHEROGENIC INDICES FOR 

THE PREDICTION OF ATHEROMATOUS PLAQUE IN PATIENTS WITH EARLY INFLAMMATORY 

POLYARTHRITIS- RESULTS FROM THE NORFOLK ARTHRITIS REGISTER (NOAR) 

Hoda Mirjafari 1 , Mark Lunt 1 , Valentine Charlton-Menys 2 , Diane Bunn 3 , Helena Edlin 4 , Tarnya 

Marshall 3 , Paddy Wilson 3 , Deborah P. Symmons 1 , Ian N. Bruce 1 ; 

1 

arc Epidemiology Unit, The University of Manchester, Manchester, United Kingdom. 

2 

Cardiovascular Research Group, The University of Manchester, Manchester, United Kingdom. 

3 

Norfolk and Norwich University Hospital, Manchester, United Kingdom. 4 Department of Vascular 

Surgery, Manchester Royal Infirmary, Manchester, United Kingdom. 

OP51 CARDIOVASCULAR DISEASE DETECTED AT AUTOPSY IN RHEUMATOID ARTHRITIS PATIENTS: 

RESULTS FROM AN INCEPTION COHORT FROM THE 1980S-90s 

Nicola J. Goodson 1, 2 , Kate Morgan 4 , Jeff Marks 3 , Deborah P. Symmons 2 ; 

1 

Rheumatology, University Hospital Aintree, Liverpool, United Kingdom. 2 arc Epidemiology Unit, 

University of Manchester, Manchester, United Kingdom. 3 Rheumatology, Stepping Hill Hospital, 

Stockport, United Kingdom. 4 Histopathology, Stepping Hill Hospital, Stockport, United Kingdom. 

65

OP52 GOAL DIRECTED THERAPY FOR RHEUMATOID ARTHRITIS IN ROUTINE PRACTICE ACHIEVES 

INCREASED RATES OF REMISSION AND IMPROVES FUNCTION COMPARED TO USUAL CARE 

Nicola Gullick 1 , Stephen Oakley 1 , Tim Jones 1 , Alan Mistlin 1 , Jon Rees 1 , Terence Gibson 1 , 

Gabriel Panayi 1 , Bruce Kirkham 1 ; 

1 

Guy’s & St Thomas’ Hospital, London, United Kingdom. 

OP53 TREATMENT DECISIONS IN RHEUMATOID ARTHRITIS: DO WE UNDERTREAT THE ELDERLY 

POPULATION? 

Margaret H. Ma 1 , Fowzia Ibrahim 1 , Louise Pollard 1 , Zsuzsa Fekete 2 , Gabrielle H. Kingsley 3 , 

David L. Scott 1 ; 

1 

Rheumatology, King’s College Hospital, London, United Kingdom. 2 Rheumatology, Országos 

Reumatológiai és Fizioterápiás Intézet, Budapest, Hungary. 3 Rheumatology, University Hospital 

Lewisham, London, United Kingdom. 

Innovations and service delivery Hall 8b 

OP54 NON-PERSISTENCE TO ANTI-OSTEOPOROSIS MEDICATIONS IN THE UK USING THE GENERAL 

PRACTICE RESEARCH DATABASE (GPRD) 

Lin Li 1 , Andrew Roddam 2 , Matt Gitlin 3 , Andrew Taylor 2 , Susan Shepherd 2 , Susan Jick 1 ; 

1 

The Boston Collaborative Drug Surveillance Program, Lexington, MA, United States. 2 Amgen UK, 

Uxbridge, United Kingdom. 3 Amgen (Europe) GmBH, Zug, Switzerland. 

OP55 WEST AND EAST MIDLANDS REGION-WIDE RHEUMATOLOGY CASE MIX SURVEY 

Sangeetha Baskar 1 , Karen Obrenovic 1 , George Hirsch 1 , Anupam Paul 1 , Peter Lanyon 3 , Nicola Erb 1 , 

Ian F. Rowe 2 ; 

1 

Rheumatology, Dudley Group of Hospitals, Dudley, United Kingdom. 2 Rheumatology, Worcester 

Royal Infirmary, Worcester, United Kingdom. 3 Rheumatology, Nottingham Univerisity Hospital, 

Nottingham, United Kingdom. 

OP56 WHO IS REFERRED TO MUSCULOSKELETAL CLINICAL ASSESSMENT AND TREATMENT 

SERVICES AT THE PRIMARY-SECONDARY CARE INTERFACE? THE SAMBA STUDY 

Edward Roddy 1, 2 , Irena Zwierska 1 , Peter Dawes 2 , Samantha L. Hider 1, 2 , Kelvin P. Jordan 1 , 

Jon Packham 2, 1 , Kay Stevenson 2, 3 , Elaine Hay 1, 2 ; 

1 

Arthritis Research Campaign National Primary Care Centre, Keele University, Stoke-on-Trent, 

United Kingdom. 2 Staffordshire Rheumatology Centre, Haywood Hospital, Stoke-on-Trent, United 

Kingdom. 3 University Hospital of North Staffordshire, Stoke-on-Trent, United Kingdom. 

OP57 CLINIC BASED MSK ULTRASOUND IN THE DIAGNOSIS AND TREATMENT OF SHOULDER PAIN: 

A RANDOMIZED PROSPECTIVE STUDY. 

Aamir Saeed 1 , Mumtaz Khan 1 , Siobhan Morrissey 1 , Alexander Fraser 1 ; 

1 

Rheumatology, Mid Western Regional Hospital, Limerick, Ireland. 

OP58 MY FEET, MY WORLD: A DESCRIPTIVE PHENOMENOLOGICAL STUDY OF LIVING WITH FEET 

AFFECTED BY RHEUMATOID ARTHRITIS 

Steven Walmsley 2 , Anita E. Williams 2 , Michael Ravey 1 , Andrea Graham 2 ; 

1 

Centre for Nursing, Midwifery & Collaborative Research , University of Salford, Greater 

Manchester, United Kingdom. 2 Directorate of Prosthetics, Orthotics and Podiatry and Centre for 

Rehabilitation & Human Performance Research, University of Salford, Greater Manchester, United 

Kingdom. 

66


10.00 – 12.00 

Rheumatoid arthritis: aetiopathogenesis Hall 7 

OP59 THE VALUE OF INTERLEUKIN-17 SERUM LEVEL IN RHEUMATOID ARTHRITIS 

IMMUNOPATHOGENESIS 

Iuliia V. Biliavska 1 , Oleg P. Bortkevych 1 ; 

1 

Noncoronarogenic Diseases of Myocardium and Clinical Rheumatology, National Scientific 

Center ‘Acad. M.D. Strazhesko Institute of Cardiology’, Kyiv, Ukraine. 

OP60 DEFECTIVE CD3+CD8+CD28- SUPPRESSOR FUNCTION IN RA PATIENTS IS PARTIALLY 

RESTORED AFTER ANTI-TNFα INHIBITOR THERAPY AND MAY BE ASSOCIATED WITH REDUCED 

ICOS AND PD-1 EXPRESSION 

Sabrina Ceeraz 1 , Jo Spencer 2 , Ernest H. Choy 1 , Valerie Corrigall 1 ; 

1 

Academic Department of Rheumatology, Centre of Molecular and Cellular Biology of 

Inflammation, King’s College, London, United Kingdom. 2 Department of Immunobiology, King’s 

College, London, United Kingdom. 



OP61 RHEUMATOID SYNOVIAL FIBROBLASTS SUPPORT AID EXPRESSION AND IG 

CLASS-SWITCHING IN B CELLS VIA A BAFF-DEPENDENT TLR3-STIMULATED PATHWAY 

Michele Bombardieri 1 , Yvonne Ngar Woon Kam 1 , Fabia Brentano 2 , Ken Choi 1 , Diego Kyburz 2 , 

Steffen Gay 2 , Iain B. McInnes 3 , Costantino Pitzalis 1 ; 

1 

Queen Mary University of London, William Harvey Research Institute, Centre for Experimental 

Medicine and Rheumatology, London, United Kingdom. 2 University Hospital Zürich Department of 

Rheumatology, Zurich, Switzerland. 3 Glasgow Biomedical Research Centre, University of Glasgow, 

Glasgow, United Kingdom. 


OP62 QUANTIFYING IN VIVO FLUORESCENCE IMAGING IN MURINE ARTHRITIS BY TARGETING 

E-SELECTIN 

Luke L. Gompels 1 , Tonia Vincent 1 , Leigh Madden 1 , Ngee H. Lim 1 , Ellen McConnell 2 , 

Kay Mcnamee 1 , Dorian O. Haskard 2 , Ewa M. Paleolog 1 ; 

1 

Kennedy Institute of Rheumatology, Imperial College, London, United Kingdom. 2 Eric Bywaters 

Centre, National Heart and Lung Institute, Imperial College, London, United Kingdom. 

OP63 TSG-6: AN AUTOCRINE REGULATOR OF INFLAMMATORY JOINT DISEASE? 

Catherine Swales 1 , David J. Mahoney 1 , Nicholas A. Athanasou 1 , Michele Bombardieri 2 , 

Costantino Pitzalis 2 , Omar Sharif 3 , Anthony J. Day 4 , Caroline M. Milner 4 , Afsie Sabokbar 1 ; 

1 

Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar 

Research Centre, Oxford, United Kingdom. 2 Department of Experimental Medicine and 

Rheumatology, William Harvey Research Institute, London, United Kingdom. 3 Department of 

Anatomy, University of Bristol, Bristol, United Kingdom. 4 Wellcome Trust Centre for Cell-Matrix 

Research, University of Manchester, Manchester, United Kingdom. 

67

OP64 OSTEOCLAST-MEDIATED BONE RESORPTION: REGULATION BY HYPOXIA-INDUCIBLE FACTOR 

(HIF) AND ANGIOPOIETIN-LIKE 4 (ANGPTL4) 

Helen Knowles 1 , Anne-Marie Cleton-Jansen 2 , Eberhard Korsching 3 , Nick Athanasou 1 ; 

1 

Nuffield Dept of Orthopaedics Rheumatology and Musculoskeletal Sciences, University of Oxford, 

Oxford, United Kingdom. 2 Dept of Pathology, Leiden University Medical Centre, Leiden, 

Netherlands. 3 Pathology Institute, University of Munster, Munster, Germany. 

Connective tissue disease Hall 6 

OP65 MOLECULAR AND CELLULAR EVOLUTION OF FUNCTIONAL TERTIARY LYMPHOID STRUCTURES 

IN SALIVARY GLANDS OF NOD MICE 

Elisa Astorri 1 , Michele Bombardieri 1 , Elisa Corsiero 1 , Silvia Gabba 1 , Francesca Barone 2 , 

Gordon Proctor 3 , Costantino Pitzalis 1 ; 

1 

Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen 

Mary University, London, United Kingdom. 2 Department of Immunobiology, King’s College, London, 

United Kingdom. 3 Dental Institute, King’s College, London, United Kingdom. 

OP66 INDIRECT COSTS ESTIMATION IN PRIMARY SJÖGREN’S SYNDROME 

Simon J. Bowman 1 , Yvan St Pierre 2 , Nurhan Sutcliffe 3 , David A. Isenberg 4 , Fiona Goldblatt 4 , 

Elizabeth Price 5 , John Hamburger 6 , Andrea Richards 6 , Saaeha Rauz 7 , Marian Regan 8 , 

Adrian Jones 9 , Shirley Rigby 10 , Diarmiud Mulherin 11 , Ann Clarke 2 ; 

1 

Rheumatology, Selly Oak Hospital, Birmingham, United Kingdom. 2 McGill University, Montreal, QC, 

Canada. 3 Rheumatology, Barts & the Royal London Hospital, London, United Kingdom. 

4 

Rheumatology, University College London Hospital, London, United Kingdom. 5 Rheumatology, 

Great Western Hospital, Swindon, United Kingdom. 6 Oral Medicine, Birmingham Dental Hospital & 

School, Birmingham, United Kingdom. 7 Academic Unit of Ophthalmology, University of 

Birmingham, Birmingham, United Kingdom. 8 Rheumatology, Derbyshire Royal Infirmary, Derbyshire, 

United Kingdom. 9 Rheumatology, Nottingham University Hospital, Nottingham, United Kingdom. 

10 

Rheumatology, Warwick Hospital, Warwick, United Kingdom. 11 Rheumatology, Cannock Chase 

Hospital, Cannock, United Kingdom. 

OP67 THROMBOCYTOSIS AND HIGH SKIN SCORE ASSOCIATE WITH ELEVATED SERUM IL-6 LEVEL IN 

SYSTEMIC SCLEROSIS 

Voon Ong 1 , Svetlana Nihtyanova 1 , Carol Black 1 , Christopher Denton 1 ; 

1 

Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School, Royal Free 

Hospital, London, United Kingdom. 

OP68 A POTENTIAL ROLE FOR INTERLEUKIN-6 IN THE PATHOGENESIS OF SYSTEMIC SCLEROSIS 

Theresa Barnes 1 , Dave Spiller 2 , Marina Anderson 1 , Steven Edwards 2 , Robert Moots 1 ; 

1 

School of Clinical Sciences, University of Liverpool, Liverpool, United Kingdom. 2 School of 

Biological Sciences, University of Liverpool, Liverpool, United Kingdom. 

OP69 SUPERIOR MESENTERIC ARTERY VASCULOPATHY IN SYSTEMIC SCLEROSIS PATIENTS 

Mohamed Gamal E. Zaki 1 , Henaz F. Khaled 1 , Ola A. Abdul-Aziz 1 , Asmaa A. Shaaban 1 , 

Hala Abu Senna 2 ; 

1 

Rheumatology, Physical Medicine and Rehabilitation, Faculty of Medicine, Ain Shams University, 

Cairo, Egypt. 2 Radiodiagnosis, Faculty of Medicine, Ain Shams University, Cairo, Egypt. 

68

OP70 BODY MASS INDEX IS ASSOCIATED WITH MALABSORPTION BUT NO OTHER CLINICAL 

MANIFESTATIONS IN PATIENTS WITH SYSTEMIC SCLEROSIS 

Victoria L. Bishop 1 , Ariane Herrick 1, 2 , Elizabeth Wragg 2 ; 

1 

University of Manchester, Manchester, United Kingdom. 2 Salford Royal Hospital, Manchester, 


OP71 NATURALLY OCCURRING FREE THIOLS WITHIN ß2-GLYCOPROEIN I IN VIVO: FUNCTIONAL 

IMPLICATIONS IN THE REGULATION OF OXIDATIVE STRESS INDUCED ENDOTHELIAL CELL 

INJURY 

Yiannis Ioannou 1, 2 , Jing-Yun Zhang 1, 3 , Freda H. Passam 1 , Soheila Rahgozar 1 , Jian C. Qi 1 , 

Bill Giannakopoulos 1 , Miao Qi 1 , Pei Yu 1, 3 , Demin M. Yu 3 , Philip J. Hogg 4 , Steven A. Krilis 1 ; 

1 

Department of Immunology, Allergy and Infectious Diseases, University of New South Wales, 

Sydney, NSW, Australia. 2 Centre for Rheumatology, University College London, London, United 

Kingdom. 3 Tianjin Medical UniversIty, Tianjin, China. 4 Cancer Research Centre, University of New 

South Wales, Sydney, NSW, Australia. 

Medical student bursary winner: 

OP72 HYPOVITAMINOSIS D IN PATIENTS WITH CONNECTIVE TISSUE DISEASE 

Christopher W. Hopkins 1 , Laura R. Spiers 1 , Shweta S. Bhagat 2 , Andrew J. Ostör 2 , 

Frances C. Hall 2 ; 

1 

School of Clinical Medicine, University of Cambridge, Cambridge, United Kingdom. 2 Department 

of Rheumatology, Addenbrooke’s Hospital, Cambridge, United Kingdom. 


13.45 – 15.15 

Osteoarthritis Hall 7 

OP73 MECHANICAL LOAD DRIVES INFLAMMATORY GENE EXPRESSION AND DISEASE IN 

MURINE OA 

Annika Burleigh 1 , Jeremy Saklatvala 1 , Tonia L. Vincent 1 ; 

1 

Cell Signalling, Kennedy Institute of Rheumatology, London, United Kingdom. 

OP74 CHONDROCYTE IL-1ß EXPRESSION IS A CLINICALLY SIGNIFICANT MARKER OF PROGRESSION 

AND RADIOGRAPHIC SEVERITY IN OSTEOARTHRITIS OF THE HIP 

Evin Sowden 1 , David Kynaston 1 , Madhurima Rai 3 , Elliot Yates 3 , Winston Kim 2 , Anthony Freemont 3 ; 

1 

Rheumatology, Salford Royal NHS Foundation Trust, Salford, United Kingdom. 2 Orthopaedics, 

Salford Royal NHS Foundation Trust, Salford, United Kingdom. 3 School of Clinical & Laboratory 

Sciences, University of Manchester, Manchester, United Kingdom. 

OP75 MILD RADIOGRAPHIC FEATURES PREDICT STRUCTURAL PROGRESSION OF KNEE 

OSTEOARTHRITIS 

Kirsten M. White 1 , Anushka Soni 1 , Amit Kiran 1 , Lyndsey M. Goulston 2 , Deborah J. Hart 3 , 

Tim D. Spector 3 , Kassim Javaid 1 , Nigel K. Arden 1, 2 ; 

1 

NIHR Musculoskeletal BRU, University of Oxford, Oxford, United Kingdom. 2 MRC Epidemiology 

Resource Centre, University of Southampton, Southampton, United Kingdom. 3 Department of 

Twin Research and Genetic Epidemiology, King’s College London, London, United Kingdom. 

69

OP76 INCIDENCE AND PROGRESSION OF RADIOGRAPHIC KNEE OSTEOARTHRITIS IN A 

SYMPTOMATIC POPULATION 

Rachel Duncan 1 , George Peat 1 , Elaine Thomas 1 , Elaine Hay 1 , Peter Croft 1 ; 

1 

Arthritis Research Campaign National Primary Care Centre, Keele University, Keele, Staffordshire, 


OP77 INTER-RATER RELIABILITY AND VALIDITY OF ULTRASOUND IMAGING FOR FEATURES OF 

OSTEOARTHRITIS IN THE KNEE IN THE COMMUNITY 

Ajay Abraham 1, 3 , Iain Goff 1, 3 , Mark S. Pearce 3 , Roger M. Francis 2, 3 , Fraser Birrell 1, 3 ; 

1 

Northumbria Healthcare NHS Trust, Newcastle, United Kingdom. 2 The Newcastle upon Tyne 

Hospitals NHS Foundation Trust, Newcastle, United Kingdom. 3 Newcastle University, Newcastle, 


OP78 SHORT-TERM EFFECTS OF TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION (TENS) AND 

EXERCISE ON KNEE OSTEOARTHRITIS (OA) 

Shea Palmer 1 , Melissa Domaille 2 , Fiona Cramp 1 , Mark I. Johnson 3 ; 

1 

School of Health & Social Care, University of the West of England, Bristol, United Kingdom. 

2 

Rheumatology Centre, University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom. 

3 

Faculty of Health, Leeds Metropolitan University, Leeds, United Kingdom. 

70

Poster viewing: 



Wed 21 April 2010

Poster viewing: Wednesday 21 April 2010 

For information on Guided Poster Tours see page 13 

12.30 – 14.00 

Biology of bone, cartilage and connective tissue disease 

1 EFFECT OF CORTICOSTEROID ON TENOCYTES: SHOULD STEROIDS BE USED AS A TREATMENT 

FOR TENDONOPATHIES? 

Christopher J. Wincup 1 , Darrell Evans 2 , Karen Walker-Bone 2 ; 

1 

Northwick Park Hospital, London, United Kingdom. 2 Brighton and Sussex Medical School, 

Brighton, United Kingdom. 


2 JOINT HYPERMOBILITY AND RECTAL EVACUATORY DYSFUNCTION: AN AETIOLOGICAL LINK IN 

ABNORMAL CONNECTIVE TISSUE? 

Sahar Mohammed 1 , Peter J. Lunniss 1 , Natalia Zarate 1 , Qasim Aziz 1 , S Mark Scott 1 ; 

1 

GI Physiology Unit (Academic Surgical Unit) and Neurogastroenterology Group,Centre for 

Digestive Diseases, Institute of Cell and Molecular Science. Barts and the London School of 

Medicine and Dentistry., London, United Kingdom. 

Case reports 

3 AN UNUSAL CASE OF FOCAL MYOSITIS 

Clare Seiber 1 , Sandeep Bawa 1 , David Ritchie 2 ; 

1 

Rheumatology, Gartnavel General Hospital, Glasgow, United Kingdom. 2 Radiology, Gartnavel 

General Hospital, Glasgow, United Kingdom. 

4 PAINFUL LYMPHADENOAPATHY AND PLEURAL EFFUSION FOLLOWING ETANERCEPT THERAPY 

Sandeep Mukherjee 1 , Kristoffer Ostridge 2 , Katherine Spinks 2 , Ernest Wong 1 ; 

1 

Rheumatology Department, Queen Alexandra Hospital, Portsmouth, Hampshire, United Kingdom. 

2 

Respiratory Department, Queen Alexandra Hospital, Portsmouth, Hampshire, United Kingdom. 

5 CHURG-STRAUSS SYNDROME (CSS): POSTPARTUM PRESENTATION AND FLARE WITH 

CONSECUTIVE PREGNANCIES 

Mark Edwards 1 , Joanna Ledingham 1 ; 

1 

Rheumatology Department, Queen Alexandra Hospital, Portsmouth, United Kingdom. 

6 ASYMPTOMATIC BOWEL DISEASE PRESENTING AS POLYMYALGIA RHEUMATICA 

Chandhri S. Wijesooriya 1 , Anurag N. Bharadwaj 1 , Adikesavalu Anilkumar 2 , Nagui S. Gendi 1 ; 

1 

Rheumatology and Rehabilitation, Basildon University Hospital, Basildon, Essex, United Kingdom. 

2 

Radiology, Basildon University Hospital, Basildon, Essex, United Kingdom. 

7 AN UNUSUAL PRESENTATION OF MALIGNANT MESOTHELIOMA 

Sarah J. Evans 1 , Martin Bevan 1 ; 

1 

Rheumatology, Princess of Wales Hospital, Bridgend, United Kingdom. 

8 THE DOMICILIARY VISIT AND RHEUMATOLOGICAL CARE 

Keightley R. Adams 1 , Robin Hunter 1 , Lois Craddock 1 ; 

1 

Dept of Rheumatology, NHS Bolton, Bolton, United Kingdom. 

71

9 INFLAMMATORY POSTERIOR INTEROSSEOUS NERVE PALSY IN A PATIENT WITH PSORIATIC 

ARTHROPATHY 

Caroline Ali 1 , Nora Ng 1 , Robert Colaco 2 , Erden Ali 3 , C. Bernard Colaco 1 ; 

1 

Rheumatology Department, Central Middlesex Hospital, London, United Kingdom. 2 Bristol 

University, Bristol, United Kingdom. 3 Addenbrookes Hospital, Cambridge, United Kingdom. 

10 SUDDEN ONSET OF CONFLUENT LUMBOSACRAL PLEXOPATHY AND SEVERE HAEMOLYTIC 

ANAEMIA IN A PATIENT WITH LONGSTANDING MILD SLE 

Vijay KR Rao 1 , Robin Butler 1, 2 ; 

1 

Rheumatology, Royal Shrewsbury Hospital, Shrewsbury, Shropshire, United Kingdom. 

2 

Rheumatology, Robert Jones and Agnes Hunt Orthopaedic Hospital, Oswestry, Shropshire, 


11 INFLAMMATORY JOINT EFFUSION ALTERS TENDON-MUSCLE PROPERTIES IN RHEUMATOID 

ARTHRITIS: A CASE STUDY 

Verena Matschke 1, 2 , Jeremy G. Jones 1, 2 , Andrew B. Lemmey 1 , Peter J. Maddison 1, 2 , 

Jeanette M. Thom 1 ; 

1 

School of Sport, Health and Exercise Sciences, Bangor University, Bangor, United Kingdom. 

2 

Department of Rheumatology, Betsi Cadwaladr University Health Board, Bangor, United Kingdom. 

12 SIMULTANOUS OCCURANCE OF MACROPHAGIC MYOFASCIITIS AND ANTI-JO-1 ANTIBODY 

POSITIVE POLYMYOSITIS: COINCIDENCE OR REAL ASSOCIATION? 

Muhammad Haroon 1 , Ahmed Eltahir 1 , Sinead Harney 1 ; 

1 

Department of Rheumatology, Cork University Hospital, Cork, Ireland. 

13 TRAVELLER’S ARTHRALGIA 

Arumugham Moorthy 1 , Mudita Tripathi 1 ; 

1 

Rheumatology, Leicester Royal Infirmary, Leicester, United Kingdom. 

14 FEVER, RASH AND JOINT PAIN: AN UNUSUAL CAUSE WITH UNIQUE HISTOLOGICAL FEATURES 

G. Hirsch 1 , A. Pace 1 ; 

1 

Dept of rheumatology, Dudley group of hospitals, Dudley, United Kingdom. 

15 REACTIVE ARTHRITIS FOLLOWING INTRAVESICAL BCG THERAPY 

Wing Hoi Yau 1 ; 

1 

Dept of Rheumatology, Musgrave Park Hospital, Belfast, United Kingdom. 

16 A CASE OF COMPLEX REGIONAL PAIN SYNDROME WITH EXTENSIVE SEVERE ALLODYNIA, 

REFFERRED SENSATIONS AND CLINICAL EVIDENCE OF PARIETAL LOBE DYSFUNCTION: 

CORTICAL REORGANISATION CONTRIBUTES TO CLINICAL PRESENTATION. 

Helen Cohen 1, 2 , Candy McCabe 1, 2 ; 

1 

Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom. 2 University of Bath, Bath, 


17 A CASE OF STEROID RESISTANT SARCOID DACTYLITIS RESPONDING TO ANTI-TNF THERAPY 

Neil Mo 1 , Margaret O’Sullivan 1 ; 

1 

Rheumatology, Wrexham Maelor Hospital, Wrexham, United Kingdom. 

18 BIOPSY PROVEN HODGKIN’S LYMPHOMA (HL) AND SARCOID IN A PATIENT WITH RHEUMATOID 

ARTHRITIS (RA) 

Emma Williams 1 , Joanna Ledingham 1 ; 

1 

Rheumatology Department, Queen Alexandra Hospital, Cosham, United Kingdom. 

72

19 CYTOMEGALOVIRUS RETINITIS: A POTENTIAL CAUSE OF PERMANENT VISUAL LOSS IN 

RHEUMATOLOGY PATIENTS 

Catherine Gwynne 1 , Sarah Hale 2 , Anurag Negi 1 ; 

1 

Rheumatology, University Hospital of Wales, Cardiff, United Kingdom. 2 Ophthalmology, University 

Hospital of Wales, Cardiff, United Kingdom. 

20 CHRONIC Q FEVER INFECTION MIMICKING SYSTEMIC LUPUS ERYTHEMATOSUS 

Emyr Humphreys 1 , Julian Nash 1 ; 

1 

Rheumatology, University Hospital of Wales, Cardiff, United Kingdom. 

21 IS IT LUPUS? IS IT TTP? OR IS IT BOTH? 

Aruna S. Malipeddi 1 , Rebecca Neame 1 ; 

1 

University Hospitals of Leicester, Leicester, United Kingdom. 


22 KIKUCHI FUJIMOTO AND CONNECTIVE TISSUE DISEASES: UNCOMMON ASSOCIATION 

COMMONLY MISSED 

Anurag Bharadwaj 1 , Nagui Gendi 1 , Abdel Abdulla 2 , Amel Ginawi 1 ; 

1 

Rheumatology, Basildon & Thurrock University Hospitals, Basildon, Essex, United Kingdom. 

2 

Pathology, Basildon & Thurrock University Hospitals, Basildon, Essex, United Kingdom. 

23 LONG ACTING PHOSPHODIESTERASE 5 INHIBITION WITH TADALAFIL: A NOVEL TREATMENT 

FOR VASCULAR MANIFESTATIONS OF SYSTEMIC SCLEROSIS 

Anshuman P. Malaviya 1 , Bhaskar Dasgupta 1 ; 

1 

Department of Rheumatology, Southend University Hospital NHS Trust, Westcliff-on-Sea, Essex, 


24 AN UNUSUAL CASE OF MASSIVE HEPATOMEGALY AS THE PRESENTING FEATURE IN LUPUS 

Sudipto Das1, Ai Lyn Tan 1 , Sarah Miles 1 , Lesley Hordon 1 , Nurani Sivaramakrishhan 2 ; 

1 

Department of Rheumatology, Dewsbury District Hospital, Dewsbury, United Kingdom. 

2 

Department of Gastroenterology, Dewsbury District Hospital, Dewsbury, United Kingdom. 

Cell receptor-ligand interaction, signalling, activation and apoptosis 

25 EXPRESSION OF GPR15/BOB ON MONOCYTES AND NEUTROPHILS IN PERIPHERAL BLOOD 

AND ON MONOCYTE/MACROPHAGES IN SYNOVIAL TISSUE AND SYNOVIAL FLUID OF 

RHEUMATOID ARTHRITIS PATIENTS 

Alison Cartwright 1, 3 , Caroline Schmutz 2 , Ayman Askari 1 , Jim Middleton 1, 3 ; 

1 

Arthritis Resaearch Centre, RJAH Orthopaedic Hospital, Oswestry, Shropshire, United Kingdom. 

2 

Division of Immunity and Infection, University of Birmingham, Birmingham, West Midlands, 

United Kingdom. 3 ISTM, Medical School, University of Keele, Stoke on Trent, Staffordshire, 


26 MOLECULAR MECHANISMS OF DISEASE SEVERITY IN JUVENILE IDIOPATHIC ARTHRITIS 

Anne M. Pesenacker 1 , Tessa Crompton 2 , Lucy R. Wedderburn 1 ; 

1 

Rheumathology, UCL-Institute of Child Health, London, United Kingdom. 2 Immunobiology, 

UCL-Institute of Child Health, London, United Kingdom. 

27 DIFFERENTIAL EXPRESSION OF FACTORS INVOLVED IN THE EXTRINSIC APOPTOTIC PATHWAY 

IN JUVENILE SYSTEMIC LUPUS ERYTHEMATOSUS 

Angela J. Midgley 1 , Michael W. Beresford 1 ; 

1 

Institute of Child Health, University of Liverpool, Liverpool, United Kingdom. 

73

28 MEASURING TOLL-LIKE RECEPTOR (TLR) EXPRESSION IN PERIPHERAL BLOOD MONONUCLEAR 

CELLS (PBMC) IN JUVENILE-ONSET SYSTEMIC LUPUS ERYTHEMATOSUS (JSLE) AND 

INFLAMMATORY CONTROLS 

Colin Thorbinson 1 , Angela Midgley 1 , Michael W. Beresford 1 ; 

1 

Alder Hey Children’s Hospital, Institute of Child Health, Liverpool, United Kingdom. 

29 COX-2 INHIBITION ENHANCES BRADYKININ-INDUCED CALCIUM SIGNALLING IN ENDOTHELIAL 

CELLS 

Khatiga Rauf 1 , Allan P. Kiprianos 1 , Paul A. Bacon 1 , Stephen P. Young 1 ; 

1 

School of Immunity & Infection, University of Birmingham, Birmingham, United Kingdom. 

Cytokines and inflammatory mediators 

30 THE LPS STIMULATED PRODUCTION OF INTERLEUKIN-10 IS NOT ASSOCIATED WITH -819C/T 

AND -592C/A PROMOTER POLYMORPHISMS IN HEALTHY INDIAN SUBJECTS 

Skanda Shukla 1 , Able Lawrence 1 , Amita Aggarwal 1 , Sita Naik 1 ; 

1 

Immunology, SGPGIMS, Lucknow, Uttar Pradesh, India. 

31 IL-17 PRODUCING CELLS ARE INCREASED IN THE PERIPHERAL BLOOD OF PATIENTS WITH RA 

AND ARE ENRICHED AT THE SITE OF INFLAMMATION 

Nicola J. Gullick 1, 2 , Hayley G. Evans 1, 2 , David Jayaraj 1, 2 , Bruce W. Kirkham 2, 3 , Leonie S. Taams 1, 2 ; 

1 

CMCBI, King’s College, London, United Kingdom. 2 NIHR Comprehensive Biomedical Research 

Centre, Guy’s & St Thomas’ NHS Foundation Trust and King’s College, London, United Kingdom. 

3 

Rheumatology, Guy’s & St Thomas’ NHS Foundation Trust, London, United Kingdom. 

32 BIOMARKER PROFILES ASSOCIATED WITH DISEASE FEATURES IN PATIENTS WITH EARLY RA 

Sunita M. Judah 1, 2 , Nicola Nixon 2 , Peter Dawes 2 , Derek L. Mattey 1, 2 ; 

1 

Institute for Science and Technology in Medicine, Keele University, Stoke On Trent, United 

Kingdom. 2 Rheumatology, Haywood Hospital, Stoke On Trent, United Kingdom. 

33 MAPPING THE CYTOKINE NETWORK: SIMULTANEOUS ANALYSIS OF CYTOKINE MRNA 

EXPRESSION PROFILES OF FIVE IMMUNE CELL POPULATIONS ISOLATED FROM SYNOVIAL 

FLUID AND PERIPHERAL BLOOD OF RA PATIENTS 

Lorraine Yeo 1 , Caroline Schmutz 1 , Kai-Michael Toellner 1 , Mike Salmon 1 , Andrew D. Filer 1 , 

Christopher Buckley 1 , Karim Raza 1 , Dagmar Scheel-Toellner 1 ; 

1 

Rheumatology Research Group, University of Birmingham, Birmingham, United Kingdom. 

34 BLOOD LIPID LEVELS ARE LOWERED BY INCREASED INTERLEUKIN-6 CONCENTRATIONS VIA 

UP-REGULATION OF THE VERY LOW DENSITY LIPOPROTEIN RECEPTOR 

M. Hashizume 1 , H. Yoshida 1 , N. Koike 1 , M. Suzuki 1 , M. Mihara 1 ; 

1 

Product Research Department, Chugai Pharmaceutical Co Ltd, Gotemba, Japan. 

35 EFFECTS OF ANTI-TUMOUR NECROSIS FACTOR α THERAPY ON INSULIN KINETICS IN 

NORMAL-WEIGHT AND OBESE PATIENTS WITH RHEUMATOID ARTHRITIS 

Antonios Stavropoulos-Kalinoglou 1, 2 , Giorgos S. Metsios 1, 3 , Karen M. Douglas 1 , 

Vasileios F. Panoulas 1 , Yiannis Koutedakis 3 , George D. Kitas 1 ; 

1 

Rheumatology, Dudley Group of Hospitals, Dudley, United Kingdom. 2 School of Sports and Exercise 

Science, University of Birmingham, Birmingham, United Kingdom. 3 School of Sports, Performing Arts 

and Leisure, University of Wolverhampton, Walsall, United Kingdom. 

74

36 CYTOKINE PROFILE AND FREQUENCY OF IL-17-PRODUCING CD4 T CELLS IN BLOOD, 

SYNOVIAL FLUID AND SYNOVIUM OF PATIENTS WITH RHEUMATOID ARTHRITIS 

Leigh D. Church 1 , Andrew D. Filer 1 , Ester Hildago 1 , Katherine Howlett 1 , Andrew Thomas 2 , 

Stephen Rapecki 3 , Dagmar Scheel-Toellner 1 , Christopher D. Buckley 1 , Karim Raza 1 ; 

1 

Rheumatology Research Group, School of Immunity and infection, College of Medicine and 

Dental Sciences, University of Birmingham, Birmingham, United Kingdom. 2 The Royal Orthopaedic 

Hospital, Birmingham, United Kingdom. 3 UCB-Celltech, Slough, United Kingdom. 

37 OBESITY IS A MAJOR DETERMINANT OF CRP LEVELS IN HEALTHY INDIVIDUALS 

Maria Juarez 1 , James Kolasinski 1 , Jyothish Govindan 2 , Annette Quilter 3 , Lyn Williamson 1 , 

David A. Collins 1 , Elizabeth J. Price 1 ; 

1 

Rheumatology, The Great Western Hospital NHS Foundation Trust, Swindon, United Kingdom. 

2 

Diabetes and Endocrinology, The Great Western Hospital NHS Foundation Trust, Swindon, 

United Kingdom. 3 Cardiology, The Great Western Hospital NHS Foundation Trust, Swindon, 



38 DETERMINANTS OF MEAN PLATELET VOLUME IN PATIENTS WITH RHEUMATOID ARTHRITIS 

Armen Y. Gasparyan 1 , Antonios Stavropoulos-Kalinoglou 1 , Tracey E. Toms 1 , Karen Douglas 1 , 

George D. Kitas 1 ; 

1 

Department of Rheumatology, Clinical Research Unit, Russell’s Hall Hospital, Dudley Group of 

Hospitals NHS Foundation Trust, Dudley, West Midlands, United Kingdom. 

39 EFFICACY AND SAFETY OF CANAKINUMAB (ILARIS) IN A LARGE COHORT OF PATIENTS 

ACROSS DIFFERENT SEVERITY PHENOTYPES OF CRYOPYRIN ASSOCIATED PERIODIC 

SYNDROME (CAPS) 

H. J. Lachmann 1 , J. B. Kuemmerle-Deschner 2 , E. Hachulla 3 , J. Hoyer 4 , J. Smith 5 , K. Laslie 6 , 

I. Kone-Paut 7 , J. Braun 8 , A. Widmer 9 , N. Patel 10 , R. Preiss 10 , P. N. Hawkins 1 ; 

1 

Royal Free and University College Medical School, London, United Kingdom. 2 Universitätsklinikum 

Tübingen, Klinik fuer Kinder-und Jugendmedizin, Germany. 3 Hopital Claude Huriez, Lille Cedex, 

France. 4 Univ.- Klinikum Gießen und Marburg, Marburg, Germany. 5 University of Wisconsin 

Hospital and Clinics, Madison, WI, United States. 6 UCSF, School of Medicine, San Francisco, CA, 

United States. 7 Hopital Kremlin Bicetre, Le Kremlin Bicetre, France. 8 Rheumazentrum Ruhrgebiet, 

Herne, Germany. 9 Novartis, Basel, Switzerland. 10 Novartis, East Hanover, NJ, United States. 

Spondyloarthropathies including psoriatic arthritis 

40 EAGLE’S SYNDROME: AN UNUSUAL ASSOCIATION WITH SERO-NEGATIVE ARTHROPATHY 

Surabhi Wig 1 , Paul Bischoff 2 , Mary Holt 1 ; 

1 

Rheumatology, Rotherham NHS foundation trust, Rotherham, United Kingdom. 2 Maxillofacial 

Surgery, Rotherham NHS foundation trust, Rotherham, South Yorkshire, United Kingdom. 

41 DOES ANTI-TNF TREATMENT NEGATE THE NEED FOR REGULAR, TAILORED PHYSIOTHERAPY 

AND OCCUPATIONAL THERAPY IN PATIENTS WITH ANKYLOSING SPONDYLITIS? 

Sally Collins 1 , Rhian Goodfellow 2 , James Martin 2 , Ceril Rhys-Dillon 2 , Sharon Lyle 2 , Jacqui Rowan 

Phillips 3 ; 

1 

Physiotherapy, Royal Glamorgan Hospital, Ynysmaerdy, United Kingdom. 2 Rheumatology, Royal 

Glamorgan Hospital, Ynysmaerdy, United Kingdom. 3 Occupational Therapy, Royal Glamorgan 

Hospital, Ynysmaerdy, United Kingdom. 

75

42 TREATMENT OF PSORIATIC ARTHRITIS WITH ADALIMUMAB: APPLICATION OF A NEW 

COMPOSITE MEASURE OF MINIMAL DISEASE ACTIVITY USING DATA FROM ADEPT 

P. J. Mease 1 , R. Perdok 2 , S. Kary 3 , H. Kupper 3 ; 

1 

Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, 

United States. 2 Abbott Laboratories, Abbott Park, IL, United States. 3 Abbott GmbH & Co. KG, 

Ludwigshafen, Germany. 

43 SWITCHING ANTI-TNF AGENTS FOR ANKYLOSING SPONDYLITIS: EXPERIENCES AT CARDIFF 

SINCE 2003 

Emyr Humphreys 1 , Nicholas Amos 1 , Julian Nash 1 , Sharon Jones 1 ; 

1 

Rheumatology, University Hospital of Wales, Cardiff, United Kingdom. 

44 HLA-B27 FORMS HEAVY CHAIN HOMODIMERS IN VITRO AND IN VIVO THAT BIND TO CELLULAR 

RECEPTORS INCLUDING LILR AND KIR FAMILY MEMBERS 

Kirsty McHugh 1 , Joanna Giles 1 , Simon Kollnberger 1 , Kimiko Kuroi 2 , Katsumi Maenaka 2 , 

Paul Bowness 1 ; 

1 

Human Immunology Unit, Weatherall Institute of Molecular Medicine, Oxford, United Kingdom. 

2 

Division of Structural Biology, Medical institute of Bioregululation, Fukuoka, Japan. 

45 RESPONSIVENESS TO CHANGE OF THE MULTIDIMENSIONAL PATIENT REPORTED OUTCOME 

MEASURES QUESTIONNAIRE FOR PATIENTS WITH ANKYLOSING SPONDYLITIS/ 

SPONDYLOARTHRITIS 

Yasser El Miedany 1 , Maha El Gaafary 2 , Sally Youssef 1 , Deborah Palmer 1 ; 

1 

Rheumatology, Darent Valley Hospital, Dartford, United Kingdom. 2 Community, Environmental and 

Occupational Medicine, Ain Shams University, Cairo, Egypt. 

46 VALIDATION OF A PSORIATIC ARTHRITIS SCREENING QUESTIONNAIRE IN RHEUMATOLOGY AND 

DERMATOLOGY OUTPATIENTS 

Claire L. Marshall 3 , Philip V. Harrison 2 , Marwan Bukhari 1, 3 ; 

1 

Department of Rheumatology, Royal Lancaster Infirmary, Lancaster, United Kingdom. 2 Department 

of Dermatology, Royal Lancaster Infirmary, Lancaster, United Kingdom. 3 University of Liverpool 

Medical School, University of Liverpool, Liverpool, United Kingdom. 

47 ANKYLOSING SPONDYLITIS AND ANTI-TNFα: EXPERIENCE IN CLINICAL PRACTICE POST 2008 

NICE GUIDANCE 

Mandy C. Greenwood 1 , Farooqui Omar 1 , Alan J. Hakim 1 , Simon P. Donnelly 1 , Margaretta M. 

Rooney 1 , John G. Lanham 1 , Hasan Tahir 1 ; 

1 

Rheumatology, Whipps Cross University Hospital, London, United Kingdom. 

48 COMPARISON OF CLINICAL AND RADIOLOGIC TREATMENT OUTCOMES FOR PATIENTS WITH 

MODERATE VS SEVERE PSORIATIC ARTHRITIS DISEASE ACTIVITY AT BASELINE: POST-HOC 

ANALYSIS OF ADEPT 

P. J. Mease 1 , A. Kavanaugh 2 , R. Perdok 3 , H. Kupper 4 , F. Lavie 5 ; 

1 

University of Washington School of Medicine, Seattle, WA, United States. 2 University of California 

San Diego, La Jolla, CA, United States. 3 Abbott Laboratories, Abbott Park, IL, United States. 

4 

Abbott GmbH & Co. KG, Ludwigshafen, Germany. 5 Abbott Laboratories, Rungis, France. 

49 FATIGUE AND PSYCHOLOGICAL WELL-BEING IN ANKYLOSING SPONDYLITIS PATIENTS 

Julie H. Barlow 1 , Lorraine McFarland 1 , Lucy Tindall 1 , Jaya Ravindran 2 , Phillip Perkins 2 ; 

1 

Coventry University, Coventry, United Kingdom. 2 Rheumatology Dept., University Hospitals Coventry 

& Warwickshire Trust, Coventry, United Kingdom. 

76

50 FAMILY HISTORY IN PATIENTS WITH PSORIATIC ARTHRITIS AND DIFFERENCE BETWEEN 

CAUCASIANS AND SOUTH ASIAN PATIENTS WITH REGARDS TO FAMILY MEMBERS AFFECTED 

BY THE SAME DISEASE 

Coziana Ciurtin 1 , Dimitra Doufexi 2 , Judit Bartko 1 , Euthalia Roussou 1 ; 

1 

Rheumatology & Rehabilitation, BHRUT King George Hospital, London, United Kingdom. 

2 

Medicine, BHRUT King George Hospital, London, United Kingdom. 

51 ARE THERE MEASURABLE BENEFITS FOR AS PATIENTS ATTENDING A DEDICATED 

OCCUPATIONAL THERAPY AND PHYSIOTHERAPY PROGRAMME? 

J. Rowan Phillips 2 , S. Collins 3 , S. Lyle 1 , Rh Goodfellow 1 , J. Martin 1 , C. Rhys-Dillon 1 ; 

1 

Dept of Rheumatology, Royal Glamorgan Hospital, Llantrisant, Rhondda Cynon Taf, United 

Kingdom. 2 Department of Occupational Therapy, Royal Glamorgan Hospital, Llantrisant, United 

Kingdom. 3 Department of Physiotherapy, Royal Glamorgan Hospital, Llantrisant, United Kingdom. 


52 EDUCATION FOR PEOPLE WITH ANKYLOSING SPONDYLITIS: PATIENTS’ AND PROFESSIONALS’ 

FEEDBACK ON OUR RESULTS 

Ben Thompson 1, 2 , Tim Rapley 2 , Wendy Broderick 3 , Carl May 2 , Lesley Kay 1, 2 ; 

1 

Newcastle-upon-Tyne Hospitals NHS Foundation Trust, Newcastle-upon-Tyne, United Kingdom. 

2 

Newcastle University, Newcastle-upon-Tyne, United Kingdom. 3 Tyne and Wear Branch, National 

Ankylosing Spondylitis Society, Tyne and Wear, United Kingdom. 

53 EVALUATION OF A MODIFIED ARTHRITIS SELF-EFFICACY SCALE FOR ANKYLOSING 

SPONDYLITIS (ASES-AS) 

Jaswant Sandhu 1 , Jon C. Packham 1 , Emma L. Healey 1 , Kelvin Jordan 1 , Andrew M. Garratt 2 , Kirstie 

L. Haywood 3 ; 

1 

Arthritis Research Campaign National Primary Care Centre, Keele University, Staffordshire, United 

Kingdom. 2 National Resource Centre for Rehabilitation in Rheumatology, Diakonhjemmet Hospital, 

Oslo, Norway. 3 Royal College of Nursing Research Institute, School of Health and Social Studies, 

University of Warwick, Coventry, United Kingdom. 

54 THE ROLE OF MIGRATING INTESTINAL DENDRITIC CELLS IN ANKYLOSING SPONDYLITIS 

Lotta Utriainen 1 , Vuk Cerovic 1 , Iain McInnes 1 , Simon Milling 1 ; 

1 

Immunology, Infection and Inflammation, University of Glasgow, Glasgow, United Kingdom. 

55 USE OF ADALIMUMAB FOR THE TREATMENT OF ENTHESITIS OF THE ACHILLES TENDON IN 

PATIENTS WITH SPONDYLOARTHRITIS 

C. T. Ritchlin 1 , P. J. Mease 2 , R. Perdok 3 , H. Kupper 4 , F. Lavie 5 ; 

1 

University of Rochester, Rochester, NY, United States. 2 Swedish Medical Center and University of 

Washington, Seattle, WA, United States. 3 Abbott Laboratories, Abbott Park, IL, United States. 

4 

Abbott GmbH & Co. KG, Ludwigshafen, Germany. 5 Abbott Laboratories, Rungis, France. 

56 ACTIVE ENTHESITIS IS INFREQUENT AND CLINICALLY OVERESTIMATED COMPARED TO POWER 

DOPPLER ULTRASOUND IN EARLY PSORIATIC ARTHRITIS 

Jane E. Freeston 1 , Laura C. Coates 1 , Philip S. Helliwell 1 , Elizabeth M. Hensor 1 , 

Richard J. Wakefield 1 , Paul Emery 1 , Philip G. Conaghan 1 ; 

1 

LIMM Section of Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom. 

77

57 THE IMPACT OF ANKYLOSING SPONDYLITIS ON WORKING LIFE: A SURVEY OF VOLUNTARY 

ORGANISATION MEMBERS 

Jane Skerrett 1 , Ingrid van der Weide 1 , Julie Barlow 2 , Andrew Keat 3 ; 

1 

NASS, Richmond, United Kingdom. 2 Coventry University, Coventry, United Kingdom. 

3 

Rheumatology, Northwick Park Hospital, Harrow, United Kingdom. 

58 THE ANKYLOSING SPONDYLITIS DISEASE ACTIVITY SCORE IN SUBJECTS TREATED WITH 

ETANERCEPT (ETN) OR SULFASALAZINE: COMPARISON WITH STANDARD EFFICACY MEASURES 

Desiree van der Heijde 1 , Jurgen Braun 2 , Joachim Sieper 3 , Carole Wishneski 4 , Bonnie Vlahos 4 , 

Annette Szumski 4 , Joanne Foehl 4 , Bruce Freundlich 4 , Andrew Koenig 4 ; 

1 

Rheumatology, Leiden University Medical Center, Leiden, Netherlands. 2 Rheumatology Medical 

Center Ruhrgebiet, Bochum, Germany. 3 Charite University, Berlin, Germany. 4 Pfizer Inc, Collegeville, 

PA, United States. 

59 LIPIDS IN SPONDYLOARTHROPATHIES 

Adil Gatia 1 , Judit Bartko 1 , Dimitra Doufexi 2 , Euthalia Roussou 1 ; 

1 

Rheuatology & Rehabilitation, King George Hospital BHRUT, London, United Kingdom. 

2 

Medicine, King George Hospital, London, United Kingdom. 

60 GOLIMUMAB ADMINISTERED SUBCUTANEOUSLY EVERY FOUR WEEKS IN PSORIATIC ARTHRITIS 

PATIENTS: 52-WEEK HEALTH-RELATED QUALITY OF LIFE, PHYSICAL FUNCTION AND HEALTH 

ECONOMIC RESULTS OF THE RANDOMIZED, PLACEBO-CONTROLLED GO-REVEAL STUDY 

Arthur Kavanaugh 1 , Dafna Gladman 2 , Chandrabhusan Chattopadhyay 3 , Philip Mease 4 , 

Iain B. McInnes 5 , Anna Beutler 6 , Julie Zrubek 6 , Jacqueline Buchanan 7 , Shreekant Parasuraman 7 , 

Michael Mack 6 , Gerald G. Krueger 8 , On behalf of the GO-REVEAL Investigators 6 ; 

1 

University of California San Diego, La Jolla, CA, United States. 2 Toronto Western Hospital, Toronto, 

ON, Canada. 3 Wrightington Hospital, Wigan, United Kingdom. 4 Swedish Hospital Clinical Research 

Center, Seattle, WA, United States. 5 University of Glasgow, Glasgow, United Kingdom. 6 Centocor 

Research & Development, Inc., Malvern, PA, United States. 7 Johnson and Johnson Pharmaceutical 

Services, Malvern, PA, United States. 8 University of Utah Health Sciences Center, Salt Lake City, UT, 

United States. 

61 LONG TERM USE OF TNF INHIBITORS FOR ANKYLOSING SPONDYLITIS 

Tehseen U. Wazir 1 , Andrew P. Cairns 1 , Aubrey Bell 1 ; 

1 

Rhuematology, Musgrave Park Hospital, Belfast, United Kingdom. 

62 HLA-B*2709, A SUBTYPE NOT ASSOCIATED WITH ANKYLOSING SPONDYLITIS, FORMS FEWER 

HOMODIMERS THAN HLA-B*2705 

Joanna L. Giles 1 , Jacqueline Shaw 1 , Kirsty McHugh 1 , Anna Ridley 1 , Paul Bowness 1, 2 , 

Simon Kollnberger 1 ; 

1 

Human Immunology Unit, Weatherall Institute of Molecular Medicine, Oxford, United Kingdom. 

2 

Nuffield Orthopaedic Centre, Nuffield Orthopaedic Centre, Oxford, United Kingdom. 

63 THE RELATIONSHIP BETWEEN ANXIETY AND DEPRESSION AND THE BATH INDICES FOR 

ANKYLOSING SPONDYLITIS, ADJUSTING FOR DEPRIVATION 

Gethin S. Pritchard 2 , Marwan Bukhari 1 , Lindsey Wilcox 1 ; 

1 

Department of Rheumatology, Royal Lancaster Infirmary, Lancaster, United Kingdom. 

2 

University of Liverpool, Liverpool, United Kingdom. 

78

64 IS THERE SUB-CLINICAL JOINT DISEASE IN EARLY PSORIATIC ARTHRITIS? A CLINICAL 

COMPARISON WITH POWER DOPPLER ULTRASOUND 

Jane E. Freeston 1 , Laura C. Coates 1 , Philip S. Helliwell 1 , Elizabeth M. Hensor 1 , 

Richard J. Wakefield 1 , Paul Emery 1 , Philip G. Conaghan 1 ; 

1 

LIMM Section of Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom. 

65 RESPONSIVENESS OF THE EVALUATING ANKYLOSING SPONDYLITIS QUALITY OF LIFE 

(EASI-QOL) QUESTIONNAIRE 

Jon Packham 1, 2 , Kelvin P. Jordan 1 , Max Lebmeier 5 , Andrew M. Garratt 4 , Emma L. Healey 1 , 

Kirstie L. Haywood 3, 1 ; 

1 

Arthritis Research Campaign National Primary Care Centre, Keele University, Staffordshire, United 

Kingdom. 2 Haywood Hospital, University Hospital of North Staffordshire, Stoke on Trent, United 

Kingdom. 3 Royal College of Nursing Research Institute, School of Health and Social Studies , 

University of Warwick, Coventry, United Kingdom. 4 National Resource Centre for Rehabilitation in 

Rheumatology, Diakonhjemmet Hospital, Oslo, Norway. 5 Health Economist, Wyeth 

Pharmaceuticals UK , Maidenhead, United Kingdom. 


66 THE OVERLAP BETWEEN FIBROMYALGIA POINTS AND ENTHESITIS SITES IN PATIENTS WITH 

INFLAMMATORY BACK PAIN AND WIDESPREAD BODY PAINS (RESULTS FROM AN AUDIT) 

Coziana Ciurtin 1 , Euthalia Roussou 1 ; 

1 

Rheumatology & Rehabilitation, King George Hospital BHRUT, London, United Kingdom. 


67 BASDAI CHANGES IN ANKYLOSING SPONDYLITIS PATIENTS TREATED WITH ANTI TUMOUR 

NECROSIS FACTOR THERAPY 

Laura Clarke 1, 2 , Lesley Kay 1, 2 ; 

1 

Musculoskeletal Unit, Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne, Tyne & 

Wear, United Kingdom. 2 The Medical School, Newcastle University, Newcastle upon Tyne, Tyne & 

Wear, United Kingdom. 

68 PROGRESSION OF FUNCTIONAL DISABILITY IN PSORIATIC ARTHRITIS: A COMPARISON OF 

CONVENTIONAL DMARDS AND ANTI-TNF THERAPY 

Michael J. Gingold 1 , Nick Bansback 3 , Daphne P. Guh 3 , Charlotte Cavill 2 , Rebecca Porteous 2 , 

Stuart D. Kyle 4 , Nicola Waldron 1 , Eleanor Korendowych 1, 2 , Neil McHugh 1, 2 ; 

1 

Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United 

Kingdom. 2 Bath Institute for Rheumatic Diseases, Bath, United Kingdom. 3 Centre for Health 

Evaluation and Outcome Sciences, St Paul’s Hospital, Vancouver, BC, Canada. 4 Department of 

Rheumatology, North Devon District Hospital, Barnstaple, United Kingdom. 

69 GOLIMUMAB, A NEW, HUMAN, TNF-α ANTIBODY ADMINISTERED SUBCUTANEOUSLY EVERY 

FOUR WEEKS, IN ANKYLOSING SPONDYLITIS: 104-WEEK EFFICACY AND SAFETY RESULTS OF 

THE RANDOMIZED, PLACEBO-CONTROLLED GO-RAISE STUDY 

Jürgen Braun 1 , Desiree van der Heijde 2 , Atul Deodhar 3 , Laura Diekman 4 , Joachim Sieper 5 , 

Sung-Il Kim 6 , Anna Beutler 7 , Michael Mack 7 , Stephen Xu 7 , Julie Zrubek 7 , Benjamin Hsu 7 , 

Robert Inman 8 , On behalf of the GO-RAISE Investigators 7 ; 

1 

Rheumazentrum Ruhrgebiet, Herne, Germany. 2 Leiden University Medical Ctr, Leiden, 

Netherlands. 3 Oregon Health and Science University, Portland, OR, United States. 4 University of 

Texas Medical School, Houston, TX, United States. 5 Charite Hospital, Berlin, Germany. 6 Pusan 

National University Hospital, Busan, Korea, Republic of. 7 Centocor Research & Development, Inc., 

Malvern, PA, United States. 8University of Toronto, Toronto, ON, Canada. 

79

Metabolic and crystal arthropathies 

70 SINGLE INTRAMUSCULAR DEPOT METHYLPREDNISOLONE INJECTION: A CONVENIENT, 

EFFICACIOUS AND SAFE TREATMENT FOR GOUTY ARTHRITIS IN AN INPATIENT SETTING 

Jasmine Ishorari 1 , Nada Hassan 2 , Bhaskar Dasgupta 3 ; 

1 

Rheumatology, Southend University Hospital, Essex, United Kingdom. 2 Rheumatology, Southend 

University Hospital, Essex, United Kingdom. 3 Rheumatology, Southend University Hospital, Essex, 


71 ACUTE GOUTY ARTHRITIS IN PREGNANCY 

Nada Hassan 1 , Nagui Gendi 2 ; 

1 

Rheumatology, Southend, Essex, United Kingdom. 2 Rheumatology, Basildon Hospital, Essex, 


72 CANAKINUMAB (ACZ885) VERSUS TRIAMCINOLONE ACETONIDE FOR TREATMENT OF ACUTE 

FLARES AND PREVENTION OF RECURRENT FLARES IN GOUTY ARTHRITIS PATIENTS 

REFRACTORY TO OR CONTRAINDICATED TO NSAIDS AND/OR COLCHICINE 

Alexander So 1 , Marc D. Meulemeester 2 , Bhavesh Bodalia 3 , Talha Shamim 4 , Andrey Pikhlak 5 , 

A. Eftal Yücel 6 , Udayasankar Arulmani 7 , Dominik Richard 7 , Valda Murphy 7 , Peter Sallstig 7 , 

Naomi Schlesinger 8 ; 

1 

CHU Vaudois, University of Lausanne, Lausanne, Switzerland. 2 Private practice, Gozee, Belgium. 

3 

Gables Medicenter, Coventry, West Midlands, United Kingdom. 4 Heartland Clinical Research, 

Omaha, NE, United States. 5 Moscow State University of Medicine and Dentistry, Moscow, Russian 

Federation. 6 Baskent University, Ankara, Turkey. 7 Novartis Pharma AG, Basel, Switzerland. 

8 

UMDNJ-Robert Wood Johnson Medical School, New Brunswick, NJ, United States. 

Miscellaneous rheumatic diseases 

73 IS THERE A DELAY IN SPECIALIST REFERRAL OF HOT SWOLLEN JOINT? 

Emma Mannan 1 , Venkat Reddy 1 , Christopher Pearce 1 , James Peters 1 , Ian Giles 1 , Mike Shipley 1 ; 

1 

Rheumatology, University College Hospital, London, United Kingdom. 

74 A PROSPECTIVE AUDIT OF THE DIAGNOSIS AND MANAGEMENT OF HOT SWOLLEN JOINTS IN 

ADULTS AT A DISTRICT GENERAL HOSPITAL 

Anupam Paul 1 , Shirley Rigby 1 ; 

1 

Rheumatology, Warwick Hospital, Warwick, Warwickshire, United Kingdom. 

75 PREVALENCE OF EXTRAHEPATIC RHEUMATOLOGICAL MANIFESTATIONS IN EGYPTIAN PATIENTS 

WITH CHRONIC HEPATITIS C VIRUS INFECTION 

Reem H. Abdellatif mohammed 1 , Hesham I. Elmakhzangy 2 , Gamal Esmat 2 , Amira Gamal 3 , 

Fatma Mekky 3 , Nabil M. Ibrahim 4 , Mohammed A. Elhamid 5 ; 

1 

Rheumatology and Rehabilitation, Faculty of Medicine, Cairo University Hospitals, Cairo, Egypt. 

2 

Tropicalmedicine Department, Faculty of Medicine, Cairo University Hospitals, Cairo, Egypt. 

3 

Department of Community, Enviromental and Occupational Medicine, Faculty of Medicine, Ein 

Shams University Hospitals, Cairo, Egypt. 4 Dermatology, National Hepatology and Tropical Medicine 

Institute, Cairo University Hospitals, Cairo, Egypt. 5 Clinical Pathology, Nationalhepatology and 

Tropical Medicine Institute, Cairo, Egypt. 

80

76 CHRONIC PAIN IN HEPATITIS PATIENTS PRE AND POST PEG-INTERFERON TREATMENT 

Camille Lallemant 1 , Matthew Greenwood 1 , Jane Muir 2 , Majella Keller 1 , Jerry Tibble 1 , Richard 

Whale 2 , Inam Haq 2 ; 

1 

Rheumatology, Brighton and Sussex University Hospitals, Brighton, United Kingdom. 2 Brighton 

and Sussex Medical School, Brighton, United Kingdom. 

77 DISTORTING PROPRIOCEPTION IN PATIENTS WITH RHEUMATIC DISEASES EXACERBATES 

SENSORY DISTURBANCES: FURTHER EVIDENCE FOR CENTRAL PAIN MECHANISMS 

Helen Cohen 1, 2 , Nigel Harris 2 , Candy McCabe 1, 2 ; 

1 

Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom. 2 University of Bath, 

Bath, United Kingdom. 


78 SARCOPENIA IS HIGHLY PREVALENT IN THE VERY ELDERLY AND PREDICTS MORTALITY IN 

MALES 

Michael Cocker 1 , Roger Francis 2 , Marco Narici 3 , Fraser Birrell 4, 1 ; 

1 

Newcastle University, Newcastle Upon Tyne, United Kingdom. 2 Newcastle Hospitals NHS 

Foundation Trust, Newcastle Upon Tyne, United Kingdom. 3 Manchester Metropolitan University, 

Manchester, United Kingdom. 4 Northumbria Healthcare NHS Foundation Trust, Newcastle Upon 

Tyne, United Kingdom. 


79 DOES THE DEGREE OF CORTICAL REORGANISATION DETERMINE DIFFERENT CLINICAL 

PHENOTYPES IN COMPLEX REGIONAL PAIN SYNDROME (CRPS)? A SENSORIMOTOR STUDY 

Helen Cohen 1, 2 , Nigel Harris 2 , G. Van Velsen 1 , Candy McCabe 1, 2 ; 

1 

Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom. 2 University of Bath, 

Bath, United Kingdom. 

80 IMPROVED HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH CRYOPYRIN-ASSOCIATED 

PERIODIC FEVER SYNDROME (CAPS) AFTER TREATMENT WITH CANAKINUMAB (ILARIS®)–A 

FULLY HUMAN ANTI-IL-1 BETA MONOCLONAL ANTIBODY 

H. J. Lachmann 1 , I. Kone-Paut 2 , J. B. Kuemmerle-Deschner 3 , K. Leslie 4 , E. Hachulla 5 , P. Quartier 6 , 

A. Ferreira 7 , N. Patel 8 , K. Lheritier 7 , R. Preiss 8 , P. Hawkins 1 ; 

1 

National Amyloidosis Centre, UCL Medical School, London, United Kingdom. 2 Hopital, Kremlin 

Bicetre, Le Kremlin Bicetre, France. 3 Pediatric Rheumatology, Universitätsklinik, Tübingen, 

Germany. 4 UCSF, School of Medicine, San Francisco, CA, United States. 5 Service de Medicine 

Interne, Hopital Claude Huriez, Lille Cedex, France. 6 Unité d’Immunologie, Hopital Necker Enfants 

Malades, Paris, France. 7 Novartis Pharma AG, Basel, Switzerland. 8 Novartis Pharmaceutical 

Corporation, East Hanover, NJ, United States. 

81 MANAGEMENT OF THROMBOSIS IN 62 PATIENTS WITH BEHÇET’S SYNDROME OVER 15 

YEARS 

Puja Mehta 1 , Mike A. Laffan 2 , Dorian O. Haskard 1 ; 

1 

Department of Rheumatology, Imperial College Healthcare NHS Trust, London, United Kingdom. 

2 

Department of Haematology, Imperial College Healthcare NHS Trust, London, United Kingdom. 

82 RECHALLENGE WITH ETANERCEPT IN FOUR PATIENTS WITH ETANERCEPT-INDUCED 

NEUTROPENIA 

Muhammad Haroon 1 , Mary Daly 1 , Ahmed Eltahir 1 , Sinead Harney 1 ; 

1 

Department of Rheumatology, Cork University Hosital, Cork, Ireland. 

83 Abstract withdrawn 

81

Orthopaedics and rehabilitation 

84 A COMPARISON OF PATIENTS REFERRED AFTER FRACTURES OF THE FOREARM AND 

FRACTURES OF THE SPINE AND HIP 

Marwan Bukhari 1, 2 , Cathi Greenbank 1 , Bronwen Evans 1 , Nicola Goodson 2 , John Halsey 1 ; 

1 

Rheumatology, Royal Lancaster Infirmary, Lancaster, United Kingdom. 2 Clinical Sciences, 

Univeristy of Liverpool, Liverpool, United Kingdom. 

85 IS HIP INJECTION SAFE AND EFFECTIVE: THE PATIENT’S PERSPECTIVE? 

Debbie Haughton 1 , Christine Davey 1 , David Sapherson 3 , Graham Sefton 2 , Andrew Gough 1 ; 

1 

Rheumatology, Harrogate District Hospital, Harrogate, N Yorkshire, United Kingdom. 2 Orthopaedics, 

Harrogate District Hospital, Harrogate, N Yorkshire, United Kingdom. 3 Radiology, Harrogate District 

Hospital, Harrogate, N Yorkshire, United Kingdom. 

Health services research, economics and outcomes research 

86 WHAT HAPPENS TO PATIENTS WITH COMPLEX REGIONAL PAIN SYNDROME OF GREATER THAN 

TWELVE MONTHS DURATION? 

Maliha F. Shaikh 1 , Nicholas G. Shenker 1 ; 

1 

Rheumatology Research Unit, Addenbrooke’s Hospital, Cambridge, United Kingdom. 

87 DO PATIENTS WITH DIFFERENT INFLAMMATORY ARTHRITIDIES EXPERIENCE THE SAME 

BENEFITS FROM ANTI-TNFα THERAPY? 

James Dale 1 , Sara Else 1 , Anne Stirling 1 , Janice France 1 , Margaret-Mary Gordon 1 , John Hunter 1 , 

Duncan Porter 1 ; 

1 

Rheumatology, Gartnavel General Hospital, Glasgow, United Kingdom. 

88 VACCINATION UPTAKE IN IMMUNOSUPPRESSED RHEUMATIC POPULATIONS: TIME FOR CHANGE 

Ralph Smith 1 , Jaffar Khan 1 , Antoni Chan 1 ; 

1 

Rheumatology, Royal Berkshire Hospital, Reading, United Kingdom. 

89 EIGHT YEARS’ EXPERIENCE OF REGIONAL AUDIT IN RHEUMATOLOGY: WHAT HAVE WE LEARNT? 

Zoe Paskins 1 , Holly John 2 , Andrew Hassell 1 , Ian F. Rowe 3 ; 1 Department of Rheumatology, University 

Hospital of North Staffordshire, Stoke-on-Trent, United Kingdom. 2 Department of Rheumatology, 

Dudley Group of Hospitals NHS Trust, Dudley, United Kingdom. 3 Department of Rheumatology, 

Worcester Royal Hospital, Worcester, United Kingdom. 

90 CLINCIAL AUDIT OF THE MANAGEMENT OF SUSPECTED SEPTIC ARTHRITIS IN THE 

EMERGENCY DEPARTMENT 

Mohammad H. Al-Mossawi 1 ; 

1 

Medicine, Wycombe Hospital, High Wycombe, United Kingdom. 

91 THE IMPACT OF NEW OSTEOPOROSIS GUIDANCE ON NUMBERS NEEDING TREATMENT: 

ESTIMATES FROM A DISTRICT HOSPITAL 

Thomas Chambers 1 , Cathi Greenbank 1 , Evans Bronwen 1 , John Halsey 1 , Marwan Bukhari 1, 2 ; 

1 

Rheumatology, Royal Lancaster Infirmary, Lancaster, United Kingdom. 2 Clinical Sciences, University 

of Liverpool, Liverpool, United Kingdom. 

82

92 AN AUDIT OF THE EFFECT OF WARD LOCATION ON INPATIENT ACTIVITY 

Fiona A. Pearce 1 , Peter Lanyon 1 ; 

1 

Department of Rheumatology, Nottingham University Hospitals NHS Trust, Nottingham, 


93 GP REFERRALS TO A POLYMYALGIA RHEUMATICA RAPID ACCESS CLINIC 

Samy Zakout 1 , Lyndsey Clarke 1 , John Kirwan 1 ; 

1 

Academic Rheumatology Unit, University Hospitals Bristol NHS Foundation Trust, Bristol, United 

Kingdom. 

94 VASCULAR DISEASE AS A CAUSE OF DEATH IN OA AND RA MATCHED FOR THE PHYSICAL 

IMPACT OF THE DISEASE 

Ann Marie Smith 1 , Liz Lingard 1 , Peta Heslop 1 , David J. Walker 1 ; 

1 

Musculoskeletal Unit, Freeman Hospital, Newcastle upon Tyne, United Kingdom. 


95 RHEUMATOID FACTOR SHOULD NOT BE USED AS A SCREENING TOOL IN PRIMARY CARE 

Anne Miller 1 , Margaret Johnston 1 , Anthony Timms 2 , Siraj Misbah 2 , Raashid Luqmani 1 ; 

1 

Rheumatology, Nuffield Orthopaedic Centre, Oxford, United Kingdom. 2 Immunology, Churchill 

Hospital, Oxford, United Kingdom. 

96 IMPACT OF A COMMUNITY-BASED RHEUMATOLOGY SERVICE ON A HOSPITAL DEPARTMENT 

Andrew Bamji 1 , Jennifer Lane 1 ; 

1 

Queen Mary’s Hospital, Sidcup, United Kingdom. 

97 DOCUMENTATION OF BIOLOGIC AGENTS IN PRIMARY CARE RECORDS 

Anver A. Donnelly 1 , John P. Halsey 1 , Marwan A. Bukhari 1 ; 

1 

Rheumatology, Lancaster Royal Infirmary, Lancaster, Lancashire, United Kingdom. 

98 IMPACT OF RADIOGRAPHIC DAMAGE ON EMPLOYMENT STATUS FOR PATIENTS WITH EARLY 

RHEUMATOID ARTHRITIS (RA): RESULTS FROM THE PREMIER HEALTH-ECONOMIC 

COMPANION STUDY DE032 

R. van Vollenhoven 1 , M. Cifaldi 2 , S. Roy 2 , N. Chen 2 , M. Bergman 3 ; 

1 

Karolinska University Hospital and Karolinska Institute, Stockholm, Sweden. 2 Abbott Laboratories, 

Abbott Park, IL, United States. 3 Taylor Hospital, Ridley Park, PA, United States. 

99 HEALTH CARE COSTS ALONE DO NOT DESCRIBE THE TOTAL COSTS DIRECTLY ATTRIBUTABLE 

TO ANKYLOSING SPONDYLITIS 

Roberta Ara 1 , Rachid Rafia 1 , Jon Packham 2 , Kirstie Haywood 3 , Emma Healey 4 ; 

1 

ScHARR, University of Sheffield, Sheffield, United Kingdom. 2 Staffordshire Rheumatology Centre, 

Haywood Hospital, Sheffield, United Kingdom. 3 Arthritis Research Campaign National Primary 

Care Centre, Keele University, Keele, United Kingdom. 4 School of Health & Social Studies, 

University of Warwick, Keele, United Kingdom. 

83

100 CAN RESULTS FROM RANDOMISED CONTROLLED TRIALS BE GENERALISED TO ALL PATIENTS 

SEEKING CARE? RESULTS FROM THE MUSICIAN TRIAL OF MUSCULOSKELETAL PAIN 

Elizabeth A. Jones 1 , Gareth T. Jones 1 , Philip C. Hannaford 2 , Philip Keeley 3 , Karina Lovell 3 , 

John McBeth 4 , Paul McNamee 5 , Gordon J. Prescott 6 , Steve Woby 7 , Gary J. Macfarlane 1 ; 

1 

Aberdeen Pain Research Collaboration (Epidemiology Group), University of Aberdeen, Aberdeen, 

United Kingdom. 2 Aberdeen Pain Research Collaboration (Primary Care Group), University of 

Aberdeen, Aberdeen, United Kingdom. 3 School of Nursing, Midwifery and Social Work, University of 

Manchester, Manchester, United Kingdom. 4 Arthritis Research Campaign Epidemiology Unit, 

University of Manchester, Manchester, United Kingdom. 5 Aberdeen Pain Research Collaboration 

(Health Economics Research Unit), University of Aberdeen, Aberdeen, United Kingdom. 6 Aberdeen 

Pain Research Collaboration (Statistics Group), University of Aberdeen, Aberdeen, United Kingdom. 

7 

The Pennine Acute Hospitals NHS Trust, Manchester, United Kingdom. 

101 AN OBSERVATIONAL STUDY OF SPECIALIST INTERVENTIONS IN RHEUMATOLOGY OUTPATIENT 

CLINICS 

Muhammad Munir 1 , Abhay R. Joshi 2, 1 , Hilary Johnson 1 , Elaine C. Smith 1 ; 

1 

Rheumatology, Gloucestershire Hospitals NHS Foundation Trust, Gloucester, United Kingdom. 

2 

Rheumatology, Bristol Royal Infirmary, Bristol, United Kingdom. 

102 ESTIMATION OF HEALTHCARE COSTS AS A FUNCTION OF DISEASE SEVERITY IN PEOPLE WITH 

PSORIATIC ARTHRITIS IN THE UNITED KINGDOM 

Chris D. Poole 1 , Max Lebmeier 2 , Craig J. Currie 3 ; 

1 

Epidemiology, Pharmatelligence, Cardiff, United Kingdom. 2 Health Economics, Wyeth UK, 

Maidenhead, United Kingdom. 3 School of Medicine, Cardiff University, Cardiff, United Kingdom. 

103 THE CLINCAL EFFECTIVENESS OF FOOT ORTHOSES IN RHEUMATOID ARTHRITIS 

Heidi Clark 2 , Keith Rome 1 , Ian Atkinson 2 , Michael Plant 3 , John Dixon 2 ; 

1 

Division of Rehabilitation & Occupation Studies, AUT University, Auckland , New Zealand. 2 School 

of Health and Social Care, University opf Teesside, Middlesbrough, United Kingdom. 3 Department 

of Rheumatology, James Cook University Hospital, Middlesbrough, United Kingdom. 

104 JOINT INJECTIONS AND ORAL ANTICOAGULANTS: A REGIONAL PRACTICE SURVEY 

Sangeetha Baskar 1 , Nicola Erb 1 , Andy J. Whallett 1 ; 

1 

Rheumatology, Dudley Group of Hospitals, Dudley, United Kingdom. 

105 AUDIT OF RHEUMATOLOGY DRUG MONITORING AND RECORDING IN GENERAL 

PRACTICE: ABSENT DOCUMENTATION OF BIOLOGIC DRUGS ON MEDICAL RECORDS 

Anna Arhinful-Adjapong & Jessica Hawksley 1 , William Tillett 2 , Sandra Green 2 ; 

1 

University of Bristol Medical School, Bristol, United Kingdom. 2 Rheumatology, Weston Area Health 

Trust, Weston-super-Mare, United Kingdom. 

106 IMMEDIATE IMPACT OF AN EDUCATION PROGRAMME FOR PATIENTS WITH EARLY 


W. S. Tan 1 , J. Pauling 1 , L. Michell 1 , J. Russell 1 , S. Derham 1 , E. Korendowych 1 ; 

1 

Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom. 

107 MAINTENANCE OF PHYSICAL FUNCTION IMPROVES EMPLOYMENT STATUS OVER TIME FOR 

PATIENTS WITH EARLY RHEUMATOID ARTHRITIS 

C. Bojke 1 , M. Cifaldi 2 , S. Ray 2 , B. Van Hout 3 ; 

1 

Pharmerit International, York, United Kingdom. 2 Abbott Laboratories, Abbott Park, IL, United 

States. 3 University Medical Centre Utrecht, Utrecht, Netherlands. 

84

108 CLINICAL AUDIT OF CARE IN RHEUMATOID ARTHRITIS (CARA) 

Catriona Grigor 1 , Duncan Porter 2 , Victoria Toner 1 , Anne Stirling 2 , Anne McEntegart 1 ; 

1 

Rheumatology, Stobhill General Hospital, Glasgow, United Kingdom. 2 Rheumatology, Gartnavel 

General Hospital, Glasgow, United Kingdom. 

109 ACUTE MONOARTHRITIS: A CLINICAL AUDIT IN A DISTRICT GENERAL HOSPITAL 

Chong Seng Edwin Lim 1 , Samantha T. Low 2 , Nilay Joshi 1 , Tom Walton 1 ; 

1 

Rheumatology, Colchester General Hospital, Colchester, Essex, United Kingdom. 2 Medicine, 


110 ‘I’D LIKE TO HAVE A PHYSICAL/MENTAL BALANCE.’ PSYCHOLOGICAL IMPACT OF DISABILITY IS 

NOT COMPREHENSIVELY REPRESENTED IN THE ICF CORE SET FOR RHEUMATOID ARTHRITIS 

Tessa Sanderson 1 , Marianne Morris 1 , Michael Calnan 2 , Pam Richards 3 , Sarah Hewlett 1 ; 

1 

University West of England, Bristol, United Kingdom. 2 Kent University, Canterbury, United 

Kingdom. 3 Bristol University, Bristol, United Kingdom. 


111 ‘THANK YOU FOR ASKING’ 

Rosemary D. Waller 1 , David A. Collins 1 , Lyn J. Williamson 1 , Elizabeth J. Price 1 ; 

1 

Rheumatology, Great Western NHS Foundation Trust, Swindon, United Kingdom. 

112 DEVELOPING A PREDICTIVE TOOL FOR OUTCOMES OF TOTAL KNEE REPLACEMENT: SOUTH 

WEST LONDON ELECTIVE ORTHOPAEDIC CENTRE DATABASE 

Andrew Judge 1 , Paul A. Dieppe 3, 1 , Nigel K. Arden 1, 2 , Cyrus Cooper 1, 2 , Andrew Carr 1 , 

Kassim Javaid 1 , Richard Field 4 ; 

1 

Oxford NIHR Musculoskeletal Biomedical Research Unit, University of Oxford, Oxford, United 

Kingdom. 2 MRC Epidemiology Resource Centre, University of Southampton, Southampton, United 

Kingdom. 3 Peninsula College of Medicine and Dentistry, University of Plymouth, Plymouth, United 

Kingdom. 4 The South West London Elective Orthopaedic Centre, Epsom General Hospital, Epsom, 


113 THE COST EFFECTIVENESS OF ETANERCEPT IN PATIENTS WITH PSORIATIC ARTHRITIS IN 

THE UK 

Rachid Rafia 1 , Roberta Ara 1 , Maximilian Lebmeier 2 ; 

1 

ScHARR, University of Sheffield, Sheffield, United Kingdom. 2 Wyeth Pharmacueticals, Taplow, 


Soft tissue and regional musculoskeletal disease, fibromyalgia 

114 FOOT AND ANKLE INJURIES IN FOOTBALLERS: A PILOT EPIDEMIOLOGICAL STUDY 

Sarah Evans 1 , Simon Otter 2 , Karen Walker-Bone 1 ; 

1 

Rheumatology, Brighton and Sussex Medical School, Brighton, United Kingdom. 2 School of 

Health Professionals: Podiatry, University of Brighton, Brighton, United Kingdom. 

115 COELIAC DISEASE AND CHRONIC PAIN. REPORT OF THREE CASES DIAGNOSED IN A 

RHEUMATOLOGY UNIT, WITH REMISSION OF PAIN AFTER GLUTEN FREE DIET 

Alejandro Prada 1 , Carlos Isasi 1 , Jose Campos 1 , Teresa Otón 1 , Jessica Polo 1 , Blanca García 1 , 

Juan Mulero 1 ; 

1 

Rheumatology, Hospital Puerta de Hierro, Majadahonda, Majadahonda, Spain. 

85

116 PATHOPHYSIOLOGICAL CHANGES IN FIBROMYALGIA 

Naglaa A. Gadallah 1 , Hanan E. El-Hefnawy 1 , Nadia H. El-Arousy 1 , Nadia G. El-Hefnawy 2 , 

Tarek A. Abdou 3 , Ehab A. El Shafie 4 , Abeer K. El Zohiery 1 ; 

1 

Rheumatology & Rehabilitation, Faculty of Medicine, Ain Shams University, Cairo, Egypt. 

2 

Pathology, Faculty of Medicine, Ain Shams University, Cairo, Egypt. 3 Neuropsychiatry, Faculty of 

Medicine, Ain Shams University, Cairo, Egypt. 4 Surgery, Faculty of Medicine, Ain Shams University, 

Cairo, Egypt. 

117 PAIN LOCATION MATTERS: THE INFLUENCE OF LEG PAIN ON SOCIETAL VALUATION OF HEALTH 

STATES FOR PATIENTS WITH LOW BACK PAIN (LBP) 

Samantha L. Hider 1 , David G. Whitehurst 1, 2 , Elaine Thomas 1 , Nadine E. Foster 1 ; 

1 

arc National Primary Care Centre, Primary Care Sciences, Keele University, Keele, United 

Kingdom. 2 Health Economics Unit, School of Health and Population Sciences, University of 

Birmingham, Birmingham, United Kingdom. 

118 A RETROSPECTIVE INSIGHT INTO THE ROLES OF NERVE CONDUCTION STUDIES AND 

SYMPTOM SEVERITY QUESTIONNAIRE SCORES IN PATIENTS WITH CARPAL TUNNEL 

SYNDROME 

Adam J. Devany 1, 2 , Patrick Musonda 2 , Julian C. Blake 1 ; 

1 

Department of Clinical Neurophysiology, Norfolk and Norwich University Hospital, Norwich, 

Norfolk, United Kingdom. 2 School of Medicine, Health Policy and Practice, University Of East 

Anglia, Norwich, Norfolk, United Kingdom. 

86




Thu 22 April 2010

Poster viewing: Thursday 22 April 2010 


08.30 – 10.00 

Osteoarthritis 

119 THE VALUE OF HFE GENOTYPING IN EXCEPTIONAL OSTEOARTHRITIS 

Subha Arthanari 1 , Mohamed Nisar 1 ; 

1 

Rheumatology Dept., Burton Hospitals NHS Foundation NHS Trust, Burton on Trent, United 

Kingdom. 


120 TOLERABILITY OF TAPENTADOL EXTENDED RELEASE (ER) BASED ON DISCONTINUATIONS 

BECAUSE OF ADVERSE EVENTS IN PATIENTS WITH MODERATE TO SEVERE CHRONIC PAIN: 

RESULTS OF A 1-YEAR RANDOMIZED PHASE 3 SAFETY STUDY 

Horst Weber 1 , Robert Lange 1 , Brigitte Kuperwasser 2 , Bettyann McCann 2 , Akiko Okamoto 2 , Achim 

Steup 1 , Mila Etropolski 2 , Christine Rauschkolb 2 ; 

1 

Research and Development, Grunenthal, Aachen, Germany. 2 Johnson and Johnson, Raritan, NJ, 


121 RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO- AND ACTIVE-CONTROLLED TRIAL OF 

TAPENTADOL EXTENDED RELEASE FOR CHRONIC LOW BACK PAIN 

Douglas Shapiro 1 , Robert Buynak 2 , Akiko Okamoto 1 , Ilse Van Hove 3 , Achim Steup 4 , Bernd Lange 4 , 

Thomas Haufel 4 , Mila Etropolski 1 ; 

1 

Research and development, Johnson and Johnson, LLC, NJ, United States. 2 Northwest Indiana 

Centre for Clinical Research, Valparaiso, IN, United States. 3 Research and Development, Johnson 

and Johnson, Beerse, Germany. 4 Grunenthal, Aachen, Germany. 

122 SIMILAR ANALGESIC EFFECT AND IMPROVED TOLERABILITY OF TAPENTADOL EXTENDED 

RELEASE (ER) VERSUS OXYCODONE CONTROLLED RELEASE (CR) FOR TREATMENT OF 

CHRONIC OSTEOARTHRITIS (OA) KNEE PAIN: RESULTS FROM A RANDOMIZED, 

DOUBLE-BLIND, PHASE 3 TRIAL 

K. Kelly 3 , M. Etropolski 3 , B. Kuperwasser 3 , A. Okamoto 3 , A. Steup 2 , I. Van Hove 1 , B. Lange 2 , 

C. Rauschkolb 3 ; 

1 

Pharmaceutical Research and Development, Johnson and Johnson, Beerse, Belgium. 2 Research 

and Development, Grunenthal, Aachen, Germany. 3 Research and Development, Johnson and 

Johnson, LLC, NJ, United States. 

123 KNEE ACOUSTIC EMISSION: A CLUE TO JOINT AGEING AND FAILURE 

Lik-Kwan Shark1, Hongzhi Chen 1 , John Goodacre 2 ; 

1 

ADSIP (Applied Digital Signal and Image Processing) Research Centre, University of Central 

Lancashire, Preston, PR1 2HE, United Kingdom. 2 School of Health and Medicine, Lancaster 

University, Lancaster, LA1 4YD, United Kingdom. 

124 SEVERE KNEE OSTEOARTHRITIS: A STUDY OF COMBINED ACUPUNCTURE AND 

PHYSIOTHERAPY VERSUS HOME EXERCISE ADVICE IN PATIENTS AWAITING TOTAL KNEE 

ARTHROPLASTY 

Anushka Soni 1 , Nicola Mudge 2 , Abbhay Joshi 1 , Matthew Wyatt 2 , Lyn Williamson 1 ; 

1 

Rheumatology, The Great Western Hospital, Swindon, United Kingdom. 2 Physiotherapy, The Great 

Western Hospital, Swindon, United Kingdom. 

87

125 ANATOMICAL ABNORMALITIES IN HAND OSTEOARTHRITIS ARE AFFECTED BY SOCIAL (HOBBIES) 

BUT NOT OCCUPATIONAL BIOMECHANICAL FACTORS 

Duncan Cramb 1 , Andrew Grainger 2 , Richard Hodgson 2 , Elizabeth Hensor 3 , Kate Willis 1 , Dennis 

McGonagle 3 , Paul Emery 3 , Andrew Jones 1 , Ai Lyn Tan 3 ; 

1 

School of Sport and Health Sciences, University of Exeter, Exeter, United Kingdom. 2 Department of 

Radiology, Chapel Allerton Hospital, Leeds, United Kingdom. 3 Academic Section of Musculoskeletal 

Disease, Leeds Institute of Molecular Medicine, University of Leeds, Leeds, United Kingdom. 

126 SYSTEMATIC SEARCH AND NARRATIVE REVIEW OF RADIOGRAPHIC FOOT OSTEOARTHRITIS IN 

POPULATION-BASED STUDIES 

Bansari Trivedi 1 , Michelle Marshall 1 , Edward Roddy 1 ; 

1 

Arthritis Research Campaign National Primary Care Centre, Keele University, Keele, United Kingdom. 

Osteoporosis and metabolic bone disease 

127 OSTEOPOROSIS, FALLS AND FRACTURES: THREE CONFOUNDERS IN ONE EQUATION. 

DEVELOPMENT AND VALIDITY OF A NEW FORM FOR ASSESSMENT OF PATIENTS REFERRED FOR 

DXA SCANNING 

Yasser El Miedany 1 , Maha El Gaafary 2 , Sally Youssef 1 , Mathias Toth 3 ; 

1 


Occupational Medicine, Ain Shams University, Cairo, Egypt. 3 Geriatrics, Darent Valley Hospital, 

Dartford, United Kingdom. 

128 FRAX AIDS IDENTIFICATION OF PRIMARY CARE PATIENTS WITH OSTEOPOROSIS 

Jessica Weightman 1 , Madeleine Kelly 2 , Emma Johnston 2 , Amanda Stone 2 , Patricia Harrison 1 , 

Peter Bartholomew 1 , Clive Kelly 1 ; 

1 

Rheumatology, Queen Elizabeth Hospital, Gateshead, United Kingdom. 2 Medical School, HYMS, 

York, United Kingdom. 

129 COMPARISION OF FRAX AND NICE GUIDANCE FOR MANAGEMENT OF OSTEOPOROSIS 

Vipul Vagadia 1 , Stephen Tuck 1 ; 

1 

Rheumatology, James Cook University Hospital, Middlesbrough, Cleveland, United Kingdom. 

130 FRAGILITY FRACTURES IN RHEUMATOID ARTHRITIS: A SYSTEMATIC REVIEW 

Israa Al-Shakarchi 1 , Ann Louise Dolan 2 ; 

1 

Rheumatology, St Peters Hospital, Chertsey, Surrey, United Kingdom. 2 Rheumatology, Queen 

Elizabeth Hospital, Woolwich, London, United Kingdom. 

131 MISSED OPPORTUNITIES: PREVALENCE OF UNTREATED FRACTURES PRIOR TO HIP FRACTURE 

IN WOMEN 

Matt J. Bridges 1 , Sheila Ruddick 2 ; 

1 

Department of Rheumatology, County Durham and Darlington Foundation Trust, Darlington, United 

Kingdom. 2 Darlington Primary Care Trust, Bishop Auckland, United Kingdom. 

132 UNCOVERING HIGH RATES OF HYPOVITAMINOSIS D: IV BISPHOSPHONATE USE IN EVERY DAY 

PRACTICE 

Claire Bracewell 1 , David Wright 1 , Terence Aspray 2 ; 

1 

Rheumatology, Sunderland Royal Hospital, Sunderland, United Kingdom. 2 Metabolic Medicine & 

Care of the Elderly, Sunderland Royal Hospital, Sunderland, United Kingdom. 

88

133 EARLY LIFE MAY INTERACT WITH ADULT DIET TO AFFECT ADULT BONE MASS: THE 

HERTFORDSHIRE COHORT STUDY 

Gareth M. Hynes 1 , Karen Jameson 1 , Avan Aihie Sayer 1 , Cyrus Cooper 1 , Elaine Dennison 1 , 

Sian Robinson 1 ; 

1 

MRC Epidemiology Resource Centre, Southampton General Hospital, Southampton, Hants, 


134 BISPHOSHONATE USE IN ATYPICAL FEMORAL FRACTURES: A CASE-CONTROL STUDY 

Thomas J. Tull 1 , Ben A. Fisher 1 , Reza Jenabzadeh 2 , Justin P. Cobb 2 , Sonya Abraham 1 ; 

1 

Rheumatology, Kennedy Institute of Rheumatology, London, United Kingdom. 2 Orthopaedics, 

Imperial College NHS trust, London, United Kingdom. 

135 SEASON OF BIRTH IS A DETERMINANT OF BONE MASS IN LATE ADULTHOOD: THE 

HERTFORDSHIRE COHORT STUDY 

Gareth M. Hynes 1 , Karen Jameson 1 , Nick Harvey 1 , Avan Aihie Sayer 1 , Cyrus Cooper 1 , 

Elaine Dennison 1 ; 

1 

MRC Epidemiology Resource Centre, Southampton General Hospital, Southampton, Hants, 



136 ARE WE MEASURING THE BONE HEALTH OF EPILEPSY PATIENTS? 

Jonathan Cheah 1 , Sybil Stacpoole 2 , Dominic Heaney 2, 3 , John Duncan 2, 3 ; 

1 

UCL Medical School, London, United Kingdom. 2 The National Hospital for Neurology and 

Neurosurgery, London, United Kingdom. 3 Department of Clinical and Experimental Epilepsy, UCL 

Institute of Neurology, London, United Kingdom. 

137 GENETIC VARIATION IN WDR77 GENE IS ASSOCIATED WITH CALCANEAL BONE ULTRASOUND 

PARAMETERS: RESULTS FROM THE EUROPEAN MALE AGEING STUDY 

Delnaz Roshandel 1 , Kate Holliday 1 , Stephen R. Pye 1 , Steven Boonen 2, 3 , Herman Borghs 3 , 

Dirk Vanderschueren 3, 4 , Judith E. Adams 5 , Kate A. Ward 5 , Joseph D. Finn 1 , Ilpo T. Huhtaniemi 6 , 

Alan J. Silman 1 , Frederick C. Wu 7 , Wendy Thomson 1 , Terence W. O’Neill 1 ; 

1 

arc Epidemiology Unit, The University of Manchester, Manchester Academic Health Science 

Centre, Manchester, United Kingdom. 2 Leuven University Division of Geriatric Medicine, Katholieke 

Universiteit Leuven, Leuven, Belgium. 3 Leuven University Center for Metabolic Bone Diseases, 

Katholieke Universiteit Leuven, Leuven, Belgium. 4 Department of Andrology and Endocrinology, 

Katholieke Universiteit Leuven, Leuven, Belgium. 5 Clinical Radiology, Imaging Science and 

Biomedical Engineering, The University of Manchester, Manchester Academic Health Science 

Centre, Manchester, United Kingdom. 6 Department of Reproductive Biology, Imperial College 

London, Hammersmith Campus, London, United Kingdom. 7 Department of Endocrinology, 

Manchester Royal Infirmary, The University of Manchester, Manchester Academic Health Science 

Centre, Manchester, United Kingdom. 


138 BONE MINERAL DENSITY AND FRACTURE RISK AMONG A UK COHORT OF HIV-POSITIVE MEN 

Susanna White 1 , Simon Shaw 2 , Charlotte Short 2 , Yvonne Gilleece 2 , Martin Fisher 2 , 

Karen Walker-Bone 1 ; 

1 

Rheumatology, Brighton and Sussex Medical School, Brighton, United Kingdom. 2 Department of 

HIV/GU Medicine, Royal Sussex County Hospital, Brighton, United Kingdom. 

139 HAS THE INTRODUCTION OF FRAX CHANGED THE PATTERN OF PRIMARY CARE REFERRAL FOR 

DIRECT ACCESS DXA SCANNING? 

Chetan B. Narshi 1 , Rhodri Martin 1 , Karen Mitchell 1 , Richard Keen 1 ; 

1 

Metabolic Bone Unit, Royal National Orthopaedic Hospital, London, United Kingdom. 

89

140 PERIPHERAL BONE DENSITOMETRY IN WOMEN OVER 75 YEARS WHO HAVE SUSTAINED A LOW 

TRAUMA FRACTURE 

Matt J. Bridges 1 , Sheila Ruddick 2 ; 

1 

Department of Rheumatology, County Durham and Darlington Foundation Trust, Darlington, County 

Durham, United Kingdom. 2 Darlington Primary Care Trust, Darlington, County Durham, United 

Kingdom. 

141 PREDICTORS OF FALLS RISK AMONG PATIENTS REFERRED FOR DXA SCANNING: A PREDICTION 

MODEL 

Yasser El Miedany 1 , Mathias Toth 2 , Sally Youssef 1 , Maha El Gaafary 3 ; 

1 

Rheumatology, Darent Valley Hospital, Dartford, United Kingdom. 2 Internal Medicine, Darent Valley 

Hospital, Dartford, United Kingdom. 3 Community, Environmental and Occupational Medicine, Ain 

Shams University, Cairo, Egypt. 

142 BENEFIT OF USING FRAX TO TARGET DXA USE IN A SPANISH POPULATION 

Prieto Alhambra Daniel 1, 2 , Azagra Rafael 2, 4 , Encabo Duro Gloria 3 , Aguye Amada 2 , Zwart Marta 2, 4 , 

Javaid M Kassim 1 ; 

1 

Rheumatology, NIHR Musculoskeletal BRU, University of Oxford, Oxford, Oxfordshire, United 

Kingdom. 2 Primary Health Care, IDIAP Jordi Gol. Institut Catala de la Salut, Barcelona, Catalonia, 

Spain. 3 Nuclear Medicine / DXA, Hospital Universitari Vall d’Hebron, Barcelona, Catalonia, Spain. 

4 

Internal Medicine, Universitat Autonoma de Barcelona, Barcelona, Catalonia, Spain. 

Paediatric and adolescent rheumatology 

143 KNEE JOINT IN JIA: A PROSPECTIVE EVALUATION OF CLINICAL EXAMINATION, ULTRASOUND 

AND MRI ASSESSMENT. A NEWLY DEVELOPED KNEE MRI SCORING SYSTEM IN JIA 

Laura Pascoli 1 , Noel J. Napier 1 , Maria Wray 1 , Maura Mc Carron 1 , Catherine Mc Allister 1 , Madeleine 

E. Rooney 2 ; 

1 

Musgrave Park Hospital - Belfast Hospital Trust, Belfast, United Kingdom. 2 Queen’s University of 

Belfast, Belfast, United Kingdom. 

144 INCREASED VITAMIN D BINDING PROTEIN EXPRESSION IN JIA PATIENTS SUFFERING DISEASE 

EXTENSION 

David S. Gibson 1 , Laura Pascoli 1 , Catherine McAlilister 1 , Caitriona Scaife 2 , Michael Dunn 2 , 

Stephen Pennington 2 , Madeleine Rooney 1 ; 

1 

Arthritis Research Group, Queen’s University Belfast, Belfast, United Kingdom. 2 Proteome Research 

Centre, University College Dublin, Dublin, Ireland. 

145 A PROSPECTIVE EVALUATION OF CLINICAL AND ULTRASOUND FINDINGS IN ANKLE DISEASE IN 

JUVENILE IDIOPATHIC ARTHRITIS 

Laura Pascoli 1 , Stephen Wright 1 , Catherine Mc Allister 1 , Madeleine E. Rooney 2 ; 

1 

Musgrave Park Hospital - Belfast Hospital Trust, Belfast, United Kingdom. 2 Queen’s University of 

Belfast, Belfast, United Kingdom. 

146 ASSOCIATION OF ERAP1 WITH ENTHESITIS RELATED ARTHRITIS 

Anne Hinks 1 , Paul Martin 1 , Edward Flynn 1 , Steve Eyre 1 , Jon Packham 2 , Anne Barton 1 , 

Jane Worthington 1 , Wendy Thomson 1 ; 

1 

arc Epidemiology unit, University of Manchester, Manchester, United Kingdom. 2 Haywood Hospital, 

University Hospital of North Staffordshire, Stoke on Trent, United Kingdom. 

90

147 USE OF BIOLOGIC AGENTS IN ADULTS WITH JUVENILE IDIOPATHIC ARTHRITIS 

Flora McErlane 1 , Priyanka Kulkarni 2 , Karl Nicholl 1 , Helen E. Foster 1, 2 ; 

1 

Paediatric Rheumatology, Royal Victoria Infirmary, Newcastle upon Tyne, Tyne and Wear, United 

Kingdom. 2 Musculoskeletal Research Group, Newcastle University, Newcastle upon Tyne, Tyne and 

Wear, United Kingdom. 

148 WORKFORCE PLANNING IN PAEDIATRIC RHEUMATOLOGY IN THE UNITED KINGDOM (UK) 

Clare Pain 1 , Eileen Baildam 1 , Helen Foster 3 , Mark Harrison 2 , Deborah Symmonds 2 ; 

1 

Paediatric Rheumatology, Royal Liverpool Children’s Hospital, Liverpool, United Kingdom. 2 arc 

Epidemiology Unit, Manchester University, Manchester, United Kingdom. 3 Musculoskeletal 

Research Group, Newcastle University, Newcastle upon Tyne, United Kingdom. 

149 INVESTIGATION OF TYPE 1 DIABETES AND CELIAC DISEASE SUSCEPTIBILITY LOCI FOR 

ASSOCIATION WITH JUVENILE IDIOPATHIC ARTHRITIS. 



1 

arc Epidemiology unit, University of Manchester, Manchester, United Kingdom. 2 Haywood 

Hospital, University Hospital of North Staffordshire, Stoke on Trent, United Kingdom. 


150 ASSOCIATION OF THE CCR5 GENE WITH JUVENILE IDIOPATHIC ARTHRITIS 



1 

arc Epidemiology unit, University of Manchester, Manchester, United Kingdom. 2 Haywood 

Hospital, University Hospital of North Staffordshire, Stoke on Trent, United Kingdom. 

Rheumatoid arthritis: treatment 

151 SHOULD WE BE LOOKING MORE CAREFULLY FOR METHOTREXATE INDUCED LIVER DISEASE? 

Mark Lloyd 1 , Raad Makadsi 3 , Aftab Ala 2 , Patrick Connor 2 ; 

1 

Rheumatology, Frimley Park Hospital, Frimley, Surrey, United Kingdom. 2 Gastroenterology, Frimley 

Park Hospital, Frimley, Surrey, United Kingdom. 3 Rheumatology, East Surrey Hospital, Redhill, 

Surrey, United Kingdom. 

152 RHEUMATOID ARTHRITIS AND BRONCHIECTASIS: TREATMENT WITH RITUXIMAB 

Catherine Gwynne 1 , Brian Rhys Dillon 2 , Tom Lawson 2 ; 

1 

Rheumatology, University Hospital of Wales, Cardiff, United Kingdom. 2 Rheumatology, Princess of 

Wales Hospital, Bridgend, United Kingdom. 

153 COMPARISON OF TWO RETREATMENT STRATEGIES WITH RITUXIMAB IN PATIENTS WITH 

RHEUMATOID ARTHRITIS (RA) 

Paul Emery 1 , Philip J. Mease 2 , Andrea Rubbert-Roth 3 , Jeffrey R. Curtis 4 , Ulf Müller-Ladner 5 , 

Norman Gaylis 6 , Gillian K. Armstrong 7 , Mark Reynard 7 , Helen Tyrrell 7 ; 

1 

Leeds General Infirmary, Leeds, United Kingdom. 2 Seattle Rheum Assoc, Seattle, WA, United 

States. 3 University of Cologne, Cologne, Germany. 4 University of Alabama, Birmingham, AL, United 

States. 5 Kerckhoff Clinic, Bad Nauheim, Germany. 6 Arth Rheum Dis Spec, Aventura, FL, United 

States. 7 Roche Products Ltd, Welwyn Garden City, United Kingdom. 

91

154 THE REPRODUCTIVE SAFETY OF DISEASE MODIFYING ANTI-RHEUMATIC DRUGS AND BIOLOGIC 

AGENTS IN MEN: A SYSTEMATIC REVIEW 

Nilay Joshi 1 , Yoon Loke 2 , Alex MacGregor 3 ; 

1 

Rheumatology Department, West Suffolk Hospital, Bury St Edmunds, United Kingdom. 2 University 

of East Anglia, Norwich, United Kingdom. 3 Rheumatology Department, Norfolk and Norwich 

University Hospital, Norwich, United Kingdom. 

155 EFFECTS OF ANTI-TNF AGENTS ON BONE DENSITY AND MARKERS OF BONE METABOLISM IN 

PATIENTS WITH RHEUMATOID ARTHRITIS 

Ritu Malaiya 1 , Satish M. Rachapalli 2 ; 

1 

Rheumatology, East Surrey Hospital, Redhill, United Kingdom. 2 Rheumatology, Royal National 

Hospital for Rheumatic Diseases, Bath, United Kingdom. 

156 THE PEG MOIETY OF CERTOLIZUMAB PEGOL IS RAPIDLY CLEARED FROM THE BLOOD OF 

HUMANS BY THE KIDNEYS ONCE IT IS CLEAVED FROM THE FAB’ 

T. Parton 1 , L. King 1 , G. Parker 2 , A. Nesbitt 3 ; 

1 

Research DMPK, UCB Celltech, Slough, United Kingdom. 2 Clinical Pharmacology, UCB Celltech, 

Slough, United Kingdom. 3 Inflammation Discovery, UCB Celltech, Slough, United Kingdom. 

157 A NOVEL, PRE-FILLED SYRINGE FOR SELF-ADMINISTRATION IN PATIENTS WITH RHEUMATOID 

ARTHRITIS MAY OFFER ADVANTAGES OVER THE RAPID 2 SYRINGE 

M. Schiff 1 , A. Sheikzadeh 2 , D. Formosa 3 , B. Domanska 4 , D. Morgan 4 ; 

1 

Rheumatology, Univ Colorado Sch of Medicine, Denver, CO, United States. 2 Occupational and 

Industrial Orthopaedic Ctr, Hosp for Joint Disease, NY Univ, NY, United States. 3 Design Research, 

Smart Design, NY, United States. 4 Device Dev and Industrialization, UCB Celltech, Slough, United 

Kingdom. 

158 IMPACT OF RHEUMATOID ARTHRITIS DISEASE DURATION AND SEVERITY ON ABILITY TO REGAIN 

NORMAL PHYSICAL FUNCTION WITH TREATMENT 

R. van Vollenhoven 1 , M. Cifaldi 2 , S. Roy 2 , N. Chen 2 , L. Gotlieb 3 , M. Malaise 4 ; 

1 

Karolinska University Hospital and Karolinska Institute, Stockholm, Sweden. 2 Abbott Laboratories, 

Abbott Park, IL, United States. 3 Abbott Immunology, Louvain-la-Neuve, Belgium. 4 University Hospital 

of Liège, Liège, Belgium. 

159 ANTI TUMOUR NECROSIS FACTOR THERAPY IN RHEUMATOID ARTHRITIS: THE RISK OF 

TUBERCULOSIS. 

Matthew Langtree 1 , Manda Lam 1 , Aruna Malipeddi 1 , Waji Hassan 1 ; 

1 

Rheumatology, University Hospitals of Leicester NHS Trust, Leicester, United Kingdom. 

160 EFFICACY AND SAFETY PROFILE OF OXYCODONE/NALOXONE IN PATIENTS WITH PERSISTENT 

SEVERE MUSCULOSKELETAL PAIN 

Yasser El Miedany 1 , Maha El Gaafary 2 , Deborah Palmer 1 ; 

1 



161 TACROLIMUS IN RHEUMATOID ARTHRITIS: A SAFE AND EFFECTIVE DMARD 

Shouma Dutta 1 , Anne Breslin 1 , Yasmeen Ahmad 1 ; 

1 

Rheumatology, Ysbyty Gwynedd, Bangor, United Kingdom. 

162 THE ASSOCIATION BETWEEN TOCILIZUMAB DOSE AND SUBSEQUENT CHANGES IN 

NEUTROPHIL COUNTS 

Peter N. MorcosV, Xiaoping Zhang 1 , Susan Grange 2 , Christophe Schmitt 2 ; 

1 

F. Hoffman La Roche, Nutley, NJ, United States. 2 F. Hoffmann-La Roche, Basel, Switzerland. 

92

163 DO PATIENTS KNOW ENOUGH ABOUT THEIR ANTI-TNF TREATMENT? 

Aruna S. Malipeddi 1 , Rebecca Neame 1 ; 

1 

University Hospitals of Leicester, Leicester, United Kingdom. 

164 RHEUMATOID FACTOR (RF) OR ANTI-CYCLIC CITRULLINATED PEPTIDE (aCCP) 

SEROPOSITIVITY IN RHEUMATOID ARTHRITIS (RA) PATIENTS MAY ENHANCE CLINICAL 

RESPONSE TO RITUXIMAB 

John D. Isaacs 1 , Ewa Olech 2 , Paul P. Tak 3 , Atul Deodhar 4 , Edward Keystone 5 , Paul Emery 6 , 

David Yocum 7 , Eva Hessey 8 , Simon Read 8 ; 

1 

Musculoskeletal Research Group, Newcastle University, Newcastle Upon Tyne, United Kingdom. 

2 

Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, OK, United States. 

3 

Academic Medical Centre, University of Amsterdam, Amsterdam, Netherlands. 4 Rheumatology, 

Oregon Health & Science University, Portland, OR, United States. 5 Rheumatology, University of 

Toronto, Toronto, ON, Canada. 6 Rheumatology, Leeds General Infirmary, Leeds, United Kingdom. 

7 

Genentech Inc., South San Francisco, CA, United States. 8 Roche Products Ltd, Welwyn Garden 

City, United Kingdom. 


165 INITIAL COMBINATION THERAPY FOR EARLY RHEUMATOID ARTHRITIS: MAKING IT HAPPEN IN 

ROUTINE CLINICAL PRACTICE 

Karina J. Blunn 1 , Richard B. Williams 1 , Jackie A. McDowell 1 , David H. Rees 1 , Adam Young 2 ; 

1 

Rheumatology, Hereford County Hospital, Hereford, United Kingdom. 2 Rheumatology, St Alban’s 

City Hospital, St Alban’s, Herts, United Kingdom. 

166 SYSTEMATIC LITERATURE REVIEW OF TREATMENTS IN UNDIFFERENTIATED PERIPHERAL 

INFLAMMATORY ARTHRITIS 

Jonathan L. Marks 1 , Sarah L. Westlake 2 , Janis Baird 3 , Patrick D. Kiely 4 , Andrew J. Östör 5 , 

Mark A. Quinn 6 , Peter C. Taylor 7 , Christopher J. Edwards 1 ; 

1 

Department of Rheumatology, Southampton University Hospitals NHS Trust, Southampton, 

Hampshire, United Kingdom. 2 Department of Rheumatology, Poole Hospital NHS Foundation Trust, 

Poole, Dorset, United Kingdom. 3 MRC Epidemiology Resource Centre, University of Southampton, 

Southampton, Hampshire, United Kingdom. 4 Department of Rheumatology, St Georges Healthcare 

NHS Trust, London, London, United Kingdom. 5 Rheumatology Research Unit, Addenbrooke’s 

Hospital, Cambridge, Cambridgeshire, United Kingdom. 6 Academic Unit of Musculoskeletal 

Disease, University of Leeds, Leeds, Yorkshire, United Kingdom. 7 Kennedy Institute of 

Rheumatology, Imperial College London, London, London, United Kingdom. 

167 CLINICAL COMPARISION OF EFFICACY AND SIDE EFFECT PROFILE OF RITUXIMAB AND 

ANTI-TNF IN RHEUMATOID ARTHRITIS 

Vipul Vagadia 1 ; 

1 

Rheumatology, James Cook University Hospital, Middlesbrough, Cleveland, United Kingdom. 

168 HOW PERSISTANT IS HYPERTENSION IN RHEUMATOID ARTHRITIS PATIENTS ON 

LEFLUNOMIDE? A 5 YEAR AUDIT AND SURVEY OF CARDIOVASCULAR RISK ASSESSMENT 

Claire Bracewell 1 , Neil McKay 1 , Anna Collini 1 , Elizabeth Kidd 1 , David Wright 1 ; 

1 

Rheumatology Department, Sunderland Royal Hospital, Sunderland, United Kingdom. 

169 LIVER FUNCTION TEST (LFT) MONITORING IN PATIENTS TAKING METHOTREXATE (MTX) FOR 

RHEUMATOID ARTHRITIS (RA) 

Kathryn Watson 1 , Emma Williams 1 , Somayyeh Mossadegh 1 , Joanna Ledingham 1 ; 

1 


93

170 INCREMENTAL BENEFIT OF OPEN-LABEL CERTOLIZUMAB PEGOL + MTX IN RHEUMATOID 

ARTHRITIS (RA) PATIENTS FOLLOWING DOUBLE-BLIND PLACEBO + MTX TREATMENT OUT TO 

2 YEARS 

B. Combe 1 , S. Schwartzman 2 , E. Massarotti 3 , E. C. Keystone 4 , K. Luijtens 5 , D. van der Heijde 6 ; 

1 

Immuno-Rheumatologie, Hospital Lapeyronie, Montpellier, France. 2 Hospital for Special Surgery, 

New York, NY, United States. 3 Brigham and Women’s Hospital, Boston, MA, United States. 

4 

Rebecca MacDonald Ctr for Arth and Autoimmune Dis, Mt Sinai Hospital, Toronto, ON, Canada. 

5 

Biostatistics, UCB, Braine l’Alleud, Belgium. 6 Department of Rheumatology, Leiden Univ Medical 

Center, Leiden, Netherlands. 

171 RITUXIMAB PLUS METHOTREXATE (MTX) IS EFFECTIVE IN A SUBSET OF PATIENTS WITH EARLY 

RHEUMATOID ARTHRITIS (RA) AND CHARACTERISTICS ASSOCIATED WITH POOR OUTCOMES: AN 

ANALYSIS FROM THE IMAGE STUDY 

Xavier Mariette 1 , Alan Kivitz 2 , John D. Isaacs 3 , William Stohl 4 , Paul P. Tak 5 , Richard Jones 6 , 

Angelika Jahreis 7 , Gillian Armstrong 8 , Tim Shaw 8 ; 

1 

Hôpital Bicêtre, Paris-Sud University, Paris, France. 2 Altoona Osteoporosis Center, Duncansville, PA, 

United States. 3 Newcastle University, Newcastle upon Tyne, United Kingdom. 4 USC, LosAngeles, CA, 

United States. 5 Academic Medical Centre/University of Amsterdam, Amsterdam, Netherlands. 6 Clinic 

for Rheumatic Diseases, Tuscaloosa, AL, United States. 7 Genentech Inc, South San Francisco, CA, 

United States. 8 Roche Products Ltd, Welwyn Garden City, United Kingdom. 

172 A FASTER CLINICAL RESPONSE TO CERTOLIZUMAB PEGOL TREATMENT IS ASSOCIATED WITH 

BETTER IMPROVEMENTS IN HOUSEHOLD PRODUCTIVITY IN PATIENTS WITH RHEUMATOID 

ARTHRITIS 

R. Westhovens 1 , V. Strand 2 , E. C. Keystone 3 , O. Purcaru 4 , D. Khanna 5 , J. Smolen 6 , A. Kavanaugh 7 ; 

1 

Dept Rheumatology, Univ Hospital KU Leuven, Leuven, Belgium. 2 Div Immunol/Rheumatol, Stanford 

Univ, Palo Alto, CA, United States. 3 Rebecca MacDonald Ctr for Arthritis and Autoimmune Diseases, 

Mt Sinai Hospital, Toronto, ON, Canada. 4 Outcomes & Access Immunology, UCB, Brussels, Belgium. 

5 

Dept Rheumatology, UCLA, Los Angeles, CA, United States. 6 Div Rheumatology, Univ of Vienna, 

Vienna, Austria. 7 Div Rheum, UCSD, San Diego, CA, United States. 

173 SUSTAINED EFFICACY IS ACHIEVED WITH REPEAT COURSES OF RITUXIMAB IN PATIENTS WITH 

RHEUMATOID ARTHRITIS (RA) WITH AN INADEQUATE RESPONSE TO ONE OR MORE TNF 

INHIBITORS (TNF-IR) 

Edward C. Keystone 1 , Roy M. Fleischmann 2 , Paul Emery 3 , Maxime Dougados 4 , 

Andrew R. Baldassare 5 , Gillian K. Armstrong 6 , Matthew Linnik 7 , Mark Reynard 6 , Helen Tyrrell 6 ; 

1 

University of Toronto, Toronto, ON, Canada. 2 University of Texas Southwestern Medical Center, 

Dallas, TX, United States. 3 Leeds General Infirmary, Leeds, United Kingdom. 4 Hôpital Cochin, Paris, 

France. 5 St Louis University, St Louis, MO, United States. 6 Roche Products Ltd, Welwyn Garden City, 

United Kingdom. 7 Biogen Idec, San Diego, CA, United States. 

174 RHEUMATOID ARTHRITIS: INSIGHTS, STRATEGIES AND EXPECTATIONS - GLOBAL RESULTS OF 

THE RAISE PATIENT NEEDS SURVEY 

Iain B. McInnes 1 , B. Combe 2 , G. Burmester 3 ; 

1 

Centre for Rheumatic Diseases, University of Glasgow, Glasgow, United Kingdom. 

2 

Immuno-rheumatology Division , Hopital Lapeyronie, Montpellier University Hospital, Montpellier, 

France. 3 Rheumatology and Clinical Immunology, Charite University Hospital, Berlin, Germany. 

94

175 2-YEAR EFFICACY AND SAFETY IN ABATACEPT-TREATED PATIENTS WITH RHEUMATOID 

ARTHRITIS WHO RECEIVED CONTINUOUS THERAPY OR SWITCHED FROM INFLIXIMAB TO 

ABATACEPT: THE ATTEST TRIAL 

Michael Schiff 1 , Mauro Keiserman 2 , Christine Codding 3 , Suthin Songcharoen 4 , Alberto Berman 5 , 

Sauithree Nayiager 6 , Cristina Saldate 7 , Richard Aranda 8 , Jean-Claude Becker 8 , Cathy Zhao 8 , 

Manuela Le Bars 9 , Maxime Dougados 10 ; 

1 

University of Colorado, Denver, CO, United States. 2 Pontificial Catholic University, Porto Alegre, 

Brazil. 3 Health Research of Oklahoma, Oklahoma City, OK, United States. 4 Arthritis & Osteoporosis 

Center, Flowood, MS, United States. 5 Centro Medico Privado De Reumatologia, Tucuman, 

Argentina. 6 St Augustine’s Hospital, Durban, South Africa. 7 Centro de Investigacion del Noroeste, 

Tijuan, Mexico. 8 Bristol-Myers Squibb, Princeton, NJ, United States. 9 Bristol-Myers Squibb, 

Rueil-Malmaison, France. 10 Hopital Cochin, Descartes University, Paris, France. 

176 TREATMENT OF RHEUMATOID ARTHRITIS WITH ADALIMUMAB IS EFFECTIVE FOR PATIENTS 

WITH AND WITHOUT HISTORY OF OTHER ANTI–TNF THERAPIES 

G. R. Burmester 1 , S. Kary 2 , K. Unnebrink 2 , B. Guérette 3 , U. Oezer 2 , H. Kupper 2 ; 

1 

Charité-University Medicine Berlin, Berlin, Germany. 2 Abbott GmbH & Co. KG, Ludwigshafen, 

Germany. 3 Abbott Laboratories, Rungis, France. 


177 TREATMENT TIME NEEDED TO PREDICT REMISSION AT 1 YEAR IN EARLY RHEUMATOID 

ARTHRITIS: A SUBANALYSIS OF PREMIER 

M. Dougados 1 , E. C. Keystone 2 , B. Guérette 3 , K. Patra 4 , F. Lavie 3 ; 

1 

University of Paris V, Cochin Hospital, Paris, France. 2 University of Toronto–Mount Sinai Hospital, 

Toronto, ON, Canada. 3 Abbott Laboratories, Rungis, France. 4 Abbott Laboratories, Abbott Park, IL, 


178 THE EFFECTS OF ANTI-TNFα THERAPY ON MEAN PLATELET VOLUME AND ENDOTHELIAL 

FUNCTION IN PATIENTS WITH RHEUMATOID ARTHRITIS 

Armen Y. Gasparyan 1 , Aamer Sandoo 1 , Antonios Stavropoulos-Kalinoglou 1 , George D. Kitas 1 ; 

1 

Department of Rheumatology, Clinical Research Unit, Russell’s Hall Hospital, Dudley Group of 

Hospitals NHS Foundation Trust, Dudley, West Midlands, United Kingdom. 

179 NICE ENOUGH? AN ALL-WALES AUDIT OF CURRENT PRACTICE IN THE TREATMENT OF EARLY 

INFLAMMATORY ARTHRITIS 

Sayam R. Dubash 1 , Stuart Linton 1 ; 

1 

Rheumatology, Aneurin Bevan Health Board, Nevill Hall Hospital, Abergavenny, United Kingdom. 

180 EFFICACY OF GOLIMUMAB, A HUMAN ANTI-TNFα ANTIBODY, BY BASELINE CRP LEVEL IN 

PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS FROM THREE PHASE 3, RANDOMIZED, 

DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES 

Paul Emery 1 , Mark C. Genovese 2 , Roy M. Fleischmann 3 , Eric L. Matteson 4 , Elizabeth C. Hsia 5, 6 , 

Stephen Xu 5 , Mittie K. Doyle 5, 6 , Mahboob U. Rahman 5, 6 , On behalf of the GO-BEFORE, 

GO-FORWARD, and GO-AFTER Investigators 5 ; 

1 

University of Leeds, Leeds, United Kingdom. 2 Stanford University, Palo Alto, CA, United States. 

3 

University of Texas Southwestern Medical Center, Dallas, TX, United States. 4 Mayo Clinic , 

Rochester, MN, United States. 5 Centocor Research & Development, Inc., Malvern, PA, United 

States. 6 University of Pennsylvania School of Medicine, Philadelphia, PA, United States. 

95

181 A FASTER CLINICAL RESPONSE TO CERTOLIZUMAB PEGOL (CZP) TREATMENT IS ASSOCIATED 

WITH BETTER 52-WEEK OUTCOMES IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA) 

E. Keystone 1 , J. Curtis 2 , R. Fleischmann 3 , P. Mease 4 , D. Khanna 5 , J. Smolen 6 , G. Coteur 7 , 

B. Combe 8 ; 

1 

Rebecca MacDonald Ctr for Arthritis and Autoimmune Diseases, Mt Sinai Hospital, Toronto, ON, 

Canada. 2 University of Alabama, Birmingham, AL, United States. 3 University of Texas, Dallas, TX, 

United States. 4 Seattle Rheumatology Associates, Seattle, WA, United States. 5 UCLA, Los Angeles, 

CA, United States. 6 Medical University of Vienna, Vienna, Austria. 7 Outcomes & Access - 

Immunology, UCB Pharma, Brussels, Belgium. 8 Hospital Lapeyronie, Montpellier, France. 

182 SAFETY UPDATE ON CERTOLIZUMAB PEGOL (CZP) IN PATIENTS WITH ACTIVE RHEUMATOID 

ARTHRITIS (RA) 

R. van Vollenhoven 1 , J. Smolen 2 , M. Schiff 3 , R. Fleischmann 4 , B. Combe 5 , N. Goel 6 , C. Desai 7 , 

J. Curtis 8 , E. Keystone 9 , P. Emery 10 , E. Choy 11 ; 

1 

Karolinska Institute, Stockholm, Sweden. 2 Rheumatology, Medical University of Vienna, Vienna, 

Austria. 3 Rheumatology Division, School of Medicine, University of Colorado, Denver, CO, United 

States. 4 MCRC, University of Texas, Dallas, TX, United States. 5 Immuno-Rheumatologie, Hospital 

Lapeyronie, Montpellier, France. 6 Global Projects and Development, UCB, Smyrna, Georgia. 

7 

Biostatistics, UCB, Slough, United Kingdom. 8 Division of Clinical Immunology and Rheumatology, 

University of Alabama, Birmingham, AL, United States. 9 Rebecca MacDonald Centre for Arthritis and 

Autoimmune Disease, Mt Sinai Hospital, Toronto, ON, Canada. 10 Department of Rheumatology, 

University of Leeds, Leeds, United Kingdom. 11 Department of Rheumatology, Kings College London, 

London, United Kingdom. 

183 GASTROINTESTINAL SAFETY OF TOCILIZUMAB: DATA FROM PATIENTS WITH RHEUMATOID 

ARTHRITIS IN ROCHE CLINICAL TRIALS AND CLINICAL PRACTICE 

Ronald Van Vollenhoven 1 , Edward Keystone 2 , Richard Furie 3 , Anne Blesch 4 , Candace D. Wang 4 , 

Jeffrey R. Curtis 5 ; 

1 

Karolinska University Hospital, Stockholm, Sweden. 2 University of Toronto, Toronto, ON, Canada. 

3 

ND-LIJ Health System, Lake Success, NY, United States. 4 F. Hoffman La Roche, Nutley, NJ, United 

States. 5 University of Alabama at Birmingham, Birmingham, AL, United States. 

184 A FIVE ITEM COMPLIANCE QUESTIONNAIRE FOR RHEUMATOLOGY (CQR5) CAN EFFECTIVELY 

PREDICT LOW ADHERENCE TO DMARDS IN RHEUMATOLOGY CLINICS 

Lyndsay D. Hughes 1 , Adam Young 2 , D. John Done 1 , Gareth Treharne 3 ; 

1 

CLiCIR, University of Hertfordshire, Hatfield, United Kingdom. 2 ERAS, Rheumatology, City Hospital, 

St Albans, United Kingdom. 3 Psychology, University of Otago, Dunedin, New Zealand. 

185 LONG-TERM SAFETY OF RITUXIMAB IN RHEUMATOID ARTHRITIS: LONG-TERM FOLLOW-UP OF 

CLINICAL TRIALS AND RETREATMENT POPULATION 

Ronald F. van Vollenhoven 1 , Paul Emery 2 , Clifton O. Bingham 3 , Edward C. Keystone 4 , Roy M. 

Fleishmann 5 , Daniel E. Furst 6 , Katherine Macey 7 , Marianne T. Sweetster 8 , Patricia B. Lehane 7 , 

Pamela Farmer 9 , Simon G. Long 7 ; 

1 

The Karolinska Institute, Stockholm, Sweden. 2 Leeds General Infirmary, Leeds, United Kingdom. 

3 

Johns Hopkins University, Baltimore, MD, United States. 4 University of Toronto, Toronto, ON, 

Canada. 5 University of Texas Southwestern Medical Center at Dallas, Dallas, TX, United States. 

6 

UCLA, Los Angeles, CA, United States. 7 Roche Products Ltd, Welwyn Garden City, United Kingdom. 

8 

Biogen Idec Inc, Cambridge, MD, United States. 9 Genentech, Inc., South San Francisco, CA, 


96

186 ABATACEPT DEMONSTRATES CONSISTENT SAFETY AND SUSTAINED IMPROVEMENTS IN 

EFFICACY THROUGH 5 YEARS OF TREATMENT IN BIOLOGIC-NAÏVE PATIENTS WITH 


Joel M. Kremer 1 , Anthony S. Russell 2 , Paul Emery 3 , Carlos Abud-Mendoza 4 , Jacek Szechinski 5 , 

Jean-Claude Becker 6 , George Wu 7 , Rene Westhovens 8 ; 

1 

Center for Rheumatology, Albany Medical College, Albany, NY, United States. 2 University of 

Alberta Hospital, Edmonton, AB, Canada. 3 University of Leeds, Leeds, United Kingdom. 

4 

Rheumatology Hospital, San Luis Potosi, Mexico. 5 Department of Rheumatology, Medical 

University of Wroclaw, Wroclaw, Poland. 6 Bristol-Myers Squibb, Princeton, NJ, United States. 

7 

Bristol-Myers Squibb, Plainsboro, NJ, United States. 8 UZ Gasthuisberg, Leuven, Belgium. 

187 LONG-TERM EFFICACY OF ADALIMUMAB PLUS METHOTREXATE FOR PATIENTS WITH 

RHEUMATOID ARTHRITIS: IMPACT ON RADIOGRAPHIC, CLINICAL, AND FUNCTIONAL 

OUTCOMES 

E. C. Keystone 1 , A. Kavanaugh 2 , D. van der Heijde 3 , S. Sinisi 4 , B. Guérette 5 ; 

1 

University of Toronto–Mount Sinai Hospital, Toronto, ON, Canada. 2 University of California, San 

Diego, CA, United States. 3 Leiden University Medical Center, Leiden, Netherlands. 4 Abbott 

Laboratories, Abbott Park, IL, United States. 5 Abbott Laboratories, Rungis, France. 


188 THE EFFICACY OF CERTOLIZUMAB PEGOL ADDED TO METHOTREXATE IS SUSTAINED OVER 2 

YEARS IN THE TREATMENT OF RHEUMATOID ARTHRITIS 

E. C. Keystone 1 , R. Fleischmann 2 , J. Smolen 3 , V. Strand 4 , R. Landewe 5 , B. Combe 6 , P. Mease 7 , 

Z. Ansari 8 , N. Goel 9 , D. van der Heijde 10 , P. Emery 11 ; 

1 

Rebecca MacDonald Centre for Arthritis and Autoimmune Disorders, Mt Sinai Hospital, Toronto, 

ON, Canada. 2 MCRC, Univ of Texas, Dallas, TX, United States. 3 Div of Rheum, Univ of Vienna, 

Vienna, Austria. 4 Div of Immunol/Rheumatol, Stanford Univ, Palo Alto, CA, United States. 5 Div of 

Rheum, Univ Hospital Maastricht, Maastricht, Netherlands. 6 Immuno-Rheumatologie, Hospital 

Lapeyronie, Montpellier, France. 7 Seattle Rheum Associates, Seattle, WA, United States. 

8 

Biostatistics, UCB, Slough, United Kingdom. 9 UCB, Smyrna, GA, United States. 10 Dept of Rheum, 

Leiden Univ Medical Center, Leiden, Netherlands. 11 University of Leeds, Leeds, United Kingdom. 

189 DIFFERENTIAL SERUM GLYCOSYLATION CHANGES IN RHEUMATOID AND PSORIATIC ARTHRITIS 

– IN RESPONSE TO ANTI-TNF THERAPY 

Azita Alavi 1 , Oliver Fitzgerald 3 , Emily S. Collins 3 , Owen Fraser 1 , Edward Tarelli 2 , Vincent C. Ng 3 , 

Barry Breshnihan 3 , Douglas J. Veale 3 , John S. Axford 1 ; 

1 

The Sir Joseph Hotung Centre for Musculoskeletal Disorders, St George’s University of London, 

London, United Kingdom. 2 Biomics, St George’s University of London, London, United Kingdom. 

3 

Rheumatology, St Vincents University Hospital, Dublin, Ireland. 

190 ACR20 RESPONSE IN TOCILIZUMAB (TCZ)-TREATED PATIENTS IS NOT INFLUENCED BY DIRECT 

EFFECTS ON THE ACUTE-PHASE RESPONSE (APR) 

D. Aletaha 1 , F. Alasti 1 , J. S. Smolen 1 ; 

1 

Division of Rheumatology, Department of Internal Medicine, Medical University of Vienna, 

Vienna, Austria. 

191 IMPROVEMENT OF ACR CORE SET COMPONENTS OBSERVED IN MOST 

TOCILIZUMAB-TREATED DMARD-IR PATIENTS IN DAS28 REMISSION 

E. C. Keystone 1 , M. H. Schiff 2 , J. Rovensky 3 , M. Taylor 4 , A. K. John 4 , A. Balbir-Gurman 5 ; 

1 

University of Toronto, Toronto, ON, Canada. 2 University of Colorado, Denver, CO, United States. 

3 

National Institue of Rheumatic Diseases, Piestany, Slovakia. 4 F. Hoffmann-La Roche, Nutley, NJ, 

United States. 5 Rambam Health Care Center, Haifa, Israel. 

97

192 HOW CAN WE EFFECTIVELY MEASURE MEDICATION ADHERENCE IN RHEUMATOLOGY CLINICS? 

EVIDENCE FOR A REDUCED VERSION OF THE COMPLIANCE QUESTIONNAIRE FOR 

RHEUMATOLOGY (CQR19) 

Lyndsay D. Hughes 1 , Adam Young 2 , D. John Done 1 , Gareth J. Treharne 3 ; 

1 

CLiCIR, University of Hertfordshire, Hatfield, United Kingdom. 2 ERAS, Rheumatology, City Hospital, 

St Albans, United Kingdom. 3 Psychology, University of Otago, Dunedin 9054, New Zealand. 


193 WHAT IS MEANT BY ‘ACTIVE’ DISEASE IN THE NICE RECOMMENDATION ON USE OF 

COMBINATION THERAPY IN EARLY RA? 

Carsten Ezard 1 , Ruth Willott 1 , Sayqa Butt 1 , Kate Gadsby 1 , Chris Deighton 1 ; 

1 

Rheumatology, Royal Derby Hospital, Derby, United Kingdom. 

194 RHEUMATOID ARTHRITIS PATIENTS WITH NORMAL SERUM INTERLEUKIN-6 LEVELS CAN CEASE 

CORTICOSTEROID THERAPY WITHOUT FLARE DURING TOCILIZUMAB THERAPY 

T. Tsuru 1 , K. Terao 2 , M. Suzaki 1 , H. Nakashima 3 , A. Akiyama 4 , N. Nishimoto 5 ; 

1 

PS Clinic, Medical Co. Ltd, Fukuoka, Japan. 2 Clinicalpharmacology, Chugai Pharmaceutical Co., Ltd, 

Tokyo, Japan. 3 Fukuoka University, Fukuoka, Japan. 4 Chugai Clinical Research Center Co., Ltd, Tokyo, 

Japan. 5 Wakayama Medical University, Wakayama, Japan. 

195 GOLIMUMAB IS EFFICACIOUS IN ANTI-TNF EXPERIENCED PATIENTS WITH ACTIVE RA 

REGARDLESS OF TYPE OF AGENT OR REASON FOR DISCONTINUATION OF PRIOR ANTI-TNF: 

GO-AFTER STUDY 

Josef Smolen 1 , Paul Wordsworth 2 , Mittie K. Doyle 3 , Jonathon Kay 4 , Eric L. Matteson 5 , Robert 

Landewe 6 , Elizabeth Hsia 3 , Yiying Zhou 7 , Mahboob U. Rahman 3 , On behalf of the GO-AFTER 

Investigators 7 ; 

1 

Medical University of Vienna/Hietzing Hospital, Vienna, Austria. 2 Nuffield Orthopaedic Centre, Oxford, 

United Kingdom. 3 Centocor R&D/University of Pennsylvania School of Medicine, Malvern/Philadelphia, 

PA, United States. 4 Massachusetts General Hospital/Harvard Medical School, Boston, MA, United 

States. 5 Mayo Clinic, Rochester, MN, United States. 6 University Hospital Maastricht, Maastricht, 

Netherlands. 7 Centocor Research & Development, Inc., Malvern, PA, United States. 

196 PROLONGED EXPOSURE TO TOCILIZUMAB IS WELL TOLERATED WITH A FAVOURABLE SAFETY 

PROFILE 

Ronald Van Vollenhoven 1 , Daniel Siri 2 , Richard Furie 3 , Joel Krasnow 4 , Emma Alecock 5 , Rieke Alten 6 ; 

1 

Karolinska Institute, Stockholm, Sweden. 2 CAICI Institute, Rosario, Argentina. 3 NS-LIJ Health 

System, Lake Success, NY, United States. 4 F. Hoffmann-La Roche, Nutley, NJ, United States. 

5 

F. Hoffmann-La Roche, Welwyn, United Kingdom. 6 Schlosspark Clinic, University of Berlin, Berlin, 

Germany. 

197 RESPONSIVENESS TO TOCILIZUMAB IN RHEUMATOID ARTHRITIS PATIENTS IS PREDICTED BY 

GENE EXPRESSION PROFILE IN PERIPHERAL BLOOD CELLS AT BASELINE 

N. Nishimoto 1 , Y. Kawata 2 , C. Aoki 1 , T. Mima 1 ; 

1 

Laboratory of Immune Regulation, Wakayama Medical University, Ibaraki-City, Japan. 2 Clinical 

Research, Chugai Pharmaceutical Co., Ltd, Tokyo, Japan. 

198 LOW INCIDENCE OF MYCOBACTERIUM TUBERCULOSIS INFECTION IN PATIENTS TREATED WITH 

TOCILIZUMAB 

R. F. Van Vollenhoven 1 , N. Nishimoto 2 , H. Yamanaka 3 , T. Woodworth 4 , M. H. Schiff 5 , A. Taylor 6 , 

J. E. Pope 7 ; 

1 

Karolinska Institute, Stockholm, Sweden. 2 Wakayama Medical University, Wakayama, Japan. 

3 

Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan. 4 F. Hoffmann-La Roche, 

Welwyn, United Kingdom. 5 University of Colorado School of Medicine, Denver, CO, United States. 

6 

Royal Perth Hospital, Perth, WA, Australia. 7 University of Western Ontario, London, ON, Canada. 

98

199 IMPACT OF GOLIMUMAB ON PHYSICAL FUNCTION, HEALTH-RELATED QOL, PRODUCTIVITY AND 

EMPLOYMENT IN RA PATIENTS: WK 52 RESULTS FROM GO-FORWARD 

Mark C. Genovese 1 , Andrea Rubbert 2 , Edward C. Keystone 3 , Elizabeth C. Hsia 4 , Jacqueline 

Buchanan 5 , Lars Klareskog 6 , Frederick T. Murphy 7 , Zhong Wu 8 , Shreekant Parasuraman 5 , Mahboob 

U. Rahman 4 , On behalf of the GO-FORWARD Investigators 8 ; 

1 

Stanford University, Palo Alto, CA, United States. 2 University Hospital of Cologne, Cologne, 

Germany. 3 Rebecca MacDonald Ctr for Arthritis and Autoimmune Disease, Toronto, ON, Canada. 

4 

Centocor R&D, Inc/University of Pennsylvania School of Medicine, Malvern/Philadelphia, PA, 

United States. 5 Johnson and Johnson Pharmaceutical Services, Malvern, PA, United States. 

6 

Karolinska Institutet & Karolinska Hospital, Stockholm, Sweden. 7 Altoona Center for Clinical 

Research, Duncansville, PA, United States. 8 Centocor Research & Development, Inc., Malvern, 

PA, United States. 

200 GOLIMUMAB SIGNIFICANTLY IMPROVES PHYSICAL FUNCTION AND FATIGUE IN RA PATIENTS 

PREVIOUSLY TREATED WITH ANTI-TNF AGENTS: RESULTS FROM THE GO-AFTER STUDY 

Jonathan Kay 1 , Paul Wordsworth 2 , Mittie K. Doyle 3 , Josef Smolen 4 , Jacqueline Buchanan 5 , 

Eric L. Matteson 6 , Elizabeth C. Hsia 3 , Robert Landewe 7 , Yiying Zhou 8 , Parasuraman Shreekant 5 , 

Mahboob U. Rahman 3 , On behalf of the GO-AFTER Investigators 8 ; 

1 

Massachusetts General Hospital/Harvard Medical School, Boston, MA, United States. 2 Nuffield 

Orthopaedic Centre, Oxford, United Kingdom. 3 Centocor R&D, Inc./University of Pennsylvania 

School of Medicine, Malvern/Philadelphia, PA, United States. 4 Medical University of Vienna, 

Vienna, Austria. 5 Johnson and Johnson Pharmaceutical Services, LLC, Malvern, PA, United States. 

6 

Mayo Clinic, Rochester, MN, United States. 7 University Hospital Maastricht, Maastricht, 

Netherlands. 8 Centocor Research & Development, Inc., Malvern, PA, United States. 


201 TOCILIZUMAB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS: LONG-TERM EFFICACY FOR 

UP TO 3.5 YEARS 

J. S. Smolen 1 , J. J. Gomez-Reino 2 , C. Davies 3 , E. Alecock 3 , A. Rubbert-Roth 4 , P. Emery 5 ; 

1 

Medical University of Vienna, Vienna, Austria. 2 Universidad de Santiago de Compostela, Santiago 

de Compostela, Spain. 3 F. Hoffmann-La Roche, Welwyn, United Kingdom. 4 University of Cologne, 

Cologne, Germany. 5 St James’ University Hospital, Leeds, United Kingdom. 

Scleroderma and related disorders 

202 MULTI-CENTRE AUDIT OF TREATMENT OF INTERSTITIAL LUNG DISEASE IN SYSTEMIC 

SCLEROSIS WITH IV CYCLOPHOSPHAMIDE 

Ramin Yazdani 1 , Abhishek Abhishek 2 , Pearce Fiona 3 , Ken Lim 3 , Marian Regan 2 , Peter Lanyon 1 ; 

1 

Rheumatology, Queen’s Medical Centre, Nottingham, United Kingdom. 2 Rheumatology, Derby 

Acute Hospitals, Derby, United Kingdom. 3 Rheumatology, King’s Mill Hospital, Mansfield, United 

Kingdom. 

203 FIBROCYTE RECRUITMENT AND MYOFIBROBLAST DIFFERENTIATION AFTER ACUTE LUNG 

INJURY IS BLOCKED BY SELECTIVE INHIBITION OF TGFß SIGNALING IN RESIDENT INTERSTI- 

TIAL FIBROBLASTS 

Korsa Khan 1 , Rachel K. Hoyles 1 , Xu Shiwen 1 , Emma Derrett-Smith 1 , David Abraham 1 , 

Christopher P. Denton 1 ; 

1 

Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School, London, United 

Kingdom. 

99

204 ULTRASOUND (US) ASSESSMENT OF SKIN THICKNESS IN SYSTEMIC SCLEROSIS (SSC) 

PATIENTS TREATED WITH IV CYCLOPHOSPHAMIDE (CYC) FOR INTERSTITIAL LUNG DISEASE 

(ILD): A PILOT STUDY TO ASSESS SENSITIVITY TO CHANGE 

Lesley Ottewell 1 , Karen Walker 1 , Bridget Griffiths 1 ; 

1 

Newcastle Musculoskeletal Research Group, Freeman Hospital, Newcastle upon Tyne, United 

Kingdom. 

205 CLINICAL AND LABORATORY CHARACTERISTICS OF IRANIAN PATIENTS WITH SYSTEMIC 

SCLEROSIS (SS) 

Mohammad Ali Nazarinia 1 , Neda Abbasi 2 , Aliasghar Karimi 2 , Ali Amiri 2 ; 

1 

Rheumatology, Shiraz University of Medical Sciences, Fasa, Fars, Iran, Islamic Republic of. 

2 

Student Research Committee Fasa University of Medical Sciences, Fasa, Fars, Iran, Islamic 

Republic of. 

206 FIBROBLAST-SPECIFIC ACTIVATION OF TGFß IN VIVO RECAPITULATES A HYPOXIC PULMONARY 

HYPERTENSION PHENOTYPE IN MICE 

Emma C. Derrett-Smith 1 , Reshma Baliga 2 , Audrey Dooley 1 , Korsa Khan 1 , Xu Shi-Wen 1 , David 

Abraham 1 , Christopher P. Denton 1 ; 

1 

Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School, London, United 

Kingdom. 2 Centre for Cardiovascular Pharmacology, UCL, London, United Kingdom. 

207 ASSESSMENT OF HAND ISCHAEMIA IN SYSTEMIC SCLEROSIS 

Kate Stretton 1 , Skand Shukla 1 , Frances Hall 1 ; 

1 

Department of Clinical Medicine, University of Cambridge, Cambridge, United Kingdom. 

208 IMMUNOSUPPRESSIVE THERAPY IN SYSTEMIC SCLEROSIS ASSOCIATED INTERSTITIAL LUNG 

DISEASE-SYSTEMATIC REVIEW 

Anupama Nandagudi 2, 1 , Gabriella Kingsley 2 , David Scott 2 , Richard Stratton 1 ; 

1 

Rheumatology, King’s College, London, United Kingdom. 2 Rheumatology, Royal Free Hospital, 


209 ROLE OF THE RAS/MEK/ERK SIGNAL TRANSDUCTION PATHWAY IN FIBROBLAST ACTIVATION IN 

SYSTEMIC SCLEROSIS 

Anupama Nandagudi 1 , Xu Shiwen 1 , Andrew Leask 2 , Christopher P. Denton 1 , David Abraham 1 , 

Richard Stratton 1 ; 

1 

Rheumatology, Royal Free Hospital, London, United Kingdom. 2 Department of Physiology & 

Pharmacology, University of Western Ontario, London, ON, Canada. 

210 DEMOGRAPHICS AND PREVIOUS COMPLICATIONS/INTERVENTIONS IN PATIENTS WITH DIGITAL 

ULCERS AND DIFFERENT SUBSETS OF SCLERODERMA: PRELIMINARY FINDINGS FROM THE 

DUO REGISTRY 

Christopher P. Denton 1 , Loïc Guillevin 2 , Thomas Krieg 3 , Barbara Schwierin 4 , Daniel Rosenberg 4 , 

Mariabeth Silkey 4 , Marco Matucci-Cerinic 5 ; 

1 

Royal Free Hospital, London, United Kingdom. 2 Université Paris Descartes, Paris, France. 

3 

Universität zu Köln, Köln, Germany. 4 Actelion Pharmaceuticals AG, Allschwil, Switzerland. 

5University of Florence, Florence, Switzerland. 

211 NON-INVASIVE IMAGING FOR THE ASSESSMENT OF DERMAL FIBROSIS 

H. Jones 1 , E. Derrett-Smith 1 , X. Shiwen 1 , K. Khan 1 , C. P. Denton 1 , D. Abraham 1 , G. Bou-Gharios 2 , 

P. So 3 ; 

1 

Centre for Rheumatology, UCL Medical School, London, United Kingdom. 2 Kennedy Institute of 

Rheumatology, Imperial College London, London, United Kingdom. 3 Pre-clinical Imaging Unit, 

Institute of Psychiatry, King’s College London, London, United Kingdom. 

100

212 ANGIOTENSIN II PROMOTES THE INDUCTION OF PULMONARY MYOFIBROBLASTS THROUGH 

THE AT1 RECEPTOR VIA THE PI3-KINASE/AKT SIGNAL TRANSDUCTION PATHWAY 

Xu Shiwen 1 , Elizabeth Renzoni 2 , Chris Denton 1 , Athol Wells 2 , David Abraham 1 ; 

1 

Centre for Rheumatology, UCL- Medical School, London, United Kingdom. 2 Royal Brompton 

Hospital, Imperial College School of Medicine, London, United Kingdom. 

Sjögren’s syndrome and other connective tissue disorders 

213 SJÖGREN’S SYNDROME ACTIVITY AND DAMAGE INDICES COMPARISON 

A. Campar 2 , D. A. Isenberg 1 ; 

1 

Centre for Rheumatology, University College London Hospital, London, United Kingdom. 

2 

Internal Medicine, Centro Hospitalar do Porto - Hospital Santo António, Porto, Portugal. 


214 AUDIT ON THE ROLE OF LIP GLAND BIOPSY IN DIAGNOSING SJÖGREN’S SYNDROME IN 

BASILDON HOSPITAL 

Nada Hassan 1 , Nazar Alsanjari 2 , Nagui Gendi 3 ; 

1 

Rheumatology, Southend, Essex, United Kingdom. 2 Histopathology, Basildon, Essex, United 

Kingdom. 3 Rheumatology, Basildon, Essex, United Kingdom. 

215 INTERSTITIAL LUNG DISEASE IN THE INFLAMMATORY MYOSITIDES: DEMOGRAPHIC 

CHARACTERISTICS AND INTERRELATION OF LUNG AND MUSCLE PHENOTYPES. 

Patrick D. Kiely 1 , Alexandra M. Higton 2 , Katrina McNulty 2 , Ioannides Vlahos 3 , Sisa Grubnic 3 , 

Elizabeth J. Edwards 2 , Felix Chua 2 ; 

1 

Rheumatology, St Georges Hospital, London, United Kingdom. 2 Respiratory Medicine, St Georges 

Hospital, London, United Kingdom. 3 Radiology, St Georges Hospital, London, United Kingdom. 

216 VALIDATION OF A HISTOPATHOLOGICAL SCORE TOOL FOR THE MEASUREMENT OF SEVERITY 

IN MUSCLE BIOPSIES FROM PATIENTS WITH JUVENILE DERMATOMYOSITIS 

Lucy R. Wedderburn 1 , Hemlata Varsani 1 , Susan C. Charman 14 , Anthony A. Amato 2 , Brenda 

Banwell 3 , Kevin E. Bove 4 , Andrea M. Corse 5 , Alison Emslie-Smith 6 , Thomas S. Jacques 7 , Ingrid E. 

Lundberg 8 , Suely Marie 12 , Carlo Minetti 13 , Inger Nenesmo 8 , Elisabeth J. Rushing 9 , Caroline Sewry 10 , 

Clarissa A. Pilkington 1 , Janice L. Holton 11 , U. K. JDM Research Group 1 ; 

1 

Rheumatology, Institute of Child Health UCL, London, United Kingdom. 2 Neurology, Brigham and 

Women’s Hospital, Boston, MA, United States. 3 Neurology, The Hospital for Sick Children,, 

Toronto, ON, Canada. 4 Pathology, Cincinnati Children’s Hospital Medical Center,, Cincinnati, OH, 

United States. 5 Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, United 

States. 6 Neurology, Mayo Clinic, Rochester, MN, United States. 7 Pathology, Institute of Child 

Health UCL, London, United Kingdom. 8 Medicine, Karolinska University Hospital, Stockholm, 

Sweden. 9 Neuropathology, Armed Forces Institute of Pathology, Washington, DC, United States. 

10 

Dubowitz Neuromuscular Centre, Institute of Child Health UCL, London, United Kingdom. 

11 

Neuropathology, Institute of Neurology UCL, London, United Kingdom. 12 Neurology, Universidade 

de Sao Paulo, Sao Paulo, Brazil. 13 Neuromuscular Disease Unit, Gaslini Institute, Genoa, Italy. 

14 

Health Services Research Unit, London School of Hygiene & Tropical and Medicine, London, 


217 ALPHA-FODRIN ANTIBODIES ARE NOT USEFUL FOR THE DIAGNOSIS OF SJÖGREN’S 

SYNDROME 

Theodoros Dimitroulas 1 , Eleni Sidiropoulou 2 , Vasiliki Tsavdaridou 2 , Loukas Settas 1 ; 

1 

Department of Rheumatology, AHEPA University Hospital, Thessaloniki, Greece. 2 Department of 

Immunology, Laboratory of Microbiology, AHEPA University Hospital, Thessaloniki, Greece. 

101

218 PHYSIOLOGICAL DETERIORATION VERSUS STABILISATION IN MYOSITIS-ASSOCIATED 

INTERSTITIAL LUNG DISEASE: PHENOTYPIC DIFFERENCES. 

Alexandra M. Higton 1 , Felix Chua 1 , Katrina McNulty 1 , Sisa Grubnic 2 , Ioannides Vlahos 2 , Elizabeth J. 

Edwards 1 , Patrick D. Kiely 3 ; 

1 

Respiratory Medicine, St Georges Hospital, London, United Kingdom. 2 Radiology, St Georges 

Hospital, London, United Kingdom. 3 Rheumatology, St Georges Hospital, London, United Kingdom. 

219 PRIMARY SJÖGRENS SYNDROME: MUCH MALIGNED! 

Tilly Ratnaike 1 , Susan Pugmire 1 , Vadivelu Saravanan 1 , Clive Kelly 1 ; 

1 

Rheumatology, Queen Elizabeth Hospital, Gateshead, United Kingdom. 

220 EFFECT OF B CELL DEPLETION THERAPY (RITUXIMAB) IN 46 CAUCASIAN PATIENTS WITH 

CONNECTIVE TISSUE DISEASE 

Carolyn Lavelle 2 , Nicola Maguire 2 , Zoe McKinstry 2 , David Paton 2 , Eleanor Murray 3 , Martin Perry 1, 2 , 

Max Field 1, 2 ; 

1 

Centre for Rheumatic Diseases, Glasgow Royal Infirmary, Glasgow, United Kingdom. 2 Wolfson 

Medical School, The University of Glasgow, Glasgow, United Kingdom. 3 Dept Medicine, Western 

Infirmary, Glasgow, United Kingdom. 

221 CD146 EXPRESSION ON CIRCULATING T CELLS IN AUTOIMMUNE CONNECTIVE TISSUE DISEASE 

Andreas V. Hadjinicolaou 1 , Philippa A. Watson 1 , Brian Fang 1 , Frances C. Hall 1 , Robert Busch 1 ; 

1 

Division of Rheumatology, Department of Medicine, University of Cambridge, Cambridge, United 

Kingdom. 

222 LUNG CYSTS IN PRIMARY SJÖGREN’S SYNDROME: MORE COMMON THAN WE THINK? 

Matthew Rogers 1 , Mark Lloyd 2 , Nicholas Hughes 3 , Timothy Ho 1 ; 

1 

Respiratory Medicine, Frimley Park Hospital, Frimley, United Kingdom. 2 Rheumatology, Frimley Park 

Hospital, Frimley, United Kingdom. 3 Radiology, Frimley Park Hospital, Frimley, United Kingdom. 

SLE and antiphospholipid syndrome 

223 ACID DISRUPTION BIACORE ANALYSIS OF ANTIBODIES AGAINST RITUXIMAB IN SLE PATIENTS 

Fiona Burke 1 , Matthew D. Morgan 1 , Christine Biela 1 , Lorraine Harper 1 , Caroline Gordon 1 , 

Stephen P. Young 1 ; 

1 


224 DISEASE ACTIVITY AND LEVELS OF ANTI-APOA1, ANTI-HDL AND ANTI-OXLDL IN PATIENTS WITH 

SLE: A PROSPECTIVE STUDY 

Bethan S. Goulden 1 ; 

1 

Centre for Rheumatology Research, University College London, London, United Kingdom. 

225 ANTI-SERINE PROTEASE ANTIBODIES ARE DISTINGUISHABLE FROM ANTIPHOSPHOLIPID 

ANTIBODIES IN PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME 

Tabitha J. Turner-Stokes 1, 2 , Charis Pericleous 1, 2 , Anastasia Lambrianides 1, 2 , Katie Bell 1, 2 , Yiannis 

Ioannou 1, 2 , David Latchman 2 , David Isenberg 1, 2 , Anisur Rahman 1, 2 , Ian Giles 1, 2 ; 

1 

Centre for Rheumatology Research, Windeyer Building, University College London, London, United 

Kingdom. 2 Medical Molecular Biology Unit, Institute of Child Health, University College London, 


102

226 HUMAN ENDOTHELIAL CELLS SECRETE OXIDOREDUCTASES ON THE CELL SURFACE AND CAN 

BOTH NITROSYLATE AND MODULATE THE REDOX STATE OF ß2-GLYCOPROTEIN I 

Yiannis Ioannou 1, 2 , Jing-Yun Zhang 1, 3 , Freda H. Passam 1 , Soheila Rahgozar 1 , Jian C. Qi 1 , 

Bill Giannakopoulos 1 , Miao Qi 1 , Pei Yu 1, 3 , Demin Yu 3 , Philip J. Hogg 4 , Steven Krilis 1 ; 

1 

Department of Immunology, Allergy and Infectious Diseases, University of New South Wales, 

Sydney, NSW, Australia. 2 Centre for Rheumatology, University College London, London, United 

Kingdom. 3 Tianjin Medical UniversIty, Tianjin, China. 4 Cancer Research Centre, University of New 

South Wales, Sydney, NSW, Australia. 

227 SLE PATIENTS SHOW EVIDENCE OF PREMATURE BIOLOGICAL SENESCENCE 

Sahena Haque 1 , Chadi Rakieh 3 , Fiona Salway 2 , Pauline Ho 3 , Rachel Gorodkin 3 , Lee Suan Teh 4 , 

Philip J. Day 2 , Ian N. Bruce 1, 3 ; 

1 

arc Epidemiology Unit, University of Manchester, Manchester, United Kingdom. 2 Genomic 

Epidemiology, Manchester Interdisciplinary Biocentre, University of Manchester, Manchester, 

United Kingdom. 3 The Kellgren Centre for Rheumatology, Manchester Royal Infirmary, Manchester, 

United Kingdom. 4 Department of Rheumatology, Royal Blackburn Hospital, Blackburn, United 

Kingdom. 


228 THE EFFICACY OF REPEATED B-CELL DEPLETION THERAPY IN SLE 

Tabitha J. Turner-Stokes 1 , Tim Y. Lu 1 , Michael R. Ehrenstein 1 , Ian Giles 1 , Anisur Rahman 1 , 

David A. Isenberg 1 ; 

1 

Centre for Rheumatology Research, University College Hospital, London, United Kingdom. 

229 ACCRUAL OF DAMAGE IN VERY LATE-ONSET SYSTEMIC LUPUS ERYTHEMATOSUS 

Raquel M. Faria 2 , Sharon A. Chambers 1 , Amanda Pegden 3 , David A. Isenberg 1 ; 

1 

Centre for Rheumatology, University College London Hospital, London, United Kingdom. 

2 

Department of Medicine, Garcia de Orta Hospital, Almada, Portugal. 3 Acute Care Unit, 

Cheltenham General Hospital, Cheltenham, United Kingdom. 

230 LOW IGM IN A COHORT OF PATIENTS WITH SLE PRIOR TO RITUXIMAB ERA 

M. Shahbaz-Samavi 1 , J. Hewitt 2 , S. Haque 1 , J. Shelmerdine 3 , Y. Ahmad 4 , I. N. Bruce 1, 3 ; 

1 

arc Epidemiology Unit, The University of Manchester, Manchester, United Kingdom. 2 Immunology 

Department, Central Manchester Foundation Trust, Manchester, United Kingdom. 3 The Kellgren 

Centre for Rheumatology, Central Manchester Foundation Trust, Manchester, United Kingdom. 

4 

Rheumatology Department, Ysbyty Gwynedd Hospital, Bangor, United Kingdom. 

231 IS THE BILAG INDEX A USEFUL TOOL FOR A DISTRICT GENERAL HOSPITAL LUPUS CLINIC? 

Adrian Peall 1 , Sarah Whyman 1 , Rhian Goodfellow 1 , James Martin 1 , Julie Morgan 1 , 

Ceril Rhys-Dillon 1 ; 

1 

Rheumatology Department, Royal Glamorgan Hospital, Llantrisant, Wales, United Kingdom. 

Vasculitis 

232 PRIMARY SYSTEMIC VASCULITIS: A 10 YEAR TRUE TO LIFE STUDY FROM A NORTH LONDON 

DGH 

Kuntal Chakravarty 1 , Ibtisham Saeed 2 , Jasmine Sajnal 1 ; 

1 

Rheumatology, Queen’s Hospital, Romford, Essex, United Kingdom. 2 Histology, Queen’s Hospital, 

Romford, Essex, United Kingdom. 

103

233 SERUM ACID SPHINGOMYELINASE AS A MARKER AND MEDIATOR OF VASCULAR DAMAGE 

Allan P. Kiprianos 1 , Leigh D. Church 1 , Mark Little 1 , Caroline O. Savage 1 , Paul A. Bacon 1 , 

Stephen P. Young 1 ; 

1 


234 INTIMA MEDIA THICKNESS IN TAKAYASU ARTERITIS AND CHANGE WITH TREATMENT 

Sivakumar M. Rajappa 1 , Sanjeev Sivakumar 1 ; 

1 

Vasculitis Research, Cerebrovascular and Vasculitis Research Foundation, Chennai, Tamil Nadu, 

India. 

235 LONG-TERM FOLLOW-UP OF REFRACTORY SYSTEMIC VASCULITIS TREATED WITH RRITUXIMAB 

Ramin Yazdani 1 , Peter Lanyon 1 ; 

1 

Rheumatology, Queen’s Medical Centre, Nottingham, United Kingdom. 

236 EXPERIENCE OF PERFORMING TEMPORAL ARTERY ULTRASOUND SCANNING IN THE DIAGNOSIS 

OF TEMPORAL ARTERITIS IN A LARGE TEACHING HOSPITAL 

Alice Lorenzi 1 , Ismael Atchia 1 , Phil Platt 1 ; 

1 

Newcastle Musculoskeletal Resaerch Group, Freeman Hospital, Newcastle, United Kingdom. 

237 MEASUREMENT OF DAMAGE IN SYSTEMIC VASCULITIS: A COMPARISON OF THE VASCULITIS 

DAMAGE INDEX (VDI) WITH THE COMBINED DAMAGE ASSESSMENT INDEX (CDA) 

Ravi Suppiah 1 , Oliver Flossman 2 , Chetan Mukhtyar 3 , Federico Alberici 4 , Bo Baslund 5 , Denise Brown 1 , 

Nadeem Hasan 1 , Julia Holle 6 , Zdenka Hruskova 7 , David Jayne 2 , Andrew Judge 8 , Mark Little 9 , Peter 

Merkel 10 , Alessandra Palmisano 4 , Philip Seo 11 , Coen Stegeman 12 , Vladimir Tesar 7 , Augusto Vaglio 4 , 

Kerstin Westman 13 , Raashid Luqmani 1, 8 ; 

1 

Nuffield Orthopaedic Centre, Oxford, United Kingdom. 2 Addenbrooke’s Hospital, Cambridge, United 

Kingdom. 3 Norfolk and Norwich University Hospital, Norfolk, United Kingdom. 4 University of Parma, 

Parma, Italy. 5 University Hospital of Coenhagen, Copenhagen, Denmark. 6 University of Schleswig- 

Holstein, Luebeck, Germany. 7 First Faculty of Medicine and General Teaching Hospital, Prague, 

Czech Republic. 8 University of Oxford, Oxford, United Kingdom. 9 University of Birmingham, 

Birmingham, United Kingdom. 10 Boston University Vasculitis Center, Boston, MA, United States. 

11 

The John Hopkins Vasculitis Center, Baltimore, MD, United States. 12 University Medical Center 

Groningen, Groningen, Netherlands. 13 University Hospital MAS, Malmo, Sweden. 

238 A MODEL TO PREDICT CARDIOVASCULAR EVENTS IN PATIENTS WITH NEWLY DIAGNOSED 

WEGENER’S GRANULMOATOSIS AND MICROSCOPIC POLYANGIITIS 

Ravi Suppiah 1 , Andrew Judge 2 , Rajbir Batra 2 , Oliver Flossman 3 , Lorraine Harper 4 , Peter Höglund 5 , 

Kassim Javaid 2 , David Jayne 3 , Chetan Mukhtyar 6 , Kerstin Westman 5 , Raashid Luqmani 1, 2 ; 

1 

Rheumatology, Nuffield Orthopaedic Centre, Oxford, United Kingdom. 2 University of Oxford, Oxford, 

United Kingdom. 3 Addenbrooke’s Hospital, Cambridge, United Kingdom. 4 University of Birmingham, 

Birmingham, United Kingdom. 5 Lund University Hospital, Lund, Sweden. 6 Norfolk and Norwich 

University Hospital, Norfolk, United Kingdom. 

104




Fri 23 April 2010

Poster viewing: Friday 23 April 2010 


08.30 – 10.00 

BHPR: audit/service delivery 

239 ARMA-BASED AUDIT OF RHEUMATOLOGY SERVICE DELIVERED PREDOMINANTLY OUTSIDE THE 

TRADITIONAL HOSPITAL SETTING 

Beverley Travers 1 , Sonya Henderson 1 , Sreekanth Vasireddy 1 ; 

1 

Dept of Rheumatology, NHS Bolton, Bolton, Greater Manchester, United Kingdom. 


240 MODIFIED PILATES EXERCISES FOR LOW BACK PAIN: DO THEY HELP? 

Elizabeth J. SeQueira 2 , Patricia J. Cornell 1 , Selwyn Richards 1 ; 

1 

Rheumatology, Poole Hospital NHS Foundation Trust, Poole, Dorset, United Kingdom. 

2 

Physiotherapy, Poole Hospital NHS Foundation Trust, Poole, Dorset, United Kingdom. 

241 GUIDELINES FOR THE USE OF ANTI-CCP ANTIBODIES 

Abdul Khan 1 , Sharmeen Hasan 1 , Robin Withrington 1 , Alison Leak 1 ; 

1 

Rheumatology, QEQM Hospital, Margate, Kent, United Kingdom. 

242 ADHERENCE TO RCOPHTH GUIDELINES IN MONITORING PATIENTS ON 

HYDROXYCHLOROQUINE BY RHEUMATOLOGISTS IN NORTH STAFFORDSHIRE 

Jaswant Sandhu 1 , Annie Joseph 1 , Jon C. Packham 1 ; 

1 

University Hospital of North Staffordshire, Stoke-on-Trent, United Kingdom. 

243 AUDIT OF ANTI-TNF TREATMENT IN PATIENTS WITH ANKYLOSING SPONDYLITIS IN THE ROYAL 

GLAMORGAN HOSPITAL 

S. Lyle1, J. C. Martin 1 , R. M. Goodfellow 1 , C. Rhys-Dillon 1 , J. T. Morgan 1 , S. Mogford 3 , 

J. Rowan-Phillips 2 ; 

1 

Rheumatology, Royal Glamorgan, Llantrisant, United Kingdom. 2 Occupational Therapy, Royal 

Glamorgan, Llantrisant, United Kingdom. 3 Physiotherapy , Royal Glamorgan, Llantrisant, United 

Kingdom. 

244 RETROSPECTIVE AUDIT OF A PHYSIOTHERAPIST-LED SHOULDER CLINIC 

Diane Moss 1 , Hilary Wilson 1 , Anne McEntegart 1 ; 

1 

Rheumatology, Stobhill Hospital, Glasgow, United Kingdom. 

245 DO PATIENTS WHO SUFFER WITH LUPUS APPRECIATE A SPECIALIST CLINIC? 

Julie T. Morgan 1 , James C. Martin 1 , Ceril Rhys Dillon 1 , Rhian Goodfellow 1 ; 

1 

Rheumatology, Royal Glamorgan Hospital, Llantrisant, United Kingdom. 

246 AN AUDIT COMPARING THE MANAGEMENT OF PATIENTS WITH ESTABLISHED RHEUMATOID 

ARTHRITIS AT THE ROYAL LANCASTER INFIRMARY WITH RECENT NICE GUIDELINES 

Laura Gould 1 , Marwan Bukhari 2 ; 

1 

School of Medical Education, University of Liverpool, Liverpool, United Kingdom. 2 Department of 

Rheumatology, Royal Lancaster Infirmary, Lancaster, United Kingdom. 

105

247 COMPARISON OF BSR GUIDELINES 2004 AND NICE GUIDELINES 2008 ON ANTI-TNF 

TREATMENT OF ANKYLOSING SPONDYLITIS 

Sarah Hassan 1 , Sayqa Butt 1 , Chris Deighton 1 , Kate Gadsby 1 ; 

1 

Rheumatology, Derby Royal Hospital, Derby, United Kingdom. 

248 SUPPLEMENTING VITAMIN D THROUGH A NURSE-LED CLINIC 

Veronica Love 1 , Narabda Kara 1 , Marie Gohery 1 , Andrew Keat 1 ; 

1 

Arthritis Centre, Northwick Park Hospital, Harrow, Middlesex, United Kingdom. 

249 SURVEY OF MRI REQUESTS FROM AN ACUTE SPINAL ASSESSMENT SERVICE 

Alexandra Lewis 1 , Richard Robinson 1 , S. Bastawrous 1 , B. Roychowdhury 1 ; 

1 

Glan Clwyd Hospital, Denbighshire, United Kingdom. 

250 THE COST OF PATIENT ADVICE: A TELEPHONE ADVICE LINE AUDIT 

Samantha Roskell 1 , Barbara Douglas 1 , Heather Keating 1 , Sally Giles 1 , Jacky McPeake 1 , Cauline 

Molloy 1 , Venkat Chalam 1 , Diarmuid Mulherin 1 , Thomas Price 1 , Thomas Sheeran 1 ; 

1 

Rheumatology, Cannock Chase Hospital, Cannock, United Kingdom. 

251 EVALUATION OF THE POOLE RHEUMATOLOGY WEBSITE: ANALYSIS OF ‘HITS’ AND ENTRY SITES 

Susan R. Benjamin 1 , Paul W. Thompson 1 , Patricia Cornell 1 ; 

1 

Rheumatology, Poole Hospital NHS Trust, Poole, United Kingdom. 

252 AN AUDIT OF A COMBINED RHEUMATOLOGY AND ORTHOPAEDIC FOOT AND ANKLE SURGERY 

CLINIC 

Heidi J. Siddle 1 , Michael R. Backhouse 1 , Ray A. Monkhouse 2 , Nick J. Harris 2 , Philip S. Helliwell 1 ; 

1 

Section of Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom. 2 Department of 

Trauma and Orthopaedics, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom. 

253 PHARMACEUTICAL CARE FOR RHEUMATOID ARTHRITIS PATIENTS ON METHOTREXATE ATTENDING 

AN OUT-PATIENT HOSPITAL CLINIC 

Louise Azzopardi 1 , Steve Hudson 2 , Carmel Mallia 3 , Karen Cassar 4 , Bernard Coleiro 4 , Paul J. Cassar 4 , 

Doris Aquilina 5 , Franco Camilleri 4 , Anthony Serracino Inglott 6 , Lilian M. Azzopardi 6 ; 

1 

Pharmacy, Mater Dei Hospital, Msida, Malta. 2 Strathclyde Institue of Pharmaceutical Sciences, 

University of Strathclyde, Glasgow, United Kingdom. 3 Medicine, University of Malta, Msida, Malta. 

4 

Rheumatology, Mater Dei Hospital, Msida, Malta. 5 Specialist Nurse, Mater Dei Hospital, Msida, 

Malta. 6 Pharmacy, University of Malta, Msida, Malta. 

254 NEGOTIATING TARGETS FOR TREATMENT OF RA WITH PATIENTS 

Sandra Robinson 1 , Heslop Peta 1 , Lilley Margot 1 , Walker David 1 ; 

1 

Rheumatology, Freeman Hospital, Newcastle Upon Tyne, United Kingdom. 

255 HEALTH PROFESSIONALS’ AND PATIENTS’ VIEWS ON PRIMARY CARE SERVICES FOR 

OSTEOARTHRITIS 

Cindy Mann 1 , Rachael Gooberman-Hill 2 ; 

1 

Bristol Implant Research Centre, North Bristol NHS Trust, Bristol, United Kingdom. 2 Clinical Science 

at North Bristol, University of Bristol, Bristol, United Kingdom. 

256 COMPLYING WITH RA TREATMENT GUIDELINES AND BEST PRACTICE WHEN YOUR CLINICS ARE 

FULL FOR 6 MONTHS 

Darshan Jagannath 1 , Elaine Healey 1 , Carolyn Goddard 1 , Mark T. Pugh 1 ; 

1 

Department of Rheumatology, St Mary’s Hospital, Newport, United Kingdom. 

106

257 TB SCREENING BEFORE BIOLOGICS: DO WE NEED THE T-SPOT? 

Laura Gilham 1 , Sandeep Bawa 1 ; 

1 

Rheumatology, Gartnavel General Hospital, Glasgow, United Kingdom. 

258 A ONE-DAY PROGRAMME FOR PEOPLE WITH ANKYLOSING SPONDYLITIS: COACHING FOR 

EXERCISE IN AS (COAX-AS) 

Julie H. Barlow 1 , Lorraine MacFarland 1 , Lucy Tindall 1 , Sheila Leddington Wright 1 , Jane Tooby 2 , 

Jaya Ravindran 2 , Phillip Perkins 2 ; 

1 

Coventry University, Coventry, United Kingdom. 2 Rheumatology , University Hospital Coventry & 

Warwickshire Trust , Coventry, United Kingdom. 

259 DOES A NEGATIVE MRI NEGATE THE NEED FOR MUSCLE BIOPSY IN IDIOPATHIC 

INFLAMMATORY MYOSITIS? A RETROSPECTIVE ANALYSIS 

Laura McGregor 1 , Euan Mabon 1 , Sandeep Bawa 1 ; 

1 

Department of Rheumatology, Gartnavel General Hospital, Glasgow, United Kingdom. 


260 THE IMPACT OF THE H1N1 VIRUS ON OUR RHEUMATOLOGY TELEPHONE SUPPORT SERVICE 

Ursula Bond 1 , Joan Swan 1 , Mortimer B. O’Connor 1 , Jeetandera Rathi 1 , Michael J. Regan 1 , 

Mark J. Phelan 1 ; 

1 

Rheumatology, South Infirmary – Victoria University Hospital, Cork, Ireland. 

261 THE VALUE OF ANTI-CITRULLINATED PEPTIDE ANTIBODY IN THE DIAGNOSIS OF RHEUMATOID 

ARTHRITIS 

Teresa Doherty 1 , Keith Martin 1 , Chen Ruth 1 , Sathianathan Panthakalam 1 ; 

1 

Rheumatology Department, Eastbourne DGH, Eastbourne, United Kingdom. 

262 ASSESSMENT OF OUTPATIENT REFERRALS IN PATIENTS WITH INFLAMMATORY ARTHRITIS: 

AN AUDIT 

Daniela Bondin 1 , Madhura Castelino 1 , Sowden Evin 1 , Ann Gooden 1 , Christine Peacock 1 , 

Lee-Suan Teh 1 ; 

1 

Rheumatology, Royal Blackburn Hospital, Blackburn, United Kingdom. 

263 UK AQUATIC PHYSIOTHERAPY STANDARDISED DATA COLLECTION PROJECT 

Sarah-Jane Ryan 1, 5 , Elizabeth Bryant 1 , Anna Carter 3, 5 , Sarah Cox 5 , Ann P. Moore 1 , Anne Jackson 2, 5 , 

Raija Kuisma 1, 5 , Jacqui Pattman 4, 5 ; 

1 

School of Health Professions, University of Brighton, Eastbourne, East Sussex, United Kingdom. 

2 

Department of Physiotherapy, Western Sussex Hospitals NHS Trust, Worthing, West Sussex , 

United Kingdom. 3 Department of Physiotherapy, East Sussex hospitals NHS Trust, Eastbourne, 

West Sussex , United Kingdom. 4 Department of Physiotherapy, Brighton and Sussex Hopsitals 

NHS Trust, Brighton, East Sussex, United Kingdom. 5 Aquatic Therapy Association of Chartered 

Physiotherapists, London, United Kingdom. 

264 MAKING MONEY AND SAVING MONEY FOR YOUR DEPARTMENT IN THE NEW NHS 

Maria Juarez 1 , Annette Quilter 1 , Lyn Williamson 1 , David Collins 1 , Elizabeth Price 1 ; 

1 

Rheumatology, The Great Western Hospital NHS Foundation Trust, Swindon, United Kingdom. 

265 AN AUDIT OF THE BSR GUIDELINES FOR THE MANAGEMENT OF ANCA ASSOCIATED 

VASCULITIS TREATED WITH IV CYCLOPHOSPHAMIDE 

Yueyang Chao 1 , Janice Mooney 2 , Richard Watts 2 , Karly Graham 2 ; 

1 

Norwich School, Norwich, United Kingdom. 2 Health and Social Sciences Institute, University of 

East Anglia, Norwich, United Kingdom. 

107

266 IS IT FEASIBLE TO USE 10-YEAR FRACTURE RISK TO INFORM TREATMENT IN FRACTURE 

CLINIC? 

Fraser Birrell 2, 1 , Mike Reed 1 , Susan Croyle 1 ; 

1 

Orthopaedic Department, Wansbeck General Hospital, Newcastle upon Tyne, United Kingdom. 

2 

Muskuloskeletal Research Group, Newcastle University, Newcastle upon Tyne, United Kingdom. 

267 RE-AUDIT OF RHEUMATOLOGY FOOTWEAR REFERRALS TO THE SURGICAL APPLIANCES UNIT: 

PREDICTED COST SAVINGS CONFIRMED 

Julia Stell 1 , Sreekanth Vasireddy 1 ; 

1 

Dept of Rheumatology, NHS Bolton, Bolton, Greater Manchester, United Kingdom. 

268 MEASURING SLEEP DISTURBANCE IN AN ANNUAL REVIEW CLINIC USING A 10CM VISUAL 

ANALOGUE SCALE 

Penny Storrs 1 , Yoke-mei McLoughlin 1 , Gill Scott 1 , Frank McKenna 1 ; 

1 

Rheumatic Diseases Unit, Trafford General Hospital, Manchester, United Kingdom. 

269 A SURVEY OF MUSCULOSKELETAL ULTRASOUND USE IN THE OUTPATIENTS DEPARTMENT OF A 

DISTRICT GENERAL HOSPITAL 

Aliaksei Papou 1 , Fouz H. Rahmeh 1 , Selwyn CM Richards 1 , Sarah L. Westlake 1 ; 

1 

Rheumatology, Poole Hospital NHS Foundation Trust, Poole, Dorset, United Kingdom. 

270 MULTIDISCIPLINARY GROUP CLINICS CAN BE EFFECTIVE FOR OSTEOPOROSIS 

Fraser Birrell 1, 2 , Linda Morgan 1 , Wasim Baqir 1, 3 ; 

1 

Northumbria Healthcare NHS Foundation Trust, Newcastle upon Tyne, United Kingdom. 2 Newcastle 

University, Newcastle upon Tyne, United Kingdom. 3 Sunderland University, Sunderland, United 

Kingdom. 

271 PRACTICE-BASED AUDIT OF KNEE OSTEOARTHRITIS (OA): INCIDENCE AND PRIMARY CARE 

MANAGEMENT 

Nicola E. Walsh 1 , Lesley Ward 2 ; 

1 

University of the West of England, Bristol, United Kingdom. 2 South Bristol GP Network, Bristol, 


272 THE CLINICAL EFFECTIVENESS OF AN 8-WEEK EXERCISE PROGRAMME FOR PATIENTS WITH 


Robert Caine 1 , Mathew Williams 1 , Anne Breslin 2 , Catherine Owen 2 , Yasmeen Ahmad 2 ; 

1 

Physiotherapy, Betsi Cadwaladr University Health Board, Bangor, Gwynedd, United Kingdom. 

2 

Rheumatology, Betsi Cadwaladr University Health Board, Bangor, Gwynedd, United Kingdom. 

273 PARTNERSHIP WITH PRIMARY CARE TO DEVELOP OSTEOPOROSIS SERVICES AND PROMOTE 

FRACTURE RISK REDUCTION STRATEGIES 

Linda Morgan 1 , Alistair Blair 3 , Fraser Birrell 1, 2 ; 

1 

Northumbria Healthcare NHS Foundation Trust, Newcastle upon Tyne, United Kingdom. 

2 

Newcastle University, Newcastle upon Tyne, United Kingdom. 3Wellway Surgery, Northumberland, 


274 AUDIT ON UPTAKE OF INFLUENZA AND PNEUMOCOCCAL VACCINATIONS IN PATIENTS 

ATTENDING RHEUMATOLOGY CLINICS AT A UNIVERSITY HOSPITAL IN THE NORTH-WEST UK 

Jagdish Ramachandran Nair 1 , Ahmad Zia 1 , Devesh Mewar 1 ; 

1 

Rheumatology, Royal Liverpool University Hospital, Liverpool, Merseyside, United Kingdom. 

108

275 RETROSPECTIVE AUDIT OF ALL RHEUMATOLOGY ADMISSIONS OVER A SIX MONTH PERIOD AT 

A LARGE TEACHING HOSPITAL IN THE WEST MIDLANDS 

Gillian M. Peffers 1 ; 

1 

Rheumatology, Selly Oak Hospital, Birmingham, United Kingdom. 

276 WRIST BRACE REVIEW. AIM OF REVIEW: TO COMPARE SPLINT REQUESTED BY CLINICIAN ON 

REFERRAL FORM TO ACTUAL SPLINT PROVIDED AND ANY FURTHER TREATMENT GIVEN BY 

OCCUPATIONAL THERAPY 

Ruth Larder 1 , Dervil Dockrell 1 , Sarah Wilson 1 ; 

1 

Occupational Therapy, Sheffield Teaching Hospitals Royal Hallamshire Hospital, Sheffield, United 

Kingdom. 

277 ENQUIRIES MADE TO ARTHRITIS CARE’S HELPLINE IN ONE 6 MONTH PERIOD 

Jo Cummings 1 , Jas Bansal 1 , Julie Barlow 2 ; 

1 

Helpline Service, Arthritis Care, London, United Kingdom. 2 Coventry University, Coventry, United 

Kingdom. 


BHPR: research 

278 WHAT DOES THE HOSPITAL ANXIETY AND DEPRESSION SCALE MEASURE? EVIDENCE OF A 

BIFACTOR STRUCTURE AND ITEM BIAS 

Sam Norton 1 , John Done 1 , Amanda Sacker 3 , Adam Young 2, 1 , Nigel Cox 2 ; 

1 

Centre for Lifespan & Chronic Illness Research, University of Hertfordshire, Hatfield, Hertfordshire, 

United Kingdom. 2 Rheumatology, City Hospital, St Albans, Hertfordshire, United Kingdom. 

3 

Institute for Social & Economic Research, University of Essex, Colchester, Essex, United Kingdom. 

279 APPLYING THE COMMON-SENSE MODEL OF ILLNESS PERCEPTIONS TO THE GENERAL 

POPULATION’S BELIEFS ABOUT RHEUMATOID ARTHRITIS 

Gareth J. Treharne 1, 2 , Zoe C. McGavock 1 , Anna Tonks 1 , Sarah A. Kafka 1 , Elizabeth D. Hale 2 , 

George D. Kitas 1, 3 ; 

1 

Department of Psychology, University of Otago, Dunedin, New Zealand. 2 Department of 

Rheumatology, Dudley Group of Hospitals NHS Foundation Trust, Dudley, United Kingdom. 

3 

arc Epidemiology Unit, University of Manchester, Manchester, United Kingdom. 

280 ‘I DON’T DO SICK LEAVE’: THE WORK EXPERIENCES OF PEOPLE WITH INFLAMMATORY 

ARTHRITIS 

Debbie Fletcher 1 , Tessa Sanderson 2 , Gillian Baker 3 , Phil Street 3 , Sarah Hewlett 2 ; 

1 

Rheumatology, University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom. 

2 

University West of England, Bristol, United Kingdom. 3 Patient Partner, Bristol Royal Infirmary, 

Bristol, United Kingdom. 

281 FUNCTIONAL IMPACT OF DIFFERENT PATTERNS OF SELECTED PERIPHERAL JOINT PAINS IN 

COMMUNITY-DWELLING ADULTS AGED 50 YEARS AND OVER 

Siobhán Stynes 1 , George Peat 1 , Helen Myers 1 , Peter Croft 1 ; 

1 

Arthritis Research Campaign National Primary Care Centre, Keele University, Keele, Staffordshire, 


109

282 NRAS ‘I WANT TO WORK …’ RESULTS OF A SCOTLAND WIDE SURVEY ON THE IMPACT OF 

RHEUMATOID ARTHRITIS ON WORK 

Ailsa M. Bosworth 1 , Diane Crake 2 ; 

1 

National Rheumatoid Arthritis Society, Maidenhead , United Kingdom. 2 Ninewells Hospital, Dundee, 


283 LONG TERM COSTS AND COST-EFFECTIVENESS OF ‘ESCAPE-KNEE PAIN’: AN INTEGRATED 

REHABILITATION PROGRAMME FOR CHRONIC KNEE PAIN 

Mike Hurley 1 , Anita Patel 2 , Nicola Walsh 3 , Helene Mitchell 4 ; 

1 

Academic Physiotherapy, King’s College London, London, United Kingdom. 2 Centre for the 

Economics of Mental Health, King’s College London, London, United Kingdom. 3 Faculty of Health 

Life Sciences, University of the West of England, Bristol, United Kingdom. 4 Division of Psychology, 

De Montfort University, Leicester, United Kingdom. 

284 BREAKING COMMUNICATION BARRIERS FOR RA PATIENTS OF SOUTH ASIAN ORIGIN: THE USE 

OF A BILINGUAL AUDIO CD AND LINGUISTICALLY APPROPRIATE PEER SUPPORT 

Kanta Kumar 2 , Chandrika Gordhan 3 , Deva Situnayake 2 , Karim Raza 1 , Paul Bacon 3 ; 

1 

University of Birmingham, Birmingham, United Kingdom. 2 Sandwell and West Birmingham Hospitals 

NHS Trust , Birmingham, United Kingdom. 3 Birmingham Arthritis Resource Centre, Birmingham, 


285 ‘JUST SHOOT ME’: RA PATIENTS EXPERIENCE FLARE AS MORE THAN PAINFUL, SWOLLEN 

JOINTS 

Sarah Hewlett 1 , Tessa Sanderson 1 , James May 2 , Clifton O. Bingham III 3 , Lyn March 4 , Rieke Alten 5 , 

Christoph Pohl 5 , Thasia Woodworth 6 , Susan Bartlett 7 ; 

1 

University of the West of England, Bristol, United Kingdom. 2 Patient Research Partner, Seattle, WA, 

United States. 3 Johns Hopkins School of Medicine, Baltimore, MD, United States. 4 University of 

Sydney, Sydney, NSW, Australia. 5 University of Berlin, Berlin, Germany. 6 Roche Products, Welwyn 

Garden City, United Kingdom. 7 McGill University, Montreal, QC, Canada. 

286 CLINICIANS IN CLINICAL ASSESSMEMNT AND TREATMENT SERVICES (CATS): IS THERE 

CONSISTENCY ACROSS PROFESSIONS IN ASSESSMENT, DIAGNOSIS AND MANAGEMENT? 

Kay Stevenson 3, 2 , Edward Roddy 1, 2 , Kelvin Jordan 1 ; 

1 

arc National Primary Care Centre, Keele University, Stoke on Trent, United Kingdom. 

2 

Rheumatology Department, Stoke Primary Care Trust, Stoke on Trent, United Kingdom. 

3 

Physiotherapy Department, University Hospital of North Staffordshire, Stoke on Trent, United 

Kingdom. 

287 ‘IT’S MORE SCARY NOT TO KNOW’ WHAT ARE THE INFORMATION NEEDS OF PATIENTS WITH 

NEWLY DIAGNOSED SLE? 

Nicola Waldron 1 , Sue Brown 1 , Candy McCabe 1 , Neil McHugh 1 , Sarah Hewlett 2 , Jo Shelmerdine 3 , 

Ada Ferenkeh-Koroma 4 , Ann Breslin 5 , Sally Sawyer 6 , Miriam Haas 7 , Barbara Elliott 1 ; 

1 

Royal National Hospital for Rheumatic Diseases NHS Foundation Trust, Bath, United Kingdom. 

2 

University of the West of England, Bristol, United Kingdom. 3 Central Manchester and Manchester 

Children’s University Hospitals, Manchester, United Kingdom. 4 University College London Hospitals 

NHS Foundation Trust, London, United Kingdom. 5 North West Wales NHS Trust, Bangor, United 

Kingdom. 6 Southampton University Hospitals NHS Trust, Southampton, United Kingdom. 7 Royal 

Devon and Exeter NHS Foundation Trust, Exeter, United Kingdom. 

110

288 EXERCISE AND RHEUMATOID ARTHRITIS: WHAT’S IN IT FOR US? 

Rebecca-Jane Law 1 , Anne Breslin 2 , Emily Oliver 1, 3 , Lauren Mawn 1 , David Markland 1 , Maddison 

Peter 1, 2 , Jeanette Thom 1 ; 

1 

School of Sport, Health and Exercise Sciences, Bangor University, Bangor, United Kingdom. 

2 

Rheumatology Department, Betsi Cadwaladr University Health Board, Bangor, United Kingdom. 

3 

Department of Sport and Exercise Science, Aberystwyth University, Aberystwyth, United Kingdom. 

289 PATIENTS’ WORDS FOR SCALES TO MEASURE FLARE: ‘SOMETIMES IT DOESN’T FIT INTO 

THAT NEAT LITTLE BOX’ 

Sarah Hewlett 1 , Tessa Sanderson 1 , James May 2 , Clifton O. Bingham III 3 , Lyn March 4 , Rieke Alten 5 , 

Christoph Pohl 5 , Thasia Woodworth 6 , Susan Bartlett 7 ; 

1 

University of the West of England, Bristol, United Kingdom. 2 Patient Research Partner, Seattle, 

WA, United States. 3 Johns Hopkins School of Medicine, Baltimore, MD, United States. 4 University 

of Sydney, Sydney, NSW, Australia. 5 University of Berlin, Berlin, Germany. 6 Roche Products, 

Welwyn Garden City, United Kingdom. 7 McGill University, Montreal, ON, Canada. 


290 GOAL SETTING FOR MANAGING RHEUMATOID ARTHRITIS FATIGUE: A QUALITATIVE 

EXPLORATION 

Alena Cliss 1, 2 , Marianne Morris 1 , Nicholas Ambler 2 , Beverly Knops 2 , Alison Hammond 3 , 

Celia Almeida 1 , Sarah Hewlett 1 ; 

1 

Faculty of Health and Life Sciences, University of the West of England, Bristol, United Kingdom. 

2 

Pain Management, Frenchay Hospital, Bristol, United Kingdom. 3 Institute for Health and Social 

Care Research, University of Salford, Salford, United Kingdom. 

Education research 

291 MEDICAL STUDENTS’ ATTITUDE TOWARDS RHEUMATOLOGY TRAINING AT FY1 AND FY2 LEVEL: 

RESULTS FROM A NATIONAL SURVEY 

Muryum Thapper 1 , Euthalia Roussou 1, 2 ; 

1 


2 

Rheumatology & Rehabilitation, King George Hospital BHRUT, London, United Kingdom. 

292 INTEGRATING PAEDIATRIC MUSCULOSKELETAL (PMSK) CLINICAL SKILLS INTO 

UNDERGRADUATE TEACHING: BARRIERS AND CHALLENGES 

Sharmila Jandial 1 , John Pearson 2 , Helen E. Foster 1 ; 

1 

Musculoskeletal Research Group, Newcastle University, Newcastle upon Tyne, United Kingdom. 

2 

School of Medical Sciences Education Development, Newcastle University, Newcastle upon Tyne, 


293 IMPROVING THE RELIABILITY OF DAS28 MEASUREMENT: USING MUSCULOSKELETAL ULTRA- 

SOUND TO FACILITATE TRAINING 

Ben Thompson 1, 2 , Jennifer Orr 1 , Phil Platt 3 , Fraser Birrell 1, 2 ; 

1 

Northumbria Healthcare NHS Foundation Trust, Newcastle-upon-Tyne, United Kingdom. 

2 

Newcastle University, Newcastle-upon-Tyne, United Kingdom. 3 Newcastle-upon-Tyne Hospitals 

NHS Foundation Trust, Newcastle-upon-Tyne, United Kingdom. 

294 UNDERGRADUATE TEACHING IN RHEUMATOLOGY OUTPATIENTS: STUDENTS’ EXPERIENCES 

AND PERCEPTIONS 

Meera Sritharan 1 , Adam Croft 1 , Elizabeth Justice 1 , David Carruthers 1 ; 

1 

Department of Rheumatology, City Hospital, Sandwell and West Birmingham Hospitals NHS Trust, 

Birmingham, United Kingdom. 

111

295 A QUALITATIVE SURVEY OF THE IMAGES USED ON THE ARC OSTEOMALACIA MIND-MAP IN 

RELATION TO CULTURAL BACKGROUND 

David Walker 1 , Sandra Robinson 1 , Yogen Jagatsinh 1 , Ade Adebajo 2 , Phil Helliwell 3 , Anisur Rahman 4 ; 

1 

Freeman Hospital, Newcastle on Tyne, United Kingdom. 2 Barnsley District Hospital, Barnsley, 

United Kingdom. 3 Rheumatism Research Unit, Leeds, United Kingdom. 4 University College, London, 


296 HOW CAN RHEUMATOLOGY SPECIALIST TRAINING BE SUPPORTED IN THE WORKPLACE? 

P. Shah 1 , N. Snowden 2 , H. Dexter 1 , T. Dornan 1 ; 

1 

University of Manchester, Manchester, United Kingdom. 2 Rheumatology Department, Penine Acute 

Trust, Manchester, United Kingdom. 

297 UNDERSTANDING LIFE WITH RHEUMATOID ARTHRITIS: A LIFESTYLE SURVEY TO EXPLORE THE 

PATIENT’S PERSPECTIVE 

Deepwant Singh 1 , Anne Meadows 1 , Jill Frusher 3 , Claire Sampson 2 , Nicholas J. Sheehan 1 , 

Sandeep Dahiya 1 ; 

1 

Department of Rheumatology, Peterborough & Stamford Hospitals NHS Foundation Trust, 

Peterborough, United Kingdom. 2 Department of Occupational Therapy, Peterborough & Stamford 

Hospitals NHS Foundation Trust, Peterborough, United Kingdom. 3 Department of Physiotherapy, 

Peterborough & Stamford Hospitals NHS Foundation Trust, Peterborough, United Kingdom. 

298 PATIENT ATTITUDES TOWARDS MEDICAL STUDENT TRAINING IN AN OUTPATIENT 

RHEUMATOLOGY CLINIC 

Adam P. Croft 1 , Meera Sritharan 1 , Elizabeth A. Justice 1 , David M. Carruthers 1 ; 

1 

Rheumatology, City Hospital, Birmingham, United Kingdom. 

299 COMMUNICATION SKILLS FOR DOCTOR AND PATIENT: USE OF A CLINIC SPECIFIC INVITATION 

LETTER IN RHEUMATOLOGY OUTPATIENTS 

Jayne Little 1 , Sunil Melath 1 , Sarah Procter 1 , Zoey Horne 1 , Sandeep Dahiya 1 ; 

1 

Rheumatology, Peterborough & Stamford Hospitals NHS Foundation Trust, Peterborough, 

Cambridgeshire, United Kingdom. 

300 AN EXPLORATION OF CARER EXPERIENCES OF COMPLEX REGIONAL PAIN SYNDROME 

A. Lauder 1 , C. McCabe 2, 3 , K. Rodham 2, 4 ; 

1 

Bristol Doctorate in Clinical Psychology, University of Plymouth, Bristol, United Kingdom. 2 The Royal 

National Hospital for Rheumatic Diseases, Bath, United Kingdom. 3 School for Health, University of 

Bath, Bath, United Kingdom. 4 Dept. of Psychology, University of Bath, Bath, United Kingdom. 

Epidemiology 

301 THE POPULATION PREVALENCE OF FOOT AND ANKLE PAIN OVER THE AGE OF 45 YEARS: 

A SYSTEMATIC REVIEW 

Martin J. Thomas 1 , George Peat 1 , Edward Roddy 1 ; 

1 

Arthritis Research Campaign National Primary Care Centre, Keele University, Keele, United 

Kingdom. 

112

302 CHARACTERISTICS OF PRIMARY CARE CONSULTATIONS FOR MUSCULOSKELETAL FOOT AND 

ANKLE PROBLEMS 

Hylton B. Menz 1, 2 , Kelvin P. Jordan 1 , Edward Roddy 1 , Peter R. Croft 1 ; 

1 

Arthritis Research Campaign National Primary Care Centre, Primary Care Sciences, Keele 

University, Keele, United Kingdom. 2 Musculoskeletal Research Centre, Faculty of Health Sciences, 

La Trobe University, Bundoora, VIC, Australia. 

303 LONELINESS PREDICTS BACK PAIN ONSET IN OLDER PERSONS 

Rachael E. Docking 1 , Jane Fleming 2 , Jun Zhao 2 , Carol Brayne 2 , Gary J. Macfarlane 1 , 

Gareth T. Jones 1 ; 

1 

Aberdeen Pain Research Collaboration (Epidemiology Group), University of Aberdeen, Aberdeen, 

United Kingdom. 2 Public health and Primary Care, University of Cambridge, Cambridge, United 

Kingdom. 


304 DETERMINING ANALGESIC PRESCRIBING RATES IN PRIMARY CARE USING A CONSENSUS 

MODEL OF PRESCRIBING FROM GENERAL PRACTICE 

John Bedson 1 , Orsolina I. Martino 1 , Kelvin P. Jordan 1 ; 

1 

Arthritis Research Campaign National Primary Care Centre Primary Care Sciences, Keele 

University, Newcastle-under-Lyme, Staffordshite, United Kingdom. 

305 INCREASING DEPRIVATION AND OSTEOPOROSIS: FURTHER ANALYSIS ADJUSTING FOR 

GEOGRAPHICAL AND PHYSICAL VARIABLES 

Audrey Dugue 3 , Cathi Greenbank 1 , Bronwen Evans 1 , Peter Diggle 3 , Nicky Goodson 2 , John Halsey 1 , 

Marwan Bukhari 1, 2 ; 

1 

Rheumatology, Royal Lancaster Infirmary, Lancaster, Lancashire, United Kingdom. 2 Clinical 

Sciences, University of Liverpool, Liverpool, Merseyside, United Kingdom. 3 CHICAS, Lancaster 

University, Lancaster, United Kingdom. 

306 AN EPIDEMIOLOGICAL REVIEW OF PIGMENTED VILLONODULAR SYNOVITIS (PVNS) IN THE 

MALTESE ISLANDS 

Valerie Fenech 1 , Cecilia Farrugia 1 , James Degaetano 2 , Charles Grixti 3 , Andrew A. Borg 1 ; 

1 

Rheumatology, Mater Dei Hospital, Msida, Malta. 2 Pathology, Mater Dei Hospital, Msida, Malta. 

3 

Orthopaedics, Mater Dei Hospital, Msida, Malta. 

307 CHANGES IN HIP FRACTURE RATE BEFORE AND AFTER TOTAL KNEE REPLACEMENT DUE TO 

OSTEOARTHRITIS: A POPULATION-BASED COHORT STUDY 

Daniel Prieto-Alhambra 1, 2 , M Kassim Javaid 1 , Joe Maskell 4, 1 , Andrew Judge 1 , Michael Nevitt 3 , 

Cyrus Cooper 1, 4 , Nigel K Arden 1, 4 ; 

1 

Rheumatology, NIHR Musculoskeletal BRU, University of Oxford, Oxford, Oxfordshire, United 

Kingdom. 2 Internal Medicine;Primary Care, Universitat Autonoma de Barcelona; IDIAP Jordi 

Gol;Institut Catala de la Salut, Barcelona, Catalonia, Spain. 3 Department of Epidemiology and 

Biostatistics, University of California, San Francisco., San Francisco, CA, United States. 4 MRC 

Epidemiology Resource Centre, University of Southampton, Southampton General Hospital, 

Southampton, Hampshire, United Kingdom. 

308 ARE CLINICAL OUTCOMES WORSE AMONG LOW BACK PAIN CONSULTERS WITH REFERRED 

LEG PAIN IN PRIMARY CARE? 

Jonathan C. Hill 1 , Kika Konstantinou 1 , Bolaji E. Egbewale 1 , Kate M. Dunn 1 , Martyn Lewis 1 , 

Danielle van der Windt 1 ; 

1 

arc National Primary Care Centre, Keele University, Stoke-on-Trent, Staffordshire, United 

Kingdom. 

113

309 A COMPARISON OF CLINICAL CHRONIC WIDESPREAD PAIN (CWP) WITH PAIN MANIKIN DEFINED 

CWP IN PATIENTS REFERRED TO A CLINICAL ASSESSMENT AND TREATMENT SERVICE (CATS) 

Irena Zwierska 1 , Jonathan C. Packham 1 , Kelvin P. Jordan 1 , Edward Roddy 1 ; 

1 


University, Keele, United Kingdom. 

310 TREATMENT GUIDELINES FOR OSTEOPOROSIS SELECT DIFFERENT PATIENT POPULATIONS 

Thomas Chambers 1 , Helena Johansson 2 , Nicola Goodson 3 , John P. Halsey 1 , Marwan A. Bukhari 1, 3 ; 

1 

Department of Rheumatology, University Hospitals of Morecambe Bay NHS Trust, Lancaster, 

Lancashire, United Kingdom. 2 WHO Collaborating Centre for Metabolic Bone Diseases, University of 

Sheffield, Sheffield, Yorkshire, United Kingdom. 3 Department of Clinical Sciences, University of 

Liverpool, Liverpool, United Kingdom. 

311 HIGH RHEUMATOID DISEASE ACTIVITY IS ASSOCIATED WITH LOWER TRIGLYCERIDE LEVELS: A 

STUDY OF INDIAN PATIENTS WITH RHEUMATOID ARTHRITIS 

Firdaus Fatima 2, 1 , Robert J. Moots 1 , Uppuluri R. Rao 2 , Nicola J. Goodson 1 ; 

1 

Rheumatology, University Hospital Aintree, Liverpool, United Kingdom. 2 Rheumatology, Sri Deepti 

Rheumatology Center, Hyderabad, India. 

312 MUSCULOSKELETAL FOOT PROBLEMS IN PRIMARY CARE: WHAT INFLUENCES OLDER PEOPLE 

TO CONSULT? 

Hylton B. Menz 1, 2 , Kelvin P. Jordan 1 , Edward Roddy 1 , Peter R. Croft 1 ; 

1 


University, Keele, United Kingdom. 2 Musculoskeletal Research Centre, Faculty of Health Sciences, 

La Trobe University, Bundoora, VIC, Australia. 

313 THE NATURAL HISTORY OF KNEE PAIN IN A PROSPECTIVE LONGITUDINAL POPULATION-BASED 

COHORT: IDENTIFYING IMPORTANT PATIENT PHENOTYPES 

Anushka Soni1, Kirsten White 1 , Amit Kiran 1 , Lyndsey Goulston 2 , Deborah Hart 3 , Tim Spector 3 , 

M Kassim Javaid 1 , Nigel K. Arden 1, 2 ; 

1 

NIHR Musculoskeletal BRU, University of Oxford, Oxford, United Kingdom. 2 Epidemiology Resource 

Centre, University of Southampton, Southampton, United Kingdom. 3 Department of Twin Research 

and Genetic Epidemiology, King’s College London, London, United Kingdom. 

314 THE NATURAL HISTORY OF KNEE PAIN IN A PROSPECTIVE LONGITUDINAL POPULATION-BASED 

COHORT: HOW DOES PAIN CHANGE OVER TIME? 

Anushka Soni 1 , Kirsten White 1 , Amit Kiran 1 , Lyndsey Goulston 2 , Deborah Hart 3 , Tim Spector 3 , 

M Kassim Javaid 1 , Nigel K. Arden 1, 2 ; 

1 

NIHR Musculoskeletal BRU, University of Oxford, Oxford, United Kingdom. 2 Epidemiology Resource 

Centre, Southampton University, Southamptom, United Kingdom. 3 Department of Twin Research 

and Genetic Epidemiology, Kings College London, London, United Kingdom. 

Genetics 

315 INVESTIGATION OF ASSOCIATION OF THE ERAP1 GENE WITH PSORIATIC ARTHRITIS 

Madhura Castelino 1 , Laura Gibbons 1 , Neil McHugh 2 , Ellie Korendowych 2 , Ian N. Bruce 1 , Pauline Ho 1 , 

Anne Barton 1 ; 

1 

arc Epidemiology Unit, Manchester University, Manchester, United Kingdom. 2 Royal National 

Hospital for Rheumatic Diseases, Bath, United Kingdom. 

114

316 INVESTIGATING THE COMPLEX ASSOCIATIONS OF MHC WITH RHEUMATOID ARTHRITIS 

SUSCEPTIBILITY 

Gisela Orozco 1 , Anne Barton 1 , Steve Eyre 1 , Jane Worthington 1 , Xiayi Ke 2, 1 , Wendy Thomson 1 ; 

1 

ARC-EU, University of Manchester, Manchester, United Kingdom. 2 UCL Institute of Child Health, 


317 THE EFFECT OF APOLIPOPROTEIN E POLYMORPHISMS ON DYSLIPIDAEMIA AND 

INFLAMMATION IN RHEUMATOID ARTHRITIS 

Tracey E. Toms 1, 3 , Jacqueline P. Smith 2 , Vasileios F. Panoulas 1 , Karen M. Douglas 1 , 

George D. Kitas 1, 3 ; 

1 

Rheumatology, Dudley Group of Hospitals NHS Foundation Trust, Dudley, United Kingdom. 

2 

Clinical Biochemistry, Dudley Group of Hospitals NHS Foundation Trust, Dudley, United Kingdom. 

3 

arc Epidemiology Unit, Manchester University, Manchester, United Kingdom. 


318 A GENETIC MARKER AT THE OLIG3/TNFAIP3 LOCUS CORRELATES WITH METHOTREXATE 

CONTINUATION IN EARLY INFLAMMATORY POLYARTHRITIS 

Darren Plant 1 , Tracey Farragher 3 , Edward Flynn 1 , Paul Martin 1 , Steven Eyre 1 , Diane Bunn 2 , 

Jane Worthington 1 , Deborah Symmons 1 , Anne Barton 1 , Wendy Thomson 1 ; 

1 

arc Epidemiology Unit, The University of Manchester, Manchester, United Kingdom. 2 Norfolk 

Arthritis Register, UEA , Norwich, United Kingdom. 3 Centre for Medical Statistics and Health 

Evaluation, The University of Liverpool, Liverpool, United Kingdom. 

Psychology, measurement and management of pain 

319 HOSPITAL ANXIETY AND DEPRESSION (HAD) SCORES IN RHEUMATOID ARTHRITIS: 

ASSOCIATIONS WITH FUNCTION, DISEASE DURATION AND EMPLOYMENT STATUS 

Neil Mo 1 , Juliette Oakley 1 , Margaret O’Sullivan 1 ; 

1 

Rheumatology, Wrexham Maelor Hospital, Wrexham, United Kingdom. 

320 EXPLORING THE USE OF CLINICAL SIGNS TO TEST FOR CORTICAL REORGANISATION IN 

COMPLEX REGIONAL PAIN SYNDROME 

Maliha F. Shaikh 1 , Dileep Soory 2 , Richard A. Parker 3 , Nicholas G. Shenker 1 ; 

1 

Rheumatology Research Unit, Addenbrooke’s Hospital, Cambridge, United Kingdom. 2 University 

of Cambridge, Cambridge, United Kingdom. 3 Centre for Applied Medical Statistics, University of 

Cambridge, Cambridge, United Kingdom. 

321 EFFECT OF PATIENTS’ EXPECTATIONS ON OUTCOME OF FACET JOINT INJECTIONS 

Cecilia Farrugia 1 , Stefania Chetcuti Zammit 1 , Josef Lauri 2 , Andrew A. Borg 1 ; 

1 

Rheumatology, University of Malta, Tal-Qroqq, Malta. 2 Mathematics, University of Malta, 

Tal-Qroqq, Malta. 

115

Rheumatoid arthritis: clinical aspects 

322 THE EFFECT OF BIOLOGICS ON CARDIOVASCULAR DISEASE IN PATIENTS WITH RHEUMATOID 

ARTHRITIS: A SYSTEMATIC LITERATURE REVIEW 

Sarah L. Westlake 1, 2 , Alexandra N. Colebatch 2 , Janis Baird 3 , Patrick Kiely 4 , Mark Quinn 5 , 

Ernest Choy 6 , Andrew J. Ostor 7 , Christopher J. Edwards 2 ; 

1 

Department of Rheumatology, Poole Hospital NHS Foundation Trust, Poole, United Kingdom. 

2 

Department of Rheumatology, Southampton University Hospitals NHS Trust, Southampton, United 

Kingdom. 3 MRC Epidemiology Resource Centre, University of Southampton, Southampton, United 

Kingdom. 4 Department of Rheumatology, St Georges Healthcare NHS Trust, London, United 

Kingdom. 5 Department of Rheumatology, York Hospital/ Hull York Medical School, York, United 

Kingdom. 6 Department of Rheumatology, King’s College London, London, United Kingdom. 

7 

Department of Rheumatology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, 


323 QUALITY OF LIFE PREDICTORS OF PATIENTS WITH RHEUMATOID ARTHRITIS 

Beata Jankowska 1 , Izabella Uchmanowicz 1 , Jacek Polanski 2 , Krzysztof Dudek 3 ; 

1 

Faculty of Health Sciences, Medical University, Wroclaw, Poland. 2 Atos Healthcare, Sheffield, United 

Kingdom. 3 Institute of Machines Design and Operation, Technical University, Wroclaw, Poland. 

324 IS PERIPHERAL VASCULAR DISEASE INCREASED IN PATIENTS WITH RHEUMATOID ARTHRITIS 

COMPARED TO THE GENERAL POPULATION? 

Resmy Suresh 1 , Natalie Horwood 1 ; 

1 

Rheumatology, Mayday University Hospital, Croydon, Surrey, United Kingdom. 

325 ENDOTHELIAL FUNCTION ASSOCIATES WITH CLASSICAL CARDIOVASCULAR DISEASE RISK BUT 

NOT DISEASE RELATED INFLAMMATION IN RHEUMATOID ARTHRITIS 

Aamer Sandoo 1, 2 , Jet Veldhuijzen van Zanten 1, 2 , Jacqueline P. Smith 2 , Douglas Carroll 1 , 

Tracey E. Toms 2 , George D. Kitas 2, 1 ; 

1 

School of Sport and Exercise Sciences, University of Birmingham, Birmingham, United Kingdom. 

2 

Department of Rheumatology, Dudley Group of Hospitals NHS Trust, Dudley, United Kingdom. 

326 ANTI-CCP TITRE PREDICTS ONSET OF INFLAMMATORY POLYARTHRITIS IN PATIENTS PRESENTING 

WITH NON-INFLAMMATORY ARTHRALGIA 

Sarang Chitale 1, 2 , Cristina Estrach 1, 2 , Robert Thompson 2 , Sangita Sathyamurthy 2 , Nicola Goodson 1, 2 ; 

1 

School of clinical sciences, University of Liverpool, Liverpool, United Kingdom. 2 Rheumatology, 

University Hospital Aintree, Liverpool, United Kingdom. 

327 DO THE NEW 2009 METABOLIC SYNDROME JOINT CONSENSUS CRITERIA OVER DIAGNOSE THE 

METABOLIC SYNDROME IN RHEUMATOID ARTHRITIS? 

Tracey E. Toms 1, 2 , Vasileios F. Panoulas 1 , Karen M. Douglas 1 , George D. Kitas 1, 2 ; 1 Rheumatology, 

Dudley Group of Hospitals NHS Foundation Trust, Dudley, United Kingdom. 2 arc Epidemiology Unit, 

Manchester University, Manchester, United Kingdom. 

328 ETHNICITY AND RHEUMATOID ARTHRITIS: A SYSTEMATIC REVIEW 

Hanan S. Abozaid 1, 2 , Nihal A. Fathi 2 , David L. Scott 1 , Sophia Steer 1 ; 

1 

Academic Rheumatology, King’s College London, London, SE5 9RJ, United Kingdom. 

2 

Rheumatology, Sohag University, Sohag, Egypt. 

116

329 THE RISK OF SERIOUS INFECTIONS IN PATIENTS RECEIVING ANAKINRA FOR RHEUMATOID 

ARTHRITIS (RA): RESULTS FROM THE BSR BIOLOGICS REGISTER (BSRBR) 

James Galloway 1 , Will Dixon 1 , Louise Mercer 1 , Kath Watson 1 , Lunt Mark 1 , Kimme Hyrich 1 , . BSRBR 

Control Centre Consortium 2 , Deborah Symmons 1 , . On behalf of the BSR Biologics Register 1 ; 

1 

arc Epidemiology Unit, University of Manchester, Manchester, United Kingdom. 2 British Society of 

Rheumatology, London, United Kingdom. 

330 THE ROLE OF MUSCULOSKELETAL ULTRASOUND IN POTENTIAL INFLAMMATORY ARTHRITIS: A 

COMPARISON OF ULTRASOUND FINDINGS WITH SUBSEQUENT DIAGNOSIS AND TREATMENT 

G. Hirsch 1 , R. Klocke 1 ; 

1 

Dept of Rheumatology, Dudley Group of Hospitals, Dudley, United Kingdom. 

331 DO TITRES OF RHEUMATOID FACTOR AND ANTI-CCP ANTIBODY PREDICT FOR THE PRESENCE 

OF INTERSTITIAL LUNG DISEASE IN RHEUMATOID ARTHRITIS? 

Elizabeth Toberty 1 , Elizabeth Coulson 1 , Vadivelu Saravanan 1 , Carol Heycock 1 , Martin Rynne 1 , 

Jennifer Hamilton 1 , Clive Kelly 1 ; 

1 



332 EFFICACY AND SAFETY OF INTRAVENOUS IRON IN RHEUMATOID ARTHRITIS 

Rachel Tsang 1 , Elizabeth Coulson 1 , Vadivelu Saravanan 1 , Carol Heycock 1 , Jennifer Hamilton 1 , 

Clive Kelly 1 ; 

1 


333 FIVE-YEAR OUTCOME OF EARLY ARTHRITIS CLINIC: A NICE EFFECT ON THE PATIENTS’ 

OUTCOME 

Yasser El Miedany 1 , Deborah Palmer 1 ; 

1 

Rheumatology, Darent Valley Hospital, Dartford, United Kingdom. 

334 RATES AND CAUSE OF DEATH IN RHEUMATOID PATIENTS: ARE PATTERNS CHANGING? 

David Collins 1 , Tracy Arnold 1 , Maria Juarez 1 , Rosemary Waller 1 , Lyn Williamson 1 , Elizabeth Price 1 ; 

1 

Rheumatology, Great Western Hospital, Swindon, United Kingdom. 

335 LESSONS LEARNED FROM QUANTIFYING BONE MARROW OEDEMA IN THE RHEUMATOID 

CERVICAL SPINE 

Ravi Suppiah 1, 2 , Anthony Doyle 3 , Raylynne Rai 4 , Nicola Dalbeth 2, 5 , Maria Lobo 2 , Jeurgen Braun 7 , 

Fiona McQueen 2, 6 ; 

1 

Rheumatology, Nuffield Orthopaedic Centre, Oxford, United Kingdom. 2 Rheumatology, Auckland 

District Health Board, Auckland, New Zealand. 3 Radiology, Auckland District Health Board, 

Auckland, New Zealand. 4 Radiology, Counties Manukau District Health Board, Manukau, New 

Zealand. 5 Medicine, University of Auckland, Auckland, New Zealand. 6 Molecular Medicine and 

Pathology, University of Auckland, Auckland, New Zealand. 7 Rheumazentrum Ruhrgebiet, 

Ruhr-University Bochum, Herne, Germany. 

336 THE RELATIONSHIP BETWEEN ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODIES AND 

CLINICAL PHENOTYPE IN VERY EARLY RHEUMATOID ARTHRITIS 

Zaeem Cader 1 , Andrew Filer 1 , Christopher D. Buckley 1 , Karim Raza 1 ; 

1 

Rheumatology Research Group, Division of Immunity and Infection, University of Birmingham, 

Birmingham, United Kingdom. 

117

337 WORSENING LDL:HDL ATHEROGENIC INDEX DESPITE IMPROVEMENTS IN INFLAMMATORY 

POLYARTHRITIS PARAMETERS IN THE FIRST 2 YEARS OF DISEASE: RESULTS FROM THE 

NORFOLK ARTHRITIS REGISTER (NOAR) 

Hoda Mirjafari 1 , Tracey Farragher 1, 4 , Suzanne M. Verstappen 1 , Diane Bunn 3 , 

Valentine Charlton-Menys 2 , Tarnya Marshall 3 , Deborah P. Symmons 1 , Ian N. Bruce 1 ; 

1 

arc Epidemiology Unit, The University of Manchester, Manchester, United Kingdom. 2 Cardiovascular 

Research Group, The University of Manchester, Manchester, United Kingdom. 3 Norfolk Arthritis 

Register, Norfolk and Norwich University Hospital, Norfolk, United Kingdom. 4 Centre for Medical 

Statistics and Health Evaluation, The University of Liverpool, Liverpool, United Kingdom. 

338 PROTEINASE-ACTIVATED RECEPTOR-2 INFLUENCES TLR-4-MEDIATED INFLAMMATORY 

RESPONSES IN MACROPHAGES 

Rachael Steven 1 , Anne Crilly 1 , John C. Lockhart 1 , William R. Ferrell 2 , Iain B. McInnes 3 ; 

1 

School of Science, University of the West of Scotland, Paisley, Scotland, United Kingdom. 

2 

Integrative Biology, University of Glasgow, Glasgow, Scotland, United Kingdom. 3 Immunity, Infection 

& Inflammation, University of Glasgow, Glasgow, Scotland, United Kingdom. 

339 CHANGES IN ADVANCED GLYCATION ENDPRODUCTS IN SYNOVIAL FLUID IN EARLY RESOLVING 

ARTHRITIS, AND EARLY- AND ESTABLISHED- RHEUMATOID ARTHRITIS 

Usman Ahmed 1 , Naila Rabbani 1 , Andrew Filer 2 , Richard Watts 3 , Karim Raza 2 , Paul Thornalley 1 ; 

1 

Warwick Medical School, University of Warwick, Coventry, United Kingdom. 2 College of Medical and 

Dental Sciences, University of Birmingham, Birmingham, United Kingdom. 3 Department of 

Rheumatology, Ipswich Hospital NHS Trust, Ipswich, United Kingdom. 

340 MOVING FROM MONOTHERAPY TO TRIPLE THERAPY AS INITIAL THERAPY FOR EARLY RA. 

RESULTS FROM AN INCEPTION COHORT ON TREATMENT TRENDS FROM 2002 TO 2009 

Elena Nikiphorou 1 , Adam Young 1 , Patrick Kiely 1 , David Walsh 1 , Richard Williams 1 ; 

1 

ERAN, c/o St Albans City Hospital, St Albans, United Kingdom. 

341 THE ROSE ANGINA QUESTIONNAIRE DOES NOT IDENTIFY THOSE PATIENTS WITH 

INFLAMMATORY POLYARTHRITIS WHO ARE AT GREATEST RISK OF PREMATURE 

CARDIOVASCULAR MORTALITY 

Muhammad Iskandar 1 , Tracey Farragher 1 , Diane Bunn 2 , Deborah Symmons 1 ; 

1 

arc Epidemiology Unit, University of Manchester, Manchester, United Kingdom. 2 Norfolk Arthritis 

Register, University of East Anglia, Norwich, United Kingdom. 

342 FURTHER ANALYSIS OF HELPLESSNESS MEASUREMENT IN INFLAMMATORY ARTHRITIS/ 

SPONDYLOARTHRITIS: THE DEVELOPMENT OF THE MODIFIED RHEUMATOLOGY ATTITUDE INDEX 

Yasser El Miedany 1 , Maha El Gaafary 2 , Deborah Palmer 1 ; 

1 



343 UTILITY OF ULTRASOUND JOINT COUNTS AS PREDICTORS OF OUTCOME IN PATIENTS WITH VERY 

EARLY ARTHRITIS 

Andrew Filer 1 , Paola de Pablo 1 , Gina Allen 4 , Peter Nightingale 2 , Alison Jordan 3 , Paresh Jobanputra 3 , 

Chris Buckley 1 , Karim Raza 1 ; 

1 

Rheumatology Research Group, University of Birmingham, Birmingham, United Kingdom. 2 Wolfson 

Research Laboratory, University Hospital Birmingham Foundation Trust, Birmingham, United 

Kingdom. 3 Department of Rheumatology, University Hospital Birmingham Foundation Trust, 

Birmingham, United Kingdom. 4 Green Templeton College, University of Oxford, Oxford, United 

Kingdom. 

118

344 A SUPRA-DISTRICT AUDIT OF THE MANAGEMENT OF RHEUMATOID ARTHRITIS IN ADULTS 

(2009 NICE GUIDANCE) 

Ruth Gordon 1, 2 , Neil Snowden 1, 2 ; 

1 

Rheumatology and Clinical Audit, Pennine Acute NHS Trust, North Manchester General Hospital, 

Manchester, United Kingdom. 2 Greater Manchester Rheumatology Supradistrict Audit Group, 

Greater Manchester, United Kingdom. 

345 DAS ESR AND DAS CRP: THE CLINICAL IMPLICATIONS OF SWITCHING SCORES 

Catherine Gwynne 1 , Nick Amos 2 , Jeremy Camilleri 1 ; 

1 

Rheumatology, University Hospital of Wales, Cardiff, United Kingdom. 2 Cardiff University, Cardiff, 


346 INCORPORATING PATIENT REPORTED OUTCOME MEASURES IN CLINICAL PRACTICE: 

DEVELOPMENT AND VALIDATION OF A PROMS QUESTIONNAIRE FOR INFLAMMATORY 

ARTHRITIS 

Yasser El Miedany 1 , Maha El Gaafary 2 , Sally Youssef 1 , Deborah Palmer 1 ; 

1 

Darent Valley Hospital, Rheumatology, Dartford, United Kingdom. 2 Community, Environmental 

and Occupational Medicine, Ain Shams University, Cairo, Egypt. 


347 IS DLCO A USEFUL SCREENING TOOL IN DETECTING INTERSTITIAL LUNG DISEASE IN RA 

PATIENTS COMMENCING METHOTREXATE? 

Suzy Silburn 1 , T. Pullar 1 , K. Vinod 1 , T. Fardon 2 ; 

1 

Rheumatology Dept, Ninewells Hospital, Dundee, United Kingdom. 2 Dept of Chest Medicine, 

Ninewells Hospital, Dundee, United Kingdom. 

348 A SYSTEMATIC REVIEW OF THE IMPACT OF RHEUMATOID ARTHRITIS AND ITS TREATMENTS ON 

QUALITY OF LIFE 

Ian C. Scott 1 , Gabrielle Kingsley 1 , David L. Scott 2 ; 

1 

Rheumatology Department, University Hospital of Lewisham, London, United Kingdom. 

2 

Rheumatology Department, Kings College Hospital, London, United Kingdom. 

349 INCIDENCE AND PREDICTIVE VALUE OF THE CHARLSON CO MORBIDITY INDEX FOR 

OUTCOMES IN RA: RESULTS FROM AN INCEPTION COHORT 

Gouri Koduri 1 , Sam Norton 2 , Adam Young 1 , Nigel Cox 1 , Peter Prouse 1 , Josh Dixey 1 , Peter Williams 1 ; 

1 

ERAS Rheumatology, ERAS c/o St Albans City Hospital, St Albans, Hertfordshire, United Kingdom. 

2 

Centre for Lifespan & Chronic Illness Research, University of Hertfordshire, Hatfield, Hertfordshire, 


350 CORRELATION BETWEEN PHYSICAL ACTIVITY IN PATIENTS WITH INFLAMMATORY ARTHRITIS 

AND BELIEFS ABOUT AEROBIC EXERCISE: A PILOT STUDY 

Natasha Jones 1 , Ravi Suppiah 1 , Julia Newton 1 ; 

1 

Sport and Exercise Medicine, Nuffield Orthopaedic Centre, Oxford, United Kingdom. 

351 PROTECTING THEIR HEART: CARDIOVASCULAR RISK ASSESSMENT IN PATIENTS WITH 


Anna E. Litwic 1 , Joanna M. Ledingham 1 ; 

1 


119

352 PHYSICAL ACTIVITY MIGHT COUNTERACT THE ADVERSE EFFECTS OF SMOKING CESSATION ON 

BODY WEIGHT AND COMPOSITION IN PATIENTS WITH RHEUMATOID ARTHRITIS 

Antonios Stavropoulos-Kalinoglou 1, 2 , Giorgos S. Metsios 1, 3 , Vasileios F. Panoulas 1 , Yiannis 

Koutedakis 3 , George D. Kitas 1 ; 

1 

Rheumatology, Dudley Group of Hospitals, Dudley, United Kingdom. 2 Schoold of Sport and Exercise 

Science, University of Birmingham, Birmingham, United Kingdom. 3 School of Sports, Performing 

Arts and Leisure, University of Wolverhampton, Walsall, United Kingdom. 

353 EVALUATION OF THE CLINICAL UTILITY OF ANTI-CCP ANTIBODY TEST IN DAILY CLINICAL 

PRACTICE 

Jagdish Ramachandran Nair 1 , Devesh Mewar 1 ; 

1 

Rheumatology, Royal Liverpool University hospital, Liverpool, Merseyside, United Kingdom. 

354 WHAT FACTORS PREDICT PNEUMONIA IN PATIENTS WITH RHEUMATOID ARTHRITIS? 

Kin S. Long 1 , Elizabeth Coulson 1 , Vadivelu Saravanan 1 , Carol Heycock 1 , Jennifer Hamilton 1 , 

Clive Kelly 1 ; 

1 

QEH, Gateshead, United Kingdom. 

355 RHEUMATOID ARTHRITIS VS PSORIATIC ARTHRITIS: CLINICAL AND US ASSESSMENT OF THE 

WRIST AND HAND JOINTS 

Yasser El Miedany 1 , Sally Youssef 1 , Deborah Palmer 1 ; 

1 

Rheumatology, Darent Valley Hospital, Dartford, United Kingdom. 

120

Exhibition Floorplan 

Exhibition Floorplan

Exhibition Floorplan 

Exhibition Floorplan | 21-23 April 2010 

121

Exhibitor Listings 

S/No: 

Company 

1 Birmingham Arthritis Research Centre 

2 National Rheumatoid Arthritis Society 

3 National Ankylosing Spondylitis Society 

4 ARMA 

5 Arthritis Care 

6 RCN RF 

7 The Paget’s Association 

8 Fibromyalgia Association UK 

9 RSI Action UK 

10 NHS Evidence – Musculoskeletal 

Specialist Collection 

11 The Scleroderma Society 

11a Wisepress Online Bookshop 

12 Lupus UK 

13 Psoriasis Scotland Arthritis Link Volunteers 

14 British Sjögren’s Syndrome Association 

33 BSR/BHPR 

34 Rheumatology/OUP 

35 Servier Laboratories Ltd 

37 Roche Product Limited 

39 Amgen Ltd and GlaxoSmithKline UK Ltd 

41 Shire Pharmaceuticals 

43 Toshiba Medical Systems 

45 Healthcare at Home Ltd 

47 TRACE RA Trial 

48 GlaxoSmithKline UK Ltd 

49 Bristol-Myers Squibb 

50 Arthritis Research UK 

51 Medtronic 

53 Roche Product Limited 

55 PMR-GCA UK 

57 RApport 

59 Disease Activity Score (DAS) 

Information Series 

61 Bauerfeind UK 

63 Eli Lilly 

69 4S Information Systems Ltd 

71 MSD 

73 Abbott Laboratories Ltd 

75 Pfizer Ltd 

77 UCB 

79 MSD 

81 Esaote Europe BV 

83 Oxford Immunotec Ltd 

85 Biomarin Europe Ltd 

87 Grunenthal 

89 Napp Pharmaceuticals Ltd 

92 BSR Biologics Register 

93 Actelion Pharmaceuticals 

95 Medac UK 

97 Pfizer Ltd 

122

Rheumatology 2010 Exhibitors 

4S Information Systems Ltd (Stand 69) 

Address: 4 The Square, Milnthorpe 

Cumbria LA7 7QJ 

Email: sales@4s-dawn.com 

Website: www.4s-dawn.com 

4S DAWN Clinical Software heralds the new 

era of Rheumatology software. 

DAWN removes 

• the frustration of searching for results and 

information! 

• the frustration of filling out forms! 

• the fear some patients are not being 

monitored! 

Fall in love with DAWN Rheumatology Clinic 

Software and embrace improved safety, quality 

and productivity. 

Make your patients feel cared for with printed 

hand-held records, text-messaging, ... 

Abbott Laboratories Limited (Stand 73) 

Address: Abbott House, Vanwall Business Park, 

Maidenhead, Berkshire SL6 4XE 

Email: ukmedinfo@abbott.com (for queries on 

Abbott UK medicines only) 

Website: www.abbott.co.uk 

This year Abbott are focusing on how small 

changes to clinical practice can make a huge 

difference to patients with rheumatoid arthritis, 

psoriatic arthritis and ankylosing spondylitis. 

At our stand you’ll be able to see life from a 

patient’s point of view and find out how our 

practical solutions and toolkits can help you 

make the changes that will make a difference 

to your patients. 

Actelion Pharmaceuticals (Stand 93) 

Company Contact: Stephanie Kelly 

Address: BSI Building, 13th floor, 

389 Chiswick High Road, 

Chiswick, London W4 4AL 

Email: Stephanie.kelly@actelion.com 

Website: www.actelion.com 

Actelion Pharmaceuticals Ltd is a 

biopharmaceutical company headquartered in 

Allschwil/Basel, Switzerland, focusing on the 

discovery, development and commercialisation 

of innovative treatments to serve high unmet 

medical needs. Please come and visit us at 

Stand 93 for more information on our products 

and clinical data. We would also like to invite you 

to attend a session of scientific discussion and 

debate. The panel will include experts from 

around the UK and will be facilitated by journalist 

Jon Snow. Please join us for what promises to 

be an interesting and informative meeting on 

Friday 23 April, from 07.30 to 09.00 at Hall 9 

with breakfast provided. 

Amgen Ltd and GlaxoSmithKline (Stand 39) 

Company Contact: 

Alix Garn (Senior Product Manager) 

Address: Amgen Ltd, 

240 Cambridge Science Park, 

Milton Road, Cambridge CB4 0WD 

Email: gbinfoline@amgen.com 

Website: www.prolia.co.uk 

Amgen’s therapeutics have changed the practice 

of medicine, helping millions of people around 

the world in the fight against serious illnesses. 

Amgen remains committed to advancing science 

to dramatically improve people’s lives. 

GlaxoSmithKline is one of the world’s leading 

research-based pharmaceutical and health care 

companies. GlaxoSmithKline is committed to 

improving the quality of human life by enabling 

people to do more, feel better and live longer. 

Arthritis Research UK (Stand 50) 

Company Contact: Mrs Elizabeth Holloway 

Address: Copeman House, St Mary’s Court, 

St Mary’s Gate, Chesterfield S41 7TD 

Email: l.holloway@arthritisresearchuk.org 

Website: www.arthritisresearchuk.org 

Arthritis Research UK is the UK’s fourth largest 

medical research charity and the only one solely 

committed to funding high quality research into 

the causes and treatment of all types of arthritis 

and musculoskeletal conditions. We rely entirely 

on public donations to fund our research and 

education programme, spending over £20m a 

year supporting research aimed at improving the 

lives of people with arthritis. 


123

ARMA (Stand 4) 

Company Contact: Sarah Rich 

Address: 18-20 Bride Lane 

London EC4Y 8EE 

Email: sarahrich@arma.uk.net 

Website: www.arma.uk.net 

The Arthritis and Musculoskeletal Alliance (ARMA) 

brings together over 30 member organisations 

including support groups, professional societies 

and research organisations. Visit our stand to find 

out how you can use the Standards of Care and 

our local networks. 

Arthritis Care (Stand 5) 

Come and visit us at Stand 5 and see how 

Arthritis Care can enhance the value of your 

service. Influencing health policy and services 

through campaigning, and providing self 

management training courses to help patients 

manage their condition. Offering a free 

confidential helpline to support your patients 

throughout their experience of their condition 

and providing award winning information enabling 

patients to make better use of appointments. 

Bauerfeind UK (Stand 61) 

Company Contact: Lucille Cowell 

Address: Phyllis House, 229 Bristol Road, 

Birmingham B25 7UB 

Email: info@bauerfeind.co.uk 

Website: www.bauerfeind.co.uk 

Bauerfeind is one of the world’s leading 

manufacturers of medical aids with 80 years of 

experience and offers the medical professional a 

wide range of quality products. Bauerfeind’s 

superior viscoelastic shock absorbent products 

are used exclusively for the foot, relieving pain and 

redistributing pressure, these products can be 

used to manage a wide variety of foot-related 

indications, with materials of differing thickness, 

densities and shapes. 

BHPR (Stand 33) 

British Health Professionals in Rheumatology 

(BHPR) unites and supports members of the 

multi-disciplinary team in delivering best quality 

care which meets the needs of individuals with 

musculoskeletal conditions. We have over 500 

members from many professions: nursing, 

physiotherapy, occupational therapy, podiatry, 

psychology, social work, medicine, pharmacy and 

others. Come and visit our stand and celebrate 

our 25th anniversary with us. 

BioMarin Europe Ltd (Stand 85) 

Company Contact: Mike Withe 

Address: 3rd Floor, 164 Shaftesbury Avenue 

London WC2H 8HL 

Tel: +44 (0)20 7420 0800 

Fax: +44 (0)20 7420 0829 

Email: biomarin-europe@bmrn.com 

Birmingham Arthritis Resource Centre (Stand 1) 

Company Contact: 0121-464-2708 

Address: 5th Floor, Birmingham Central library, 

Chamberlain Square, 

Birmingham B3 3HQ 

Email: c.gordhan@bham.ac.uk 

Website: www.barc.org.uk 

The Birmingham Arthritis Resource Centre (BARC) 

was set up to provide education and support to 

people with arthritis and their carers, based on a 

formal Needs Assessment. Our aim is to promote 

self-coping – to help people to deal with the 

physical and social disabilities caused by their 

disease. A notable achievement to date is that 

we have developed “bottom-up” multi-lingual 

educational and support material in audio 

format to enable people with arthritis to 

access information. 

Bristol-Myers Squibb (Stand 49) 

Our mission: to discover, develop and deliver 

innovative medicines that help patients prevail 

over serious disease. 

BSR (Stand 33) 

The British Society for Rheumatology (BSR) promotes 

excellence in the treatment of people with 

arthritis and musculoskeletal conditions, and supports 

those delivering it. Come and visit our stand 

to find out more about our work and for more 

information about becoming a member. 

BSR Biologics Register (Stand 92) 

The BSR Biologics Register (BSRBR) monitors 

the long-term safety of biological treatments for 

rheumatoid arthritis. With over 15,500 people with 

rheumatoid arthritis, it is the largest register of its 

kind. Based at the Arthritis Research UK 

124

Epidemiology Unit at the University of 

Manchester, this prospective observational study 

has a comparison cohort of patients receiving 

DMARD therapy. Data collection is via 

rheumatology teams, patients and the NHS IC. 

British Sjögren’s Syndrome Association 

(Stand 14) 

Company Contact: Isabel York 

Address: PO Box 15040, Birmingham B31 3DP 

Email: office@bssa.uk.net 

Website: www.bssa.uk.net 

The British Sjögren’s Syndrome Association 

(BSSA) is a registered charity which aims to raise 

awareness of the disease and support research 

into its cause and treatment. The BSSA supports 

patients and carers, educates the public and 

professionals and raises funds for research into 

Sjögren’s by providing research grants on an 

annual basis. No cure currently exists for the 

condition and the cause remains unknown. 

Sjögren’s Syndrome is the second most common 

auto immune rheumatic disease affecting 3-4% 

of adults in the UK, but it is under diagnosed and 

may go untreated. It is characterised by the 

degeneration of mucus-secreting glands, 

particularly the tear ducts and the saliva glands 

of the mouth. Other symptoms can include 

arthritis and extreme fatigue, disabling joint pain 

and muscle aches. 

Disease Activity Score (DAS) Information 

Series (Stand 59) 

Company Name: Roche Products Limited 

Company Contact: Louise Groves 

Address: Roche Products Limited 

6 Falcon Way, Shire Park 

Welwyn Garden City 

AL7 1TW, United Kingdom 

Email: louise.groves@roche.com 

Website: www.roche.com 

The Disease Activity Score (DAS) stand provides 

a one stop shop for healthcare professionals 

seeking further information on DAS for personal 

reference or to distribute to patients. At the 

stand delegates can speak to a DAS expert and 

place orders for materials in the DAS series, 

including a training DVD and quick reference 

guide for healthcare professionals and a DVD 

and information booklet for patients. 

Eli Lilly (Stand 63) 

Eli Lilly and Company Limited is one of the 

world’s largest research-based pharmaceutical 

companies, dedicated to creating and delivering 

innovative pharmaceutical healthcare solutions 

that enable people to live longer, healthier and 

more active lives. Our research and development 

efforts constantly strive to address the world’s 

growing unmet medical needs in several different 

clinical areas. 

For information about our products or services, 

please come and talk to us at the Lilly stand, or 

log on to the Eli Lilly website at www.lilly.com 

We look forward to meeting you. 

Esaote Europe BV (Stand 81) 

Company Contact: Lee Evans 

Address: 400 Thames Valley Park Drive 

Reading, Berks RG6 1PT 

Email: lee.evans@esaote.nl or 

clare.cooper@esaote.nl 

Website: www.esaote.com 

Visit the Esaote stand to discuss the exciting 

opportunities that the latest generation of 

Ultrasound scanners can offer your Rheumatology 

practice. Showcasing will be the revolutionary 

portable ultrasound scanner the MyLab25Gold; 

as well as a must see for Rheumatology 2010 

the first showing of Esaote’s state-of-the-art 

advanced MyLabTwice Virtual Navigator fusion 

imaging system. 

Come visit us and be innovated! 

Fibromyalgia Association UK (Stand 8) 

Company Contact: Pam Stewart 

Address: PO Box 206, Stourbridge, 

West Midlands DY9 8YL 

Email: pam.stewart@fmauk.org 

Website: www.fmauk.org 

Fibromyalgia Association UK provides information 

to the general public and medical professionals. 

It lobbies for quicker diagnosis and more effective 

treatment for people with fibromyalgia. 

An estimated 1.2m people in the UK have 

fibromyalgia but there are no approved guidelines 

for its treatment. Many people suffer in constant 

pain without a diagnosis for many years. FMA UK 

is determined to improve this situation. 


125

Grünenthal (Stand 87) 

Grünenthal Ltd. is a recently established affiliate 

of a German family owned Pharmaceutical 

Company and is situated close to High Wycombe. 

Our aim is to create a highly respected 

Pharmaceutical Company locally through 

introductions of our own research and 

development products and acquired brands. 

GlaxoSmithKline UK Ltd (Stand 48) 

Company Contact: Gail Loftas 

Address: Stockley Park West 

Uxbridge, Middlesex UB11 1BT 

Email: gail.2.loftas@gsk.com 

Website: www.gsk.com 

At GSK we have a challenging and inspiring 

mission: to improve the quality of human life by 

enabling people to do more, feel better and live 

longer. This mission gives us the purpose to 

develop innovative medicines and products that 

help millions of people around the world. 

Healthcare at Home Ltd (Stand 45) 


Rheumatology Customer Services Team 

Address: Fifth Avenue, Centrum 100, 

Burton on Trent, 

Staffordshire DE14 2WS 

Tel: 0870 600 1540 

Email: info@hah.co.uk 

Website: www.hah.co.uk 

Healthcare at Home is the UK’s leading provider 

of high-tech home healthcare and speciality 

pharmacy services, covering numerous disease 

areas. We also deliver innovative services on site 

throughout the NHS and independent sector. 

Lupus UK (Stand 12) 

Company Contact: Mr Chris Maker 

Address: St James House, Eastern Road, 

Romford, Essex RM1 3NH 

Tel: 01708 731251 (24 hour answerphone) 

Email: chris@lupusuk.org.uk 

Website: www.lupusuk.org.uk 

LUPUS UK is the only national charity for people 

with lupus offering support through our voluntary 

network of over 20 Regional Groups. Our 

priorities are to increase lupus awareness 

amongst the public and the medical profession, 

provide support to our members, and raise funds 

towards research and Lupus Nurses. 

Medac UK (Stand 95) 

Company Contact: Tony Johnson 

Address: Scion House, Stirling University 

Innovation Park, Stirling FK9 4NF 

Email: info@medac-uk.co.uk 

Website: www.medac-uk.co.uk 

Metoject (licensed prefilled syringes of 

methotrexate 50mg/ml) is available in a range of 

doses (7.5mg, 10mg, 15mg, 20mg, 25mg) with 

pre-attached s.c. needles. 

Medac supply patient starter packs for new 

patients and aim to support the medical 

professionals and patients using sub-cutaneous 

methotrexate in whatever way we can. 

Come to our stand to find out more. 

Medtronic Limited (Stand 51) 

Company Contact: Michelle Turner 

Address: Medtronic Spine & Biologics Division, 

Building 9, Croxley Green Business 

Park, Watford WD18 8WW. 

Website: www.medtronic.co.uk 

Medtronic is the global leader in medical 

technology - alleviating pain, restoring health, 

and extending life for millions of people around 

the world. 

Our market leadership is largely a result of 

innovation: we’re developing many of the new 

standards of care in spinal and musculoskeletal 

therapies. Collaborating with world-renowned 

surgeons and researchers we offer state-of-the-art 

therapies for spinal, neurological and orthopaedic 

conditions. 

MSD (Stand 71 and 79) 

Address: MSD, Hertford Road, Hoddesdon, 

Hertfordshire EN11 9BU 

Website: www.msd-uk.com 

Today’s MSD is a global healthcare leader who 

is working to help the world be well. 

Through our medicines, vaccines, biologic 

therapies, and consumer and animal products, 

we collaborate with healthcare providers in the UK 

and operate in more than 140 countries to deliver 

innovative health solutions. 

126

For more information, please go to 

www.msd-uk.co.uk. 

Napp Pharmaceuticals Limited (Stand 89) 

Address: Cambridge Science Park 

Milton Road, Cambridge CB4 0AB 

Email: enquiries@napp.co.uk 

Website: www.napp.co.uk 

Napp Pharmaceuticals Limited is renowned as a 

leader in pain control with a reputation for 

expertise in novel formulations and an impressive 

list of pioneering products to help individuals fight 

the burden of chronic pain. 

National Ankylosing Spondylitis Society 

(Stand 3) 

Company Contact: Jane Skerrett 

Address: Unit 0.2, One Victoria Villas, 

Richmond, Surrey TW9 2GW 

Email: director@nass.co.uk 

Website: www.nass.co.uk 

The National Ankylosing Spondylitis Society 

(NASS) was founded over 30 years ago to 

provide support and advice for patients and their 

families. NASS works to raise awareness of AS 

and provides a website, publications and 

information as well as running a branch network 

of around 95 branches throughout the UK 

offering regular supervised exercise sessions. 

NASS members also participate in ongoing 

genetic research into the disease. 

www.nass.co.uk 

NHS Evidence – Musculoskeletal specialist 

collection (Stand 10) 


Ann Brocklehurst / Emma Bayliss 

Address: c/o Arthritis Research UK, 

Copeman House, St Mary’s Court. 

St Mary’s Gate, Chesterfield, 

Derbyshire S41 7TD 

Email: a.brocklehurst@arthritisresearchuk.org 

Website: www.arthritisresearchuk.org 

NHS Evidence – musculoskeletal specialist 

collection (formerly NLH Musculoskeletal 

Specialist Library) has been created, maintained 

and updated by a team comprising 

representatives from all of the professional 

groups involved in the care of those suffering 

from musculoskeletal disorders. The site is 

intended primarily to support those working in 

healthcare delivery but is also open to the public. 

National Rheumatoid Arthritis Society (Stand 2) 

Company Contact: Lorraine Tanner 

Address: NRAS, Unit B4 Westacott Business 

Centre, Westacott Way, Littlewick 

Green, Maidenhead, 

Berkshire SL6 3RT 

Email: lorraine@nras.org.uk 

Website: www.nras.org.uk 

NRAS is the only patient-led UK charity focusing 

on people with Rheumatoid Arthritis, their 

families and carers. We aim to help these 

groups by:- 

• providing information and support 

• facilitating networking and encouraging 

self-help 

• raising public and government awareness 

• campaigning for more funding and better use 

of existing resources 

Oxford Immunotec Ltd (Stand 83) 

Company Contact: Mr Bob Hair 

Address: 94C Milton Park, Abingdon, 

Oxfordshire OX14 4RY 

Email: info@oxfordimmunotec.com 

Website: www.oxfordimmunotec.com 

www.learntb.com 

On Stand 83, Oxford Immunotec will present the 

in-vitro T-SPOT.TB test for the diagnosis of active 

and latent tuberculosis. It is extremely sensitive 

and specific making it suitable for all patient 

groups, even immunosuppressed populations 

and extrapulmonary TB. 

The Paget’s Association (Stand 7) 

Company Contact: Marilyn McCallum 

Address: 323 Manchester Road, Walkden, 

Manchester M28 3HH 

Email: director@paget.org.uk 

Website: www.paget.org.uk 

The Paget’s Association is the only UK charity 

dealing exclusively with Paget’s disease of bone. 

We offer support and information to people with 

the condition. At the same time we work to raise 

awareness about the condition amongst both the 

public and the medical profession. We also offer 


127

funding for research projects. A helpline is 

available to both patients and health 

professionals 0161 799 4646. 

Pfizer Ltd (Stand 75 and 97) 

Company Contact: Anup Shah and Gemma Payne 

Address: Pfizer Ltd. 

Walton Oaks, Dorking Road, 

Walton-On-The-Hill, Surrey KT20 7NS 

Email: anup.shah@pfizer.com / 

gemma.payne@pfizer.com 

Website: www.pfizer.co.uk 

Pfizer Inc., founded in 1849, is dedicated to 

better health and greater access to health care 

for people and their valued animals. Every day, 

colleagues in more than 150 countries work to 

discover, develop, manufacture and deliver quality, 

safe and effective prescription medicines to 

patients. 

In the UK, Pfizer has its European R&D 

headquarters at Sandwich and its UK business 

headquarters in Surrey, and is the major supplier 

of medicines to the NHS. The company focuses 

on finding groundbreaking medical therapies, and 

has a broad portfolio of leading products across 

a wide range of therapy areas, including 

rheumatological disease, inflammation and 

pulmonary vascular disease. 

PMR-GCA UK (Stand 55) 

Company Contact: Jayne Sibley BSc(Hons), 

Trustee/Director 

Address: Centre for Disability Studies, 

Adult Community College 

Rocheway, Rochford, Essex SS0 0RY 

Email: pmrgca@googlemail.com 

Website: www.pmrgcauk.com 

PMR-GCA UK (Polymyalgia Rheumatica and Giant 

Cell Arteritis UK) is a registered charity established 

in response to patient concerns to meet the 

needs of people with these debilitating conditions. 

We will be promoting research into PMR and GCA; 

raising awareness within the public domain and 

medical profession; developing an information 

base via a website; and assisting with setting up 

a national network of support groups. 

PSALV (Stand 13) 

PSALV, Psoriasis Scotland Arthritis Link Volunteers 

The only Scottish charity for all with skin psoriasis 

and associated inflammatory arthritis – PsA. 

PSALV is a national Scottish charity with expert 

advisers, and a small grant from the Scottish 

Government. We aim to raise awareness of these 

debilitating misunderstood diseases. We provide 

literature for enquirers and clinics, hold open info 

meetings with specialists, campaign and lobby at 

Holyrood. 

RApport (Stand 57) 

Company Name: Roche Products Limited and 

Chugai Pharma UK Limited 

Company Contact: Danika Hire 

Education for nurses by nurses. Developed and 

implemented by specialist steering committees of 

leading healthcare professionals in partnership 

with Roche Products Limited and Chugai Pharma 

UK Limited, RApport is an educational platform 

designed to help the NHS enhance patient care in 

the field of rheumatoid arthritis. Roche Products 

Limited and Chugai Pharma UK Limited financially 

support every aspect of the RApport programme 

and have chosen and worked with the steering 

committee in the development of the Reading 

Between the Lines workshops. RApport is 

provided by Roche Products Limited and 

Chugai Pharma UK Limited as an educational 

service to medicine. 

RCN RF (Stand 6) 

The Royal College of Nursing Rheumatology 

Forum exists to give support to nurses involved 

in the care of rheumatology patients. Currently 

membership stands at over 1,200 nurses who 

have voiced an interest in rheumatology issues. 

The stand will be open during the break times and 

staffed by members of the committee, please 

drop by and say hello to us. 

Rheumatology/OUP (Stand 34) 

Oxford University Press publishes some of the 

most respected medical books and journals in the 

world including the Oxford Desk Reference: 

Rheumatology and the journal Rheumatology 

which is published on behalf of the British Society 

for Rheumatology. Visit our stand to discover 

more about our quality products, and to pick up a 

free copy of the journal. 

128

Roche Product Limited (Stand 37 and 53) 

Company Contact: Simon Eayrs 

Address: 6 Falcon Way, Shire Park 

Welwyn Garden City AL7 1TW 

Email: simon.eayrs@roche.com 

Website: www.rocheuk.com 

Roche aims to improve people’s health and 

quality of life with innovative products and 

services for the early detection, prevention, 

diagnosis and treatment of disease. Part of one 

of the world’s leading healthcare groups, Roche 

in the UK employs nearly 2,000 people in 

pharmaceuticals and diagnostics. Globally Roche 

is the leader in diagnostics, and a major supplier 

of medicines for the treatment of cancer, 

transplantation, virology, bone and rheumatology, 

obesity and renal anaemia. 

RSI Action UK (Stand 9) 

Company Contact: Stephen Fisher 

Address: PO Box 173, Royston, Herts SG8 0WT 

Email: Info@RSIAction.org.uk 

Website: www.RSIAction.org.uk 

RSI Action is the only national UK charity focused 

on the prevention of RSI (WRULD) conditions and 

providing support to people with these conditions. 

We promote awareness of RSI conditions among 

health professionals, in the workplace and 

government. We lobby for the prevention of RSI 

injuries, and the provision of effective treatment. 

The Scleroderma Society (Stand 11) 

Company Contact: Steve Holloway 

Address: PO Box 581, Chichester PO19 9EW 

Email: steve@sclerodermasociety.co.uk 

Website: www.sclerodermasociety.co.uk 

A registered charity that has been supporting 

people with scleroderma for over 25 years. 

The society aims are to: 

• Support people with scleroderma 

• Increase awareness of scleroderma 

• Fund scientific and medical research in 

scleroderma 

On this stand you will find our range of 

information leaflets covering many ways in which 

people can be affected by scleroderma. 

Servier Laboratories Ltd (Stand 35) 

Company Contact: Christina Dreksler 

Address: Wexham Springs, Framewood Road, 

Wexham, Slough SL3 6RJ 

Email: christina.dreksler@uk.netgrs.com 

Website: www.servier.co.uk 

Servier Laboratories is the UK subsidiary of The 

Servier Research Group, the leading independent 

French research based pharmaceutical company. 

The key franchises of the Servier Research Group 

are rheumatology, cardiovascular disease, 

diabetes, Central Nervous System and oncology. 

Servier regularly invests more than 25% of its 

annual turnover into research, discovering and 

delivering therapeutic innovations to patients 

through their healthcare professionals. 

Shire Pharmaceuticals (Stand 41) 

Company Contact: Vanessa Wills 

Address: Hampshire International Business Park, 

Chineham, Basingstoke, 

Hants RG24 8EP 

Email: vwills@shire.com 

Website: www.shire.com 

Shire is proud to sponsor Rheumatology 2010 – 

please visit us at Stand 41. Shire’s strategic 

goal is to become the leading specialty 

biopharmaceutical company that focuses on 

meeting the needs of the specialist physician. 

Shire focuses its business on attention deficit 

hyperactivity disorder, human genetic therapies 

and gastrointestinal diseases as well as 

opportunities in other therapeutic areas. Further 

information can be found at www.shire.com. 

Toshiba Medical Systems (Stand 43) 

Company Contact: Tim Palarm (01293 653700) 

Address: Boundary Court, Gatwick Road, 

Crawley RH10 9AX 

Email: tpalarm@tmse.nl 

From the inventor of the Laptop PC and with 

decades of experience in ultrasound Toshiba will 

be show casing the latest addition to their 

ultrasound range with the new standard in 

portable ultrasound, the Viamo. A stunning piece 

of imaging equipment, small yet powerful, light 

weight yet uncompromising to image quality, easy 

to use yet a fully fledged ultrasound system and 

shares specialty transducers with your Toshiba 

premium cart-based system. 


129

TRACE RA Trial (Stand 47) 

Company Contact: Hawys Williams, Rebecca 

Storey, Shobna Vasishta, Donna Watson, Donna 

Kempson and Sarah Lee. 

Address: http://www.dgoh.nhs.uk/tracera 

The TRACE RA (Trial of Atorvastatin for the 

Primary Prevention of Cardiovascular Events in 

Rheumatoid Arthritis) comprises the largest UK 

network of rheumatology research collaborators 

ever. Jointly funded by Arthritis Research UK and 

the British Heart Foundation, it aims to determine 

whether atorvastatin is more effective than 

placebo in the prevention of cardiovascular 

events in ~ 4,000 RA patients across 100 NHS 

Hospitals by early 2011. 

UCB (Stand 77) 

Address: 208 Bath Road, Slough, 

Berkshire SL1 3WE 

Website: www.ucbpharma.com/worldwide/uk 

UCB, headquartered in Brussels, Belgium is a 

biopharmaceutical company dedicated to the 

research, development and commercialisation of 

innovative medicines with a focus on the fields of 

central nervous system and immunology 

disorders. Employing more than 10,000 people in 

over 40 countries. 

Wisepress Online Bookshop (Stand 11a) 

Company Contact: Nadia Ahmed 

Address: The Old Lamp Works, 25 High Path, 

Merton Abbey, London SW19 2JL 

Email: bookshop@wisepress.com 

Website: www.wisepress.com 

Wisepress.com, Europe’s leading conference 

bookseller, has a complete range of books and 

journals relevant to the themes of the meeting. 

Books can be purchased at the stand or, if you 

would rather not carry them, posted to you. 

Wisepress has a comprehensive medical and 

scientific bookshop online with great offers. 

130


2011 

12-14 April | Brighton 

at the Hilton Brighton Metropole 

and De Vere Grand Hotel 

Dates for your diary 

Call for proposals deadline: 7 May 2010 

Exhibition booking opens: 6 September 2010 

(Corporate partners) 

Exhibition booking opens: 20 September 2010 

(all) 

Abstract submission deadline: 22 November 2010 

Early bird registration deadline: 25 February 2011 

Mark 

your 

calendar 

Rheumatology 2011: 12-14 April 2011

Abstract Reviewers 

The BSR Heberden Committee was expanded substantially for the purposes of abstract assessment to 

ensure that every abstract was peer reviewed, blind, by at least three reviewers. The Heberden Committee 

is extremely grateful for the assistance of everyone who gave up their time to review abstracts and 

acknowledges them accordingly: 

Heberden Committee: 

Dr Richard Watts 

Dr Gavin Clunie 

Prof Chris Denton 

Prof Michael Ehrenstein 

Ms Keri Hutchinson 

Dr Andrew Keat 

Dr Hoda Mirjafari 

Prof Rob Moots 

Prof Cos Pitzalis 

Dr Elizabeth Price 

Dr Clive Ryder 

Dr David Sansom 

Dr Claire Wenham 

Dr David Abraham 

Dr Yasmeen Ahmad 

Dr Nicole Amft 

Prof John Axford 

Dr Andrew Bamji 

Ms Lindsay Bearne 

Dr Rupa Bessant 

Dr Ashok Bhalla 

Dr Fraser Birrell 

Dr Simon Bowman 

Dr Paul Bowness 

Prof Matt Brown 

Prof Chris Buckley 

Dr Robin Butler 

Ms Vicki Cameron 

Dr David Carruthers 

Prof Tim Cawston 

Prof Kuntal Chakravarty 

Prof Yuti Chernajovsky 

Prof Ian Clark 

Dr David Collins 

Dr Andy Cope 

Mrs Trish Cornell 

Dr Karen Douglas 

Dr Vic Duance 

Dr Sally Edmonds 

Ms Di Finney 

Mr Stewert Glaspole 

Ms Andrea Graham 

Dr Alan Hakim 

Ms Elizabeth Hale 

Dr Inam Haq 

Prof Dorian Haskard 

Mrs Lindsey Hawley 

Prof Elaine Hay 

Dr Philip Helliwell 

Dr Neil Hopkinson 

Dr Rod Hughes 

Dr Richard Hull 

Dr Charles Hutton 

Dr John Ioannou 

Prof John Isaacs 

Dr Rachel Jeffery 

Dr Adrian Jones 

Dr Sharon Jones 

Dr Jeremy Jones 

Dr Ronald Jubb 

Dr Lesley Kay 

Dr George Kitas 

Dr Thomas Lawson 

Prof Peter Maddison 

Dr Janet McDonagh 

Prof Dennis McGonagle 

Dr Neil McHugh 

Dr Iain McInnes 

Dr Chetan Mukhtyar 

Dr Margaret O’Sullivan 

Dr Adrian Pace 

Dr Lazlo Pazmany 

Dr Ken Poole 

Dr Anisur Rahman 

Dr Karim Raza 

Dr Ruth Richmond 

Prof Drew Rowan 

Dr Ash Samanta 

Dr Dagmar Scheel-Toellner 

Prof David L. Scott 

Dr Nick Shenker 

Dr Millicent Stone 

Dr Deborah Symmons 

Dr Alistair Taggart 

Dr Paul Thompson 

Dr Robert Thompson 

Prof Patrick Venables 

Dr Tonia Vincent 

Dr David Walker 

Dr Andrew Whallet 

Dr Lyn Williamson 

Dr Gerry Wilson 

Dr Mark Wood 

Dr Adam Young 

If you would be interested in reviewing abstracts for future conferences, 

please contact bwilson@rheumatology.org.uk 

132

Dear Doctor 

Thanks to MabThera I felt well enough 

to visit “wonderful Copenhagen”. 

Not that long ago I could only dream of doing this – 

wandering around the exotic Tivoli gardens, then boarding 

a bus to go and see the little mermaid. 

My days are so much brighter now. I’ve just stopped 

at a little cafe to admire these fabulous buildings – 

and to enjoy a coffee and Danish! 

Thanks 

Mary Gibson 

 

 

 

 

 

 

 

B 

SELECTIVE E E 

CTIVE 

 

I V E 

PRESCRIBING INFORMATION MABTHERA ® 

(rituximab) 

in Rheumatoid 

Arthritis: 

Please 

refer 

to 

MabThera 

SPC 


full prescribing 

information. 

Indication: 

MabThera, 

in 

combination 

with 

methotrexate, te, 


the 

treatment 

of 

adult patients with severe active rheumatoid arthritis who 

have had an inadequate response e or 

intolerance to other 

DMARDs 

including one or 

more TNF 

inhibitor 

therapies. 

Dosage and 

Administration: 

A 

course 

of 

MabThera 

consistsof of twoinfusions:1000mg by iv infusion followed by 

a second 1000mg iv infusion two weeks later. 

Administer 

through a dedicated line, 

with full resuscitation facilities 

during 

administration. Hypotension may 

occur, 

consider 

withholding antihypertensive medications. Infections: 

Do 

not 

give 

to 

patients with an 

active 

and/or 

severe 

infection, 

or 

severely immunocompromised munocompromised 

patients. 

Exercise 

caution 

in patients with 

recurring/chronic 

infections. Treat and evaluate e promptly and appropriately. 

Use of 

MabThera may 

be associated with an increased 

risk 

of 

Progressive Multifocal Leukoencephalopathy 

(PML). 

Immunisation: 

Safety 

or efficacy ficacy 

of 

vaccination 

– 

consult 

SPC. Concomitant/sequential nt/ 

use 

of 

other 

DMARDs: 

Initial 

data suggest st 

that 

the 

rate 

of 

clinically 

of 

which were fatal, was 0.05 

per 

patient 

year. 

Very 

rare 

cases of PML have been reported. Serious cardiac events 

reported equally in 2% of MabThera and placebo treated 

patients. 

Other: generalised oedema, 

bronchospasm, 

wheezing, 

laryngeal oedema, angioneurotic 

oedema, 

generalized pruritis, anaphylaxis, anaphylactoid reaction. 

Prescriber 

should consult SPC 


full 

details 

of 

side- 

effects. 

Legal category: 

POM. 

Presentations 

and 

Basic 

NHS Costs: 

100mg of rituximab in 10ml 

(10mg/ml) 

pack of 

2 vials: 

£349.25, 

500mg of 

rituximab in 50ml(10mg/ml) 

pack 

of 

1 

vial: 

£873.15. Marketing Authorisation 

Numbers: 

immediately 

available. Premedication should 

be 

given. 

relevant 

infection 

is unchanged. nged. 

Malignancy: 

Limited EU/1/98/067/001 /067/001 

(100mg), EU/1/98/067/002 /067/002 

(500mg). 

Monitor 


onset 

of 

cytokine release ease syndrome. 

Severe 

reactionse.g.severedyspnoea,br 

e.g. severe bronchospasm ronchospasmorhypoxia 

or hypoxia 

require immediate interruption of 

infusion. 

First Infusion: 

experience in RA patients cannot exclude a possible risk 


the development of 

solid 

tumours. 

Drug Interactions: 

Limited data on drug interactions. tions. 

Co-administration with 

Marketing Authorisation on 

Holder: 

Roche Registration 

Limited, 

6 

Falcon 

Way, Welwyn Garden 

City, 

Herts 

AL7 

1TW. MABTHERA is a registered trade mark. 

MEDI00038 

Recommended 

initial 

infusion rate is 

50mg/hr. 

Second 

methotrexate 

had 

no effect fect 

on 

the 

pharmacokinetics 

of 

Date 

of 

Preparation: 

January 

2009. 

References: 

Infusion: 

Initial 

rate 

of 100mg/hr. Dose 

adjustments: 

No 

dose 

adjustment 

is required ed 

in 

elderly 

patients. 

MabThera. 

Pregnancy and Lactation: Women should not 

become pregnant, 

and should 

not breastfeed during, 

and 

1. 

Cohen SB et 

al. Arthritis Rheum 2006; 

54(9): 2793-2806. 

2. MabThera SmPC. 

Contraindications: Hypersensitivity y 

to 

this 

product 

or 

to 

murine 

proteins; 

active, severe ere 

infections; 

severe 


12 months following, treatment. tment. 

Contraception should 

be 

used 

during, 

and 


12 

months 

following, 

treatment. 

heart 

failure 

(NYHA 

Class 

IV) 

or 

severe, 

uncontrolled 

Undesirable 

effects: Common adverse 

reactions: 

 

 

 

cardiac 

disease. Precautions: Infusion reactions: 

infusion 

reactions (hypertension, nausea, 

rash, 

pyrexia, 

Anaphylactic 

and 

other hypersensitivity y 

reactions. 

pruritis, 

urticaria, 

rhinitis, 

throat 

irritation, 

hot 

flush, 

 

 

Premedication 

with 

iv glucocorticoid is 

recommended. 

hypotension, 

chills). Infectionn 

(UTI, 

URTI, any infection). 

 

 

Treatments 


hypersensitivityy 

reactions 

should 

be 

Other: 

dyspepsia, hypercholesterolaemia, holesterolaemia, 

arthralgia/ 

 

 

immediately 

available. Presence of 

HACA 

may 

be 

musculoskeletal 

pain, osteoarthritis, parasthesia, 

 

associated 

with 

worsening infusion ion 

reactions. 

Consider 

migraine. 

Medically significant events: 

Acute 

infusion 

carefully 

patients 

with 

cardiac c 

history 

and 

monitor 

reactions,incidenceofclinica 

incidence of clinically llysignificantinfection,some 

infection, some

TRANSFORM EXPECTATIONS 

for patients with rheumatoid arthritis 

RoACTEMRA is indicated in 

combination with methotrexate 

(MTX), for the treatment of 

adult patients with moderate to 

severe active rheumatoid arthritis 

who have had an inadequate 

response or intolerance to 

previous DMARDs or TNF 

antagonists. In these patients, 

RoACTEMRA can be given 

as monotherapy in case of 

intolerance to MTX or where 

continued treatment with MTX 

is inappropriate. 

® 

Legal category: POM. Please consult the Summary of Product Characteristics before prescribing, particularly in relation to side-effects, 

precautions and contra-indications. Further information is available from: Roche Products Limited, 6 Falcon Way, Welwyn Garden City, 

Herts AL7 1TW. 

Adverse events should be reported. Reporting forms and information can be 

found at www.yellowcard.gov.uk. Adverse events should also be reported to 

Roche Products Limited. Please contact UK Drug Safety Centre on: 01707 367554 

ACTE00438. Date of preparation: March 2010.

Final Programme - The British Society for Rheumatology

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?